Glaucoma, Vision & Longevity: Supplements & Science

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/laser-therapies-beyond-slt-july-2026-protocol-innovationsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Laser Therapies Beyond SLT: July 2026 Protocol Innovations Selective Laser Trabeculoplasty (SLT) is a well-known laser treatment that lowers eye pressure by targeting the eye’s drainage tissue (trabecular meshwork). Recent studies (July 2026) have explored new laser approaches and tweaks to SLT for glaucoma and ocular hypertension. These include modified SLT methods (like non-contact SLT and pulsed lasers), micropulse laser techniques, and canal-focused procedures (using either lasers or tiny implants). We summarize the latest dosing (energy), retreatment rates, pressure‐drop results, and safety findings, and explain what they mean for patients. Modified SLT Approaches (Direct SLT and Micropulse SLT) Researchers continue to refine SLT itself. For example, a new “direct SLT” system treats the drainage tissue without touching the eye. In a large series of 218 eyes, Goldberg et al. (2026) found that 67.0% of eyes reached their target pressure at 2 months after direct SLT【Goldberg2026】. The average eye pressure fell about 3.4 mmHg (a 15.6% drop) from a baseline of ~19.7 mmHg【Goldberg2026】. Importantly, eyes that had never used pressure drops before did even better: about 78.4% of these “treatment-naïve” eyes hit the pressure goal, versus 63.5% of eyes already on medication【Goldberg2026】. Side effects were mild: over half of eyes had a small subconjunctival bleed (a tiny bruise on the eye surface), and only 1.8% had a brief pressure spike; no serious complications were seen【Goldberg2026】. Another line of work uses a pulsed laser for the same 360° treatment area of SLT. This “micropulse” SLT applies many tiny bursts of laser energy to gently stimulate the drainage meshwork. In a head-to-head trial, Abramowitz et al. (2018) found that one year after treatment, micropulse SLT and standard SLT gave very similar pressure drops. About 30–37% of eyes in each group had a ≥3 mmHg drop or ≥20% reduction in pressure【Abramowitz2018】. The big difference was comfort: patients reported significantly less pain during and after the micropulse laser (P=0.005)【Abramowitz2018】. In short, modified SLT methods – whether non-contact or pulsed – appear as effective as standard SLT in lowering pressure, with the advantage of easier delivery and less discomfort【Goldberg2026】【Abramowitz2018】. New Micropulse Laser Treatments Beyond SLT-style procedures, micropulse lasers have been applied in other ways. One major application is ciliary-body cyclophotocoagulation, where laser energy is delivered through the sclera (the white of the eye) to reduce fluid production. In a recent retrospective study of 118 eyes with various refractory glaucomas, Toptan et al. (2026) reported dramatic pressure reductions from micropulse transscleral laser. After one treatment session, mean intraocular pressure (IOP) fell by about 46–56% across glaucoma types (for example, 46.5% in primary open-angle glaucoma, 50.4% in neovascular glaucoma, up to 56.2% in juvenile glaucoma)【Toptan2026】. Overall, the group-wide drop was 48.8%. Initially 66.9% of eyes succeeded (reached target IOP) after one session, and after allowing repeat treatments about 75.4% met the goal by 12 months【Toptan2026】. In practice, most patients (67%) needed just one session, while 28% required two and 5% three sessions up to one year【Toptan2026】. Notably, this powerful pressure lowering came with very few serious side effects. No eye developed dangerous chronic low pressure (hypotony) or shrunken eye (phthisis), complications seen with older cyclodestructive lasers【Toptan2026】. A few mild issues were reported (temporary eye inflammation in 3 patients, small bleeding in 1), and one patient had a transient pupil dilation【Toptan2026】. In summary, micropulse transscleral therapy can cut IOP roughly in half with a 1–2 session protocol, at the cost of mostly minor and temporary effects. The dosing used in these studies was high-power but pulsed: typically a 2,000 mW (2 W) laser with a 31% duty cycle (short “on” bursts totaling about 160 seconds of delivery around the eye)【Toptan2026】. This delivered about 70–80 joules of energy per session. The key is that micropulsing lets the tissue cool between bursts, minimizing collateral damage. Canal-Based Procedures (Excimer Trabeculostomy and Canaloplasty) Researchers are also targeting the eye’s fluid canal (Schlemm’s canal) with new techniques. Excimer Laser Trabeculostomy (ELT) is one such method: a tiny ultraviolet laser makes microscopic holes through the trabecular meshwork into Schlemm’s canal. In a small pilot study (Kallab et al., 2026), patients undergoing cataract surgery plus ELT showed measurable improvement in aqueous outflow. Dye angiography before and after the procedure found a significant increase in fluid flow (p=0.03) across the treated drainage area【Kallab2026】. This suggests ELT can enhance the natural channels, although large-scale pressure data are still pending. Separately, non-laser canal procedures (sometimes grouped here) are showing large pressure drops. For instance, an OMNI canaloplasty/trabeculotomy – a micro-catheter device that dilates Schlemm’s canal and cuts through trabecular meshwork – was studied in 18 patients (Olander et al., 2026). Baseline mean IOP was 26.1 mmHg. After 12–24 months, IOP had dropped to about 15.5 mmHg (a 9.7–10.6 mmHg reduction)【Olander2026】, and most patients reduced or stopped their drops. In fact, 67% of patients were off glaucoma medications by 24 months【Olander2026】. Adverse events were mostly mild; no eye lost vision or suffered major complications, and only one case of dry eye was thought related to the procedure【Olander2026】. This demonstrates that opening the canal can yield a ~40% pressure reduction, comparable to traditional glaucoma surgery but with a very favorable safety profile. Patient Factors and Choosing a Protocol Eye Color/Pigmentation: SLT and micropulse lasers target pigmented cells in the drainage tissue. Evidence suggests micropulse methods work well even in darkly pigmented eyes: animal data show these pulses trigger enzymes that remodel the trabecular meshwork without excessive heat【Abramowitz2018】. In practice, no major differences in efficacy by eye color have been reported. All these laser options are intended for open-angle glaucoma; they are ineffective in eyes with closed or very narrow angles. Angle Status: All the laser treatments above require at least a partially open drainage angle. If your angle is closed, the first step is typically a laser peripheral iridotomy or a cataract operation to open the angle. The canal-based surgeries are usually done in open-angle eyes too (often at the time of cataract surgery). Prior Therapy: Timing matters. The direct SLT study found bigger pressure drops in eyes that had never used drops before【Goldberg2026】. For example, medication-naïve eyes had a 20.2% IOP reduction after 2 months of DSLT, versus 14.2% in eyes already on drops【Goldberg2026】. This suggests earlier use of laser (before maximal medications) may give a better percentage drop. In general, laser trabeculoplasty (any type) can be repeated if needed. In the micropulse cyclo series, about one-third of eyes needed a second session to reach target (yielding ~75% success by one year)【Toptan2026】. Expected Results: Based on these studies, patients can expect a moderate IOP drop on average. SLT or micropulse trabeculoplasty (360° treatment) typically reduces pressure by 15–25%, helping ~30–67% of eyes reach their goal with one treatment【Goldberg2026】【Abramowitz2018】. Micropulse cyclodestruction often gives ~40–50% drops and usually requires scheduling 1–2 sessions【Toptan2026】. Canal procedures (like OMNI) can cut IOP by ~40% as well【Olander2026】. However, individual response varies widely. If you have high baseline pressure or aggressive glaucoma, a bigger intervention (multiple sessions, cyclo, or combined surgery) may be needed versus a mild case where single-session SLT suffices. Safety Profile: All these lasers are generally safe when used correctly. In the new studies, serious complications were rare. SLT (even direct SLT) mainly causes brief redness or tiny bleeds, and pressure spikes were under 2%【Goldberg2026】. Micropulse lasers spare tissue and caused minimal inflammation – in one report almost no eyes had permanent loss of vision or severe hypotony【Toptan2026】. Canal surgeries like OMNI had a few mild events (dry eye, transient inflammation) but no vision loss【Olander2026】. Overall, these methods are much less invasive than traditional surgery (trabeculectomy) and typically do not carry high risks of blindness or severe complications. Conclusion July 2026 studies show that innovations in glaucoma lasers are yielding more options beyond standard SLT. Modified SLT techniques (non-contact devices or micropulse pulses) match SLT’s pressure lowering with the promise of quicker treatment and less discomfort【Goldberg2026】【Abramowitz2018】. Micropulse cyclophotocoagulation is proving to be a powerful tool for hard-to-control glaucoma, cutting pressure by nearly half in many eyes with minimal side effects【Toptan2026】. And canal-targeted procedures (both laser and micro-surgical) are delivering large IOP drops (~10 mmHgSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/corneal-biomechanics-as-a-risk-modifier-last-month-evidenceTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Understanding Corneal Biomechanics and Glaucoma Risk Glaucoma is an eye disease where damage to the optic nerve leads to vision loss. The main known risk factor has long been high intraocular pressure (IOP). However, newer research shows the biomechanical properties of the cornea – essentially how “springy” or deformable the cornea is – also influence glaucoma risk. Two key measures are corneal hysteresis (CH) and dynamic corneal response (DCR) parameters. CH measures how well the cornea absorbs and dissipates energy (think of it as corneal “shock absorption”). DCR parameters come from devices like the Corvis ST, which use a quick air puff and high–speed camera to record corneal deformation. These measures are now easier to get in the clinic thanks to instruments such as the Ocular Response Analyzer (ORA) and Corvis ST () (). Recent evidence suggests both CH and DCR can help predict glaucoma development and progression beyond IOP and corneal thickness (CCT). Measuring Corneal Hysteresis and Corneal Response The ORA (introduced in 2005) uses an air puff and infrared light to estimate CH (). It reports two values: CH and a related Corneal Resistance Factor (CRF). The newer Corvis ST system uses a high-speed Scheimpflug camera (over 4,300 frames/sec) to visualize the actual corneal movement during an air puff (). It yields many dynamic response metrics (like deformation amplitude, inverse radius, stiffness) beyond CH () (). Importantly, each device produces different parameters, and they are not interchangeable. For example, one study found that the Corvis ST’s “biomechanically corrected” IOP (bIOP) did not match the ORA’s cornea-compensated IOP (IOPcc) – the two methods showed weak agreement and should not be used interchangeably (). In practical terms, CH (from ORA) and DCR metrics (from Corvis) reflect related but distinct corneal properties () (). Clinicians are beginning to incorporate these tests: one expert review even recommends checking corneal biomechanics at baseline in all glaucoma patients and suspects (). This means measuring CH (and possibly Corvis metrics) as part of the initial exam. In summary, corneal biomechanics can now be measured clinically, and experts suggest doing so in glaucoma care () (). ... Continue reading at https://visualfieldtest.com/en/corneal-biomechanics-as-a-risk-modifier-last-month-evidenceSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/diurnal-and-nocturnal-behavior-of-episcleral-venous-pressureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Daily Rhythms of Eye Pressure and Venous Pressure Our eyes have a natural 24-hour cycle of pressure changes. Both intraocular pressure (IOP) (the pressure of fluid inside the eye) and episcleral venous pressure (EVP) (the downstream pressure in the veins on the surface of the eye) tend to be highest in the early morning and lower by evening () (). In one recent study of healthy adults, the mean IOP and EVP were both highest at 8 AM and fell by late afternoon (). In other words, like a clock, IOP and EVP peak in the morning and wane later in the day () (). However, night‐time patterns are influenced by sleep posture. When we lie down on our back, blood settles differently, so both IOP and EVP rise. For example, one study found that as soon as a person lies down, EVP jumps by about 3–4 mmHg and stays high while supine (). This contributes to known findings that eye pressure measured at night (when a person is usually lying flat) tends to be higher than daytime sitting measurements () (). In one carefully controlled sleep-lab experiment, volunteers showed higher mean IOP at night partly due to increased EVP and fluid shifting when lying down (). Thus nighttime IOP often exceeds daytime levels because of the supine position and higher venous pressure. In general, IOP and EVP move together across the day. When one study compared them round‐the‐clock, changes in EVP closely paralleled changes in IOP () (). In both healthy people and those on blood-pressure medicines, higher EVP in the morning accompanied higher IOP, and both fell through the afternoon () (). This synchronization means factors that push IOP up (like lying down) also raise EVP, since EVP partly “holds up” IOP from falling below it () (). In short, EVP and IOP share daily rhythms with morning peaks and day/evening troughs () (), but staying flat in bed at night produces higher values for both. How Lifestyle and Body Factors Can Change EVP Several everyday factors affect eye pressures. Staying well hydrated, dietary choices, and nervous system activity all play a role: Hydration (Water Intake): Drinking lots of fluid quickly can raise eye pressure. In one classic study, healthy people who drank a liter of water saw their IOP jump by about 4.4 mmHg for over two hours (). This happens because extra fluid increases the blood and ocular fluid volume. By analogy, EVP likely rises a bit with high fluid intake, although direct EVP data is limited. In clinical practice, patients are sometimes advised to avoid gulping large volumes of water right before IOP checks. Salt Intake: Eating very salty food leads the body to retain water, raising blood volume and pressure. Recent research in a large population found that people with higher dietary salt (measured by urine sodium) had slightly higher IOP and more glaucoma (). The highest-salt group had IOP about 0.45 mmHg above the lowest-salt group. Scientists suggest this may be due to more fluid volume and higher episcleral venous pressure pushing fluid back into the eye (). In other words, excess salt can subtly elevate EVP (and thus IOP) and may increase glaucoma risk () (). Caffeine (Coffee): Caffeine is a mild stimulant that briefly raises IOP. In the same classic study, drinking caffeine led to about a 4.0 mmHg rise in IOP lasting around 95 minutes (). The mechanism likely involves caffeine’s vascular effects. We have less direct data on EVP after caffeine, but by raising overall ocular pressure, it may also raise EVP slightly. For patients sensitive to eye pressure changes, avoiding strong coffee or energy drinks before an eye exam can help avoid an artificial spike. Alcohol: Alcohol has the opposite effect. The 1986 study showed that drinking alcohol caused IOP to drop by up to 3.7 mmHg, with values returning to normal within about an hour (). Alcohol is a vasodilator (it relaxes blood vessels), which may lower both blood and venous pressures, including the episcleral veins. So moderate alcohol can transiently lower EVP and IOP, but this is not considered a therapy (and excessive drinking has many risks). For measurement, it implies having an alcoholic drink just before a pressure check might temporarily make one’s IOP/EVP look lower than usual. Autonomic (Stress and Nerves): The autonomic nervous system (our “fight-or-flight” vs “rest-and-digest” system) can adjust vessel tone throughout the body, including the episcleral vessels. Studies note that changes in autonomic activity can change EVP (). For example, being stressed or anxious (activating the sympathetic system) can constrict some eye vessels, whereas relaxation (parasympathetic) may dilate them. One observation: vigorous exercise caused an immediate drop in IOP of about 4.3 mmHg (). This might be partly due to changes in blood flow and venous tone. In practice, rapid heart rate or adrenaline can slightly alter EVP as well. It is wise to sit quietly before measuring eye pressure, to let things settle. Body Posture: Moving from sitting to lying increases EVP. Multiple studies show that IOP measured lying down is consistently ~2–4 mmHg higher than when sitting (). This is largely due to higher EVP when supine. Thus doctors usually check IOP in a seated position for consistency. But patients should remember: when they lie down (for sleep or rest), their eye pressures rise. Eyelid Closure: As it turns out, simply closing the eyelid (such as when dozing) does not significantly change EVP or IOP (). One study found no effect from keeping one eye closed overnight. So it’s the posture (supine) rather than blinking or shut eyelid that drives pressure changes at night. In summary, factors that boost blood/eye fluid (like too much salt or water, caffeine, lying flat) tend to raise EVP and IOP, while vasodilators or activity (alcohol, exercise) tend to lower them () (). Patients may be advised to minimize heavy salt, caffeine, and alcohol around the time of pressure checks. Implications for Monitoring and Treatment These rhythms and triggers have real-world impacts on glaucoma care. Because IOP (and EVP) peak in the morning, relying on a single afternoon office measurement can miss dangerous spikes () (). A patient whose IOP is “normal” at 2 PM might actually have had a higher pressure earlier that day. Therefore, doctors sometimes repeat IOP checks at different times, or even use extended monitoring. For example, one noninvasive device (the Triggerfish® contact lens sensor) records 24-hour ocular pressure patterns continuously, including while sleeping (). Studies show this lens can safely capture the ups and downs of IOP (and inferred EVP changes) around the clock (). If available, such monitoring can reveal night-time peaks or large swings that single visits miss. Without that technology, home tonometry (self-measuring IOP) or evening clinic visit can help find the highest pressures. Medication timing can also consider these patterns. Many glaucoma eye drops work over 24 hours, but some effects vary. For instance, carbonic anhydrase inhibitors and beta-blockers reduce fluid production, so giving them before the morning rush might blunt the rise. Prostaglandin analogs increase outflow and usually act over a full day, so they are often given at bedtime to cover the early morning period. In any case, discussing timing with one’s doctor is wise. A typical strategy is to try to have the maximum drug effect coincide with the known IOP peak (often morning) () (). (Some doctors note, for example, that beta-blockers like timolol may work best if dosed in the morning when sympathetic tone is higher.) There is no single rule for all patients, but understanding that EVP and IOP ebb and flow suggests chronotherapy (timed dosing) could optimize control. Practically speaking, patients should follow these tips: Record Multiple Readings: If possible, get IOP measurements at different times (morning and afternoon, or during a home period) to catch peaks. Consistent Posture: Always measure IOP sitting upright, both at home or clinic. Note that lying down (even for sleep) raises the pressure. Report Drinks or Meds: Let the doctor know about large water intake, caffeine, salt meals, or new medications (like oral decongestants or stimulants) around measurement time. Tailor Eye Drops: Ask the doctor if any medication timing should adjust for your daily schedule (e.g. take certain drops at night vs morning). By aligning treatment and monitoring with the eye’s daily cycle, one can better manage glaucoma risk. For example, if a patient’s pressure is highest upon waking, an evening dose of medication might be most effective, whereas a midday peak might call for a morning dose. There is ongoing research on “ocular chronotherapy,” but the key idea is clear: when and how often we measure and treat should reflect the clock-like behavior of eye pressure. Recommendations for Future Research Protocols To better understand EVP’s 24-hour behavior, future studies should use standardized, controlled protocols. Here are some suggestions: Controlled Environment: Use a sleep-lab or clinical research setting where lighting, temperature, and noise are kept constant. Keep subjects on a strict sleep-wake schedule (e.g. lights on at 7 AM, off at 11 Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-optic-nerve-head-perfusion-equation-venous-pressure-iop-and-susceptibility-to-damageTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:The Optic Nerve Head Perfusion “Equation”: Balancing Arterial and Venous Pressures Glaucoma (optic nerve damage) has long been linked to high intraocular pressure (IOP), but doctors now recognize that blood flow through the eye is just as important to optic nerve health. In the eye, blood enters through arteries carrying a high pressure from the heart, and must exit through veins carrying lower pressure. The perfusion pressure that drives blood through the optic nerve head (ONH, where the nerve fibers exit the eye) depends on the difference between these pressures – but with a twist. Unusually, the eyeball’s pressure (IOP) physically squeezes the veins leaving the eye (the vortex and episcleral veins) so that these veins must have pressures just above IOP to stay open (). In other words, ocular veins behave like a “Starling resistor”: their outflow pressure is kept near IOP to prevent collapse. This means eye perfusion pressure is often approximated as arterial pressure minus IOP (). In practice, doctors often estimate ocular perfusion pressure (OPP) by subtracting IOP from mean arterial pressure (roughly ⅔ of blood pressure) () (). However, this is only an approximation. Actual venous pressure can deviate from IOP, especially at low IOPs (), which makes true perfusion pressure lower than the formula predicts. In one eye model, researchers found choroidal venous pressure stayed higher than IOP, so real perfusion might be overestimated by the simple formula (). In addition to IOP acting from inside the eye, the optic nerve head lamina cribrosa (the sieve-like tissue at the back of the eye) is also pressed on by the pressure in the cerebrospinal fluid (CSF) around the optic nerve. Normally CSF pressure (essentially intracranial pressure) is somewhat lower than IOP, so the lamina sees a net gradient pushing it backwards. This translaminar pressure difference (IOP minus CSF pressure) causes posterior bowing of the lamina; when it is large, nerve fibers and blood vessels in the lamina can be strained () (). For example, if IOP is 20 mmHg and CSF pressure is 10 mmHg, the lamina experiences about a 10 mmHg difference. Since the lamina is only a few hundred micrometers thick, that works out to roughly 1 mmHg of gradient per 100 µm of tissue () – one of the steepest pressure gradients in the body. Animal and human studies suggest that this translaminar gradient itself can damage the optic nerve. In fact, modern research shows that a low CSF pressure (leading to a high IOP–CSF difference) can be as damaging to the optic nerve head as a high IOP . In normal-pressure glaucoma patients (IOP < 21 mmHg), low blood pressure or especially low CSF pressure can excessively increase this gradient, starving the lamina of blood flow () (). How Arteries and Veins Drive ONH Perfusion As in any tissue, arterial blood pressure pushes blood into the eye’s circulation, and resistance in the tiny vessels reduces pressure by the time blood reaches the veins. Normally this sets up a downward pressure gradient from arteries to veins. But in the eye the external pressure of IOP compresses the outflow veins, forcing the vein pressure to stay just above IOP (). In practice this means blood must overcome the sum of IOP and any venous pressure to reach the tissues of the ONH. In simple terms, ocular perfusion pressure is often taken as arterial pressure minus IOP (), assuming venous pressure ≈ IOP. This approximation highlights two key factors for flow: arterial pressure (linked to heart blood pressure) and IOP. If blood pressure drops (for example at night) or IOP spikes, perfusion can fall. Indeed, wide swings in IOP or blood pressure are risk factors for glaucoma damage. Recent work confirms that large fluctuations in calculated OPP (blood pressure minus IOP) are linked to progression of normal-tension glaucoma (). For instance, one trial found that although both latanoprost and bimatoprost lowered IOP equally, only latanoprost significantly raised the eye’s calculated perfusion pressure (likely through modest effects on blood flow) (). Importantly, the above formula neglects direct venous pressure terms. In reality, if venous pressure is elevated (for example by raised intracranial pressure, or conditions like heart failure or obstructive breathing that raise thoracic pressures), perfusion pressure is reduced. Research in animal eyes shows that at low IOPs venous pressure can actually exceed IOP, causing actual perfusion pressure (arterial minus venous) to be less than the simple MAP–IOP estimate (). In glaucoma patients, higher episcleral venous pressure (EVP) has been observed with some treatments, blunting pressure reduction (). In one animal model, experimentally raising venous pressure dramatically lowered ONH perfusion. Altogether, narrowing or congestion of the ocular veins lowers the overall pressure gradient that drives blood through the optic nerve, making the nerve tissue more susceptible to damage even if IOP is not very high. Imaging and Blood-Flow Studies in Glaucoma Modern imaging and blood-flow measurements confirm that glaucoma eyes often suffer from poor optic nerve perfusion. Optical coherence tomography angiography (OCTA) shows that glaucoma is associated with loss of capillaries: vessel density in the retina, around the nerve, and in the peripapillary choroid is significantly lower in glaucoma patients (). These microvascular defects correlate closely with nerve fiber loss and visual field defects, suggesting a link between poor blood supply and nerve damage (). In one OCTA study, the overall optic disc “flow index” (a measure of blood flow) was about 25% lower in glaucoma eyes than in normals, even after accounting for scan variability (). Hemodynamic imaging adds to this picture. Color Doppler ultrasound studies show that blood velocities in the eye’s feeding arteries (ophthalmic, central retinal, and short posterior ciliary arteries) are lower in both high-tension and normal-tension glaucoma than in healthy eyes (). Laser-based flowmetry assays similarly record reduced blood flow on the surface of the optic nerve head in glaucoma. For example, laser Doppler velocimetry finds less blood in the small capillaries nourishing the nerve fiber layer of glaucoma eyes (). Scanning laser flowmetry in the nerve head cup and rim also consistently shows lower microvascular perfusion in glaucoma patients than in healthy or ocular-hypertension subjects (). Notably, these reductions in flow correlate with the extent of nerve damage: more severe glaucoma tends to coincide with greater loss of ONH perfusion (). Other techniques have similar findings. Laser speckle flowgraphy (LSFG) studies indicate that even at the earliest stages of glaucoma the optic nerve head blood flow can initially rise (possibly from loss of autoregulation) and then steadily declines as damage progresses (). By the time a large fraction of the nerve fiber layer is lost, ONH blood flow can be 25% below baseline (). Long-term studies also suggest that eyes with poorer baseline perfusion – for example due to higher vascular resistance – are more likely to go on to lose visual field faster. For instance, in a 3-year study of treated glaucoma patients, those who progressed showed higher resistivity (lower flow) in the ophthalmic and ciliary arteries at baseline (). Together, these imaging and blood-flow data show a clear pattern: glaucoma optic nerves often have less blood flow and perfusion than normal. While this is partly a consequence of IOP-related compression (a narrowed pressure gradient), it also implies that any additional factor that reduces flow – such as venous congestion or low arterial pressure – can compound the problem. Therapeutic Approaches: Beyond Just Lowering IOP Because glaucoma damage can happen even at normal IOP, researchers emphasize treatments that also protect or improve optic nerve blood flow. Lowering IOP remains first-line, but supplemental strategies target the vascular side. Some glaucoma drugs have beneficial blood-flow effects. For example, the alpha-2 agonist brimonidine not only lowers IOP, it also improves retinal and ONH circulation. Although brimonidine constricts some vessels on the eye’s surface, it paradoxically dilates retinal arterioles and increases overall ocular blood flow (). Clinically, in one trial of normal-tension glaucoma, patients on brimonidine lost visual field more slowly than those on timolol even though their IOPs were the same (), suggesting the improved perfusion provided some protection. Prostaglandin analogues (first-line IOP drugs) may also affect perfusion. Laboratory studies found that latanoprost enhanced optic nerve blood circulation (in animals and humans) independently of its IOP effect (). In a clinical trial comparing latanoprost with bimatoprost, both drugs lowered IOP equally, but only latanoprost increased calculated ocular perfusion pressure (). It appears that some medications can also change the downstream venous pressure – for example, topical prostaglandins were found to raise episcleral venous pressure in animals (), partially offsetting their benefit. New approaches are looking tSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-iop-floor-how-episcleral-venous-pressure-limits-trabecular-and-canal-based-glaucoma-proceduresTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Understanding Eye Pressure and the “Floor” Set by Venous Pressure Glaucoma is caused by high pressure inside the eye (intraocular pressure, IOP). Most glaucoma surgeries work by opening new drainage routes for the fluid in the eye. Many modern procedures (known as minimally invasive glaucoma surgeries or MIGS) create openings in the natural drainage system, so fluid can exit through small veins on the surface of the eye (the episcleral veins). A key point is that these episcleral veins already have their own normal pressure – the episcleral venous pressure (EVP) – and you cannot drain eye fluid below that pressure. In other words, EVP sets a physiological floor for IOP. If the eye‐fluid pressure tries to go much below EVP, there is no pressure gradient to drive flow, so it “bottoms out.” Classic equations for eye fluid (Goldmann’s equation) even show that IOP equals the outflow pressure plus EVP (). In practice, this means no matter how much we open the drainage, the pressure cannot drop much below the level of the veins. Eveyscleral venous pressure is normally about 8–10 mmHg in a healthy eye (). So even a perfect trabecular bypass or canaloplasty can only lower IOP toward that range. How MIGS and Canal Surgeries Work Trabecular meshwork–based MIGS (like iStents, Trabectome, Kahook Dual Blade, GATT) and Schlemm’s canal surgeries (like canaloplasty or Hydrus stent) all aim to reduce resistance by removing or bypassing the trabecular meshwork and inner wall of Schlemm’s canal. Once those are opened, aqueous fluid flows through the normal canal and out through collector channels into the episcleral veins. In effect, these surgeries restore the natural pathway. Because the fluid still drains into the veins, the eye can only empty out until the pressure equalizes with the venous pressure. As one review explains, even a full 360° trabeculotomy can only lower IOP “to as low as episcleral venous pressure” (). In other words, if EVP is 9 mm, the IOP usually cannot go below about 9–10 mm from these procedures. Because of this limit, MIGS techniques are best for moderate IOP reduction. A recent evidence review noted that MIGS “typically cannot achieve extremely low IOPs since they do not bypass the episcleral venous pressure (EVP), usually ~8–10 mm Hg” (). In fact, most MIGS studies report IOP only dropping into the mid-teens (mmHg) range. For example, one long-term series found that Trabectome (an ab-interno trabeculotomy) reduced IOP by about 29% (e.g. 23→16.5 mmHg), whereas a trabeculectomy (a traditional bleb surgery) could reduce IOP by ~40–50% (e.g. 24→12 mmHg) in similar patients (). In plain language, MIGS could drop IOP from 23 to around 16–17 on average, whereas a filtering surgery often got pressures into the low teens. Patients and doctors should understand that this “floor” exists. If one needs very low IOP (for example in advanced disease where pressures in the single digits may be desired), simply opening the trabecular outflow may not suffice. By contrast, surgeries that divert fluid to low-pressure reservoirs (like a bleb) can go well below venous pressure, as we will explain below. Evidence from Clinical Studies Clinical studies of microinvasive surgeries support the idea that outflow is limited by downstream resistance. For instance, surgeons often look at the episcleral venous fluid wave (EVFW) during angle surgery: this is a sign of fluid flowing into the veins. If the wave is strong and widespread (meaning many collector channels are open and EVP is not obstructed), patients tend to achieve lower IOP after surgery. In one study of trabeculotomy (Trabectome), eyes with a clear, extensive EVFW (good flow) had a mean IOP of ~13.3 mmHg at 1 year, on only about 1–2 eye drops (). In contrast, eyes with little or no fluid wave (suggesting poor distal outflow) ended up at ~18.4 mmHg on nearly 3 medications (). In other words, when the path to the episcleral veins was effectively narrowed or pressured, the surgery did not lower pressure as much. Similar findings came from gonioscopy-assisted trabeculotomy (GATT): the greater the spread of the episcleral fluid wave during surgery (meaning more open veins), the lower the postoperative eye pressure and the fewer medications were needed (). These reports reinforce that if the eye’s veins or collecting channels are compromised or if EVP is high, simply unblocking the trabecular meshwork won’t achieve very low pressures. Conversely, high EVP can blunt the effect of trabecular surgeries. In practice, eyes with naturally high episcleral vein pressure (for example from vascular congestion or blood abnormalities) are known to respond poorly to MIGS. For example, eyes with conditions like Sturge–Weber syndrome, carotid-cavernous fistulas, or severe thyroid eye disease often have IOP at or above the level of their elevated EVP, and standard outflow surgery usually fails to drop it much further. While large trials on these exact patients are rare, the logic is clear: if EVP is already 15–20 mmHg in such cases, any surgery draining to those veins will likely leave IOP still high. Surgeries That Bypass the EVP Floor When the goal is to lower IOP below the episcleral venous pressure, surgeons turn to procedures that divert fluid away from the conventional venous route. The main options are trabeculectomy, tube shunts, and cyclodestructive treatments. Trabeculectomy (traditional filtration surgery) creates a new channel from inside the eye to a fluid reservoir (bleb) under the conjunctiva (the soft tissue covering the eye). Because the fluid drains into this bleb instead of the episcleral veins, the IOP is no longer tied to venous pressure. In fact, filtered fluid can be absorbed by the tissues or lymphatics at a pressure often well below normal EVP. Clinical studies show trabeculectomy commonly achieves very low pressures: mean postoperative IOP in one long-term study was only around 7–8 mmHg, and most patients easily achieved pressures ≤10 mmHg, on very few medications (). This is about 5–6 mm lower than typical glaucoma drains. In other words, trabeculectomy “bypasses” the EVP floor. Its power to lower IOP comes at the cost of more risks (like bleb leaks or hypotony), but it is the standard choice when very low IOP is needed. Tube shunts (glaucoma drainage devices) place a small tube from the eye to a plate implanted under the conjunctiva. The plate forms its own bleb-like space around it. Like trabeculectomy, the fluid leaves the eye to a tissue space rather than to the venous circulation. Over time, the new bleb capsule develops moderate resistance, but typically tubes achieve IOP around the low teens (often 11–12 mmHg in published comparisons) (). For example, a mixed study found tube patients averaged ~12 mmHg on medications at 5 years, compared to ~7–8 mm in trabeculectomy. Again, tubes are far less constrained by EVP than MIGS, though usually not quite as low as a perfect trabeculectomy. Cyclodestructive procedures (like cyclophotocoagulation) work differently: they reduce the eye’s fluid production by partially destroying the ciliary body (the tissue that makes fluid). These do not depend on outflow at all, so there is no venous pressure floor to consider. Cyclodestruction often achieves moderate drops in IOP (commonly into the mid-teens or lower) and can be repeated. It is generally used when other surgeries have failed or are unsuitable. Some newer MIGS-like options also bypass EVP indirectly. For example, the XEN and PreserFlo gel stents are tiny tubes placed into the eye that drain to a subconjunctival bleb (similar to a trabeculectomy). These work like “mini-trabeculectomies” and thus can achieve lower IOP than trabecular MIGS (). (They still depend on forming a bleb, so they carry some of the same healing issues as trabeculectomy.) Other experimental approaches, like suprachoroidal shunts, also avoid draining to the episcleral veins altogether. Choosing the Right Surgery When EVP is High So how should a patient and surgeon use this information? First, high EVP can often be suspected from clinical clues even if we do not measure it directly. Look for very red, dilated episcleral veins on eye exam, or “blood in Schlemm’s canal” seen on gonioscopy. Certain histories (like thyroid eye disease, Sturge–Weber, or neck vein obstruction) raise suspicion of high EVP. If a patient’s IOP seems out of proportion to their glaucoma severity or to their medications, consider whether elevated EVP could be a factor. If we suspect or know EVP is elevated, we should expect that MIGS or canaloplasty alone may not reach target IOP. These procedures are still valuable if only a modest drop is needed (for example, reducing IOP from 22 to 17 might be worth a MIGS in a mild case). But if the target IOP must be very low (say ≤12) or if the patient already has fairly high IOP despite maximum therapy, then a surgery that does not rely on episcleral outflow is likely a better choice. In practice this means: Severe glaucoma or very high IOP: Prefer trabeculectomy or tube shunt. These can reach lower pressures and can overcome even a high EVP. If a patient absolutely needSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/carotid-cavernous-fistula-and-glaucoma-venous-hypertension-at-the-eyeTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Carotid-Cavernous Fistulas and Eye Pressure Carotid-cavernous fistulas (CCFs) are abnormal connections between an artery and the venous cavernous sinus at the base of the skull. In simple terms, blood that should flow through arteries is shunted directly into veins. This raises the blood pressure inside the eye’s venous system. The extra pressure backs up into the veins around the eye, raising the episcleral venous pressure (the pressure in veins near the surface of the eyeball). When this happens, the eye’s fluid outflow is blocked, and intraocular pressure (IOP) rises, potentially causing secondary glaucoma () (). Early signs of a CCF can include a red, swollen eye, a bulging eyeball (proptosis), a noise like a whoosh in the head (bruit), and vision changes. These findings result from venous hypertension – high pressure in the eye’s veins. Because of the slow, high-pressure blood flow, the normally thin conjunctival veins become “arterialized” (bright red and corkscrew-shaped). Patients may also have chemosis (conjunctival swelling) and double vision if eye-movement nerves are affected. Knowing these symptoms helps prompt imaging and treatment, which can quickly lower eye pressure and protect vision () (). How CCFs Raise Eye Pressure There are two main types of carotid-cavernous fistulas, and both create orbital venous hypertension. Direct CCFs (Barrow type A) occur when the main internal carotid artery tears directly into the cavernous sinus. This usually happens in trauma (head injury or skull fracture), or rarely from a ruptured aneurysm. Because the tear is large, these fistulas are high-flow. A huge wave of arterial blood rushes into the venous cavernous sinus and then retrogrades (flows backward) into the eye’s veins. Indirect or dural CCFs (types B, C, D) involve small meningeal branches of the carotid or external carotid arteries feeding the sinus. These connections are smaller and low-flow, often developing spontaneously in older adults. Even though dural CCFs are lower flow, they still raise sinus pressure over time () (). In both cases, the key is that arterial blood at high pressure enters the cavernous sinus, crowding out normal venous flow. This creates venous stasis and back-pressure. The superior ophthalmic vein (and sometimes inferior ophthalmic vein) carries blood from the eye to the cavernous sinus. When the cavernous sinus pressure climbs above the pressure in those veins, flow reverses or stalls (). These veins become engorged, and the normal balance of fluid in the eye is disturbed. The eye constantly produces watery fluid (aqueous humor), and normally this drains out through veins. If the veins are jammed by high pressure, the fluid cannot drain, and the eye pressure rises to match the venous pressure () (). The normal episcleral venous pressure is only about 8–10 mmHg (). In a CCF, that pressure can jump much higher. Once the episcleral pressure reaches the level of the IOP, any further increase in venous pressure forces the IOP to rise almost equally (). In practical terms, every extra mmHg of pressure in the eye’s veins directly adds to the eye’s internal pressure. As a result, patients with CCF often develop a secondary open-angle glaucoma where fluid cannot exit because of the high back-pressure () (). (Note: In rare cases, the raised pressure can also push the iris forward, shallowing the front chamber and causing angle-closure glaucoma, or cause poor retinal blood flow and new troublesome vessels. But most CCF-related glaucoma is from the simple effect of blocked venous outflow () ().) Recognizing the Key Eye Findings When a carotid-cavernous fistula develops, it often creates striking eye signs. One of the hallmarks is arterialized conjunctival vessels. Normally the white of the eye has fine red veins. In CCF, those veins look bright red, engorged, and tortuous (often described as “corkscrew” vessels) because they carry direct arterial blood () (). Patients usually have conjunctival chemosis – swelling of the clear membrane (conjunctiva) covering the white of the eye – causing a bloodshot, puffy appearance () (). Another classic feature is proptosis (bulging of the eyeball). Because the venous congestion extends behind the eye, the eye can protrude forward, and in a high-flow fistula it may even pulsate in time with the heartbeat () (). Eye movement can become limited too, and patients often develop double vision (diplopia) if the cranial nerves or engorged eye muscles are affected. There may also be ptosis (drooping eyelid) or an enlarged pupil on that side if the nerves in the sinus are involved. A very important clue is the orbital bruit. This is an abnormal whooshing or throbbing sound heard by placing a stethoscope over the eye or temple. High-flow fistulas typically create an audible bruit synchronous with the heartbeat; even low-flow fistulas can sometimes produce a subtle bruit, especially during Valsalva (holding breath or straining) () (). Finally, and often most importantly, the affected eye shows elevated intraocular pressure (IOP). As the episodes of venous hypertension progress, the IOP may climb significantly (we have seen cases over 30 mmHg) () (). Ophthalmologists will notice an engorged episcleral venous plexus on exam, often with blood visible in Schlemm’s canal (the eye’s drainage channel). A standard applanation tonometry test may even show “wobbly” blinking tonometer mires reflecting the pulsatility of the eye. In one report, more than 64% of patients with CCF had high IOP (22–55 mmHg) (). In short, a swollen, red, pulsating eye with corkscrew vessels and a bruit should immediately raise concern for a fistula () (). Imaging the Fistula and Eyes If a CCF is suspected from the eye exam, imaging is the next step. Several tests can pick up clues: CT or MR Angiography: These non-invasive scans of brain vessels can show an enlarged cavernous sinus, a dilated superior ophthalmic vein, or early filling of the venous system. They often suggest a fistula and can guide planning () (). Ultrasound with Doppler: A skilled sonographer can sometimes detect reversed blood flow in an orbital vein or a “color bruit” of turbulent flow. Eye ultrasound may show an enlarged or pulsating ophthalmic vein. Gadolinium-enhanced MRI/MRA: Can reveal enlargement and abnormal flow voids in the orbit and cavernous sinus. However, the gold standard for diagnosis and exact classification is digital subtraction catheter angiography (DSA) () (). This is an invasive X-ray test where contrast dye is injected into the carotid and other arteries under fluoroscopy. Angiography precisely shows the location, size, and type of fistula, and whether it is draining anteriorly to the eye or posteriorly to the brain. For example, angiography will diagnose a Barrow type A vs. D fistula and show if the superior ophthalmic vein is filling backward. It also allows measurement of flow. In practice, ophthalmologists often first order a CTA or MRA if suspicious, then confirm with angiography () (). Endovascular Treatment and IOP Effects Management of a CCF usually involves an interventional radiologist or neurosurgeon working with the eye doctor. The main goal is to occlude (block) the fistula, stopping the abnormal blood flow and restoring normal venous drainage. In direct (type A) fistulas, treatment is usually urgent. A catheter is threaded through the femoral or carotid artery to the cavernous sinus, and the connection is closed off with coils, balloons, or liquid embolic agents. Modern detachable balloons or platinum coils can seal the tear in the artery. Sometimes a stent or liquid glue (onyx) is used. Heidelberg et al. reported using a detachable balloon in a direct CCF (). In dural (indirect) fistulas (types B-D), the decision to treat depends on symptoms. Because these are low-flow, some will spontaneously close or remain asymptomatic. If eye pressure is high or vision is threatened, treatment is indicated () (). The embolization may go through arterial feeders or, more commonly, a transvenous approach via the venous system (through the inferior petrosal sinus or rarely via a cutdown on the superior ophthalmic vein). The goal is to deliver coils or liquid to the cavernous sinus to plug the fistula from the vein side. These endovascular procedures have become highly effective and relatively safe (). After the fistula is closed, venous pressure in the orbit drops and the eye congestion resolves. Notably, intraocular pressure often falls quickly. Case reports and series document dramatic IOP improvement after successful embolization () (). For instance, in one case, IOP in one eye dropped from 34 mmHg to 19 mmHg just one week after CCF closure (). Another study found that embolization lowered the patient’s IOP by about 9 mmHg on average (). In that report, after angiographic occlusion of a bilateral CCF, both eyes’ pressures fell from the mid-20s into the high teens (). This confirms that fixing the fistula is often the most powerful way to reduce eye pressure. Adjunct medical therapy for glaucoma is usually given until the fistula is closed. Patients may use combinations of eyedrops (beta-blockers, carbonic anhydraSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/glutathione-centered-strategies-nac-vs-glynac-vs-dietary-sulfur-donorsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Glutathione and Eye Health Glutathione (GSH) is a small but mighty antioxidant produced by our cells. It acts like a detoxifying shield against damage from free radicals and high sugar levels. The eye, especially the retina, lens, and cornea, needs glutathione to stay healthy. In fact, diseases like glaucoma and retinal degeneration often show low glutathione levels, indicating oxidative injury (). For example, glaucoma patients have lower blood glutathione than normal, suggesting that boosting GSH could protect retinal cells and the optic nerve (). Similarly, wounds—including surgical incisions and diabetic skin wounds—heal more slowly when oxidative stress is high () (). In short, keeping glutathione high helps eyes resist stress and helps wounds heal well. Modern medicine explores ways to raise GSH inside cells. Three main strategies are used: taking N-acetylcysteine (NAC) supplements, taking NAC together with glycine (called “GlyNAC”), or eating foods rich in sulfur-containing amino acids (like cysteine and methionine). Each approach has different effects on eye tissues, surgery recovery, blood sugar, and digestive comfort. N-Acetylcysteine (NAC): A Glutathione Booster NAC is a modified form of the amino acid cysteine. When you take NAC, your body converts it into cysteine, which is one of the building blocks for making glutathione (). This makes NAC a powerful way to raise intracellular GSH. Typical oral doses are around 600–1200 mg per day (often split into two or three doses), but some studies have safely used up to 1800 mg two or three times daily (). Eye benefits. Ophthalmology studies have found promising effects of NAC for retinal diseases. In one trial of retinitis pigmentosa (an inherited retinal degeneration), patients took NAC (up to 1800 mg twice daily) for 6 months. Those taking NAC showed improved retinal light-sensing and visual function () (). This suggests NAC helped protect photoreceptors (cells that detect light in the retina) by raising antioxidants. NAC has also been tested for eye surface injuries: in experiments on corneal (front of the eye) healing, high blood sugar slowed wound closure, but adding NAC restored normal healing speed (). In other words, NAC counteracted the harmful effects of glucose on corneal cells. Wound healing. Outside the eye, NAC also helps general wound repair. Animal studies of diabetic wounds show that topical NAC (in a skin dressing) markedly sped up early wound closure, with more new tissue forming at the wound edges (). Reviews of many experiments report that NAC can improve skin wound healing (for example, by boosting new blood vessel growth and collagen formation) () (). Even complex surgical healing may benefit: chronic oxidative stress (low GSH) is known to impair post-operative recovery (), and antioxidants like NAC have been shown to reduce complications in surgical patients. Blood sugar (glycemic) effects. NAC can improve insulin sensitivity. In women with polycystic ovary syndrome (who often have high insulin and sugar levels), 1.8 g/day of NAC for 5–6 weeks significantly lowered insulin responses and improved insulin sensitivity (). NAC did not raise blood glucose, but it helped the body handle sugar better. In older people, combining NAC with glycine (see below) greatly reduced measures of insulin resistance and fasting insulin levels (). In practice, taking NAC is unlikely to cause low blood sugar problems; instead, it often slightly improves sugar metabolism. Tolerability. Most people tolerate NAC well, but digestive upset is the most common side effect. Nausea, vomiting, diarrhea or abdominal discomfort can occur, especially at higher doses (). In one ocular trial, about a third of patients had mild GI side effects on high-dose NAC (1800 mg three times daily) (). These usually improved if the dose was lowered. To minimize issues, NAC is best taken with food or in divided doses. NAC’s sulfur smell/taste may also be noticeable, but it is otherwise safe with few drug interactions (). GlyNAC (Glycine + NAC): Synergistic Precursor Pair GlyNAC refers to taking glycine together with NAC. Glutathione is built from three amino acids: glutamate, cysteine, and glycine. While NAC provides cysteine, your body also needs enough glycine to complete the process. Some research suggests glycine is often the second limiting factor for GSH production (). In other words, if glycine levels are low (as can happen in low-protein diets or aging), using NAC alone might not fully boost GSH. Human studies. A notable clinical trial in older adults tested GlyNAC supplementation (100 mg/kg of NAC plus 100 mg/kg of glycine daily, about 7 grams each for a 70-kg person) versus placebo. After 16 weeks GlyNAC doubled or tripled muscle glutathione levels and lowered markers of oxidative stress (like TBARS and F2-isoprostanes) to youthful levels () (). GlyNAC also improved insulin resistance (fasting insulin and HOMA-IR fell by ~64%) and reduced inflammation markers (CRP, TNF-α) (). Participants reported better energy and exercise capacity too. In short, GlyNAC safely and effectively reversed age-related glutathione deficiency and metabolic stress () (). These benefits would also help healing and perhaps protect nerves by reducing chronic inflammation. Glycine effects on blood sugar. Separate research shows glycine alone can blunt blood sugar spikes. In a classic study of healthy adults, 5 g of glycine given before a glucose drink halved the blood sugar rise, likely by triggering insulin or gut hormones (). So adding glycine enhances the positive metabolic effects of NAC. Importantly, GlyNAC together did not cause low blood sugar; it mostly improved insulin efficiency, meaning the same sugar load was handled with less insulin. Tolerability. Glycine is very gentle. Large doses (several grams) rarely cause side effects except occasional stomach upset or sleepiness (glycine is a calming amino acid). In the GlyNAC trial, the combination was well tolerated for 16 weeks, with no serious adverse events (). In fact, people often find taking glycine pleasant (it tastes slightly sweet) and it can even improve sleep. Thus, the GlyNAC approach tends to have fewer stomach issues compared to high-dose NAC alone. Dietary Sulfur-Donor Foods Besides supplements, your diet can supply sulfur amino acids and related nutrients to boost glutathione. Many protein-rich foods contain cysteine and methionine (the sulfur amino acids) and glycine. For example, chicken, turkey, pork, beef, fish, eggs, milk, beans, and nuts all provide these building blocks in varying amounts＊ () (). The MDPI nutrition review on dietary glutathione notes the best sources include meats and legumes: for instance, chicken breast has about 36 mg of GSH per 100 g (), and soybeans/rice have around 37 mg. Even some vegetables and fruits contain glutathione or precursors: spinach, asparagus, and avocado each have about 10–20 mg per 100 g (), while broccoli and citrus fruits offer modest amounts (). Note that cooking and processing reduce GSH in foods, so fresh or lightly cooked choices are better. There are also special dietary compounds that indirectly raise GSH. For example, garlic and onions contain water-soluble sulfur compounds (like S-allylcysteine) that help cells make more glutathione (). Vegetables in the cabbage family (broccoli, kale, Brussels sprouts) are rich in sulforaphane, which activates a gene regulator (Nrf2) that turns on the body’s GSH production enzymes (). Berries, tea, and foods with resveratrol or omega-3 fats can also boost antioxidant defenses by promoting GSH recycling (). Conversely, a strictly low-protein diet (such as some strict vegans or ancient fasting practices) may limit glutathione because it cuts glycine and cysteine intake (). Practical advice. Eating a protein-containing meal will help GSH. For example: Poultry, fish, eggs: high in methionine/cysteine. Legumes and beans: provide cysteine plus fiber and nutrients. Garlic/onions: use raw or lightly cooked for their sulfur compounds. Leafy greens & broccoli: not only give some glutathione but also activate its synthesis. Bone broth or gelatin: rich in glycine. Whole grains and nuts: contain smaller amounts but add variety. Over-supplementing protein is not needed, but ensure you get enough protein (especially when healing from surgery) to support glutathione and tissue repair. Adequate B-vitamins (B6, B12, folate) are also important to convert methionine into cysteine, completing the glutathione cycle. Overall, a balanced diet with a mix of these foods can modestly raise GSH levels without any side effects. Some people may notice gas or mild stomach upset from beans or cruciferous veggies, but such foods are generally safe. Glycemic Control and GI Tolerability When choosing a strategy, it’s helpful to compare how each affects blood sugar and digestion: Lowers Fasting Glucose or Insulin: GlyNAC has strong effects on insulin resistance (as seen above) (). NAC alone mostly lowers insulin demand in insulin-resistant states (). Glycine alone sharply reduces blood sugar spikes from a meal (). A protein-rich diet with vegetables tends to have a low glycemic load, improvSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/week-2-after-trabeculectomy-transitioning-to-light-chores-and-remote-workTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Second Week After Trabeculectomy: Easing Into Daily Activities After trabeculectomy (glaucoma filtration surgery), the first week is usually very gentle – plenty of rest, limited movement, and protective measures (like an eye shield) as directed by your surgeon. By the second week, if your doctor gives the all-clear, you can begin to gradually resume light activities. For example, many patients feel well enough to do easy housework (like dusting, cooking, or folding laundry) and even return to light desk work or remote work around 1–2 weeks post-op (). (A health guide notes most patients can return to their normal routine by week 2 ().) Listen to your body: if your eye feels uncomfortable or tired, slow down or take a break. Don’t rush; your eye is still healing. Safe Chores and Work Light household tasks: Easy chores (such as making the bed, light laundry, tidying up) are usually okay after week 2. For example, one eye clinic advises that patients can “bend and do usual household tasks” and even gardening soon after surgery (). Make simple tasks easier: use a cordless vacuum or small hand vacuum for dusting, which reduces bending and lifting. A rolling laundry cart or tote can help move clothes without carrying heavy baskets. Remote work tips: If your job allows partial remote work, start with just short periods at a computer. Position your screen at eye level, sit in a well-lit room, and minimize overhead glare. Take frequent microbreaks: follow the 20-20-20 rule, looking at something about 20 feet away for 20 seconds every 20 minutes (). This helps relax your eye muscles and prevent strain. You might also use dictation tools or screen readers to reduce long periods of reading. Many phones and computers have built-in voice-to-text or text-to-speech features. For instance, smartphones often offer voice dictation and “screen reader” accessibility tools. These can help you work without staring at the screen for hours. Lifting, Bending, and Exercise Avoid heavy lifting: For at least 2–3 weeks, do not lift heavy objects. In many guidelines, “en evitar esfor\u00e7o f\u00edsico forte” and “no carrying weight above 5 kg (about 10 lbs)” for the first 2–3 weeks are recommended (). Think twice before lifting anything heavy: ask for help with groceries or laundry bags. Bend with your knees: When picking up objects, bend at your knees rather than bending over at the waist. Keeping your head above chest level helps avoid spikes in eye pressure. A Brazilian post-op guide specifically warns to be careful “ao abaixar a cabe\u00e7a al\u00e9m linha do ombro” – i.e. not to lower the head past shoulder level (). This is similar to general advice after eye procedures: don’t stoop forward too deeply. Instead, squat or kneel to reach lower items. Gradual exercise: Avoid strenuous exercise or heavy housework for the first two weeks () (). This means no running, aerobic workouts, or intense gym sessions. After two weeks, you can slowly ease back into gentle exercise (like walking). Always follow your surgeon’s guidance: if in doubt, double-check before attempting anything too energetic. Skip head-down positions: Activities like yoga poses that put the head below the heart (e.g. downward dog or forward bends) can sharply raise intraocular pressure. It’s safest to avoid inverted or head-lowered positions until you’re fully healed. Protecting Your Healing Eye Hand hygiene and drops: Infection prevention is vital. Always wash your hands with soap and water before touching your eyes or applying drops (). Your doctor will prescribe antibiotic and anti-inflammatory eye drops (and sometimes a steroid drop) to prevent infection and control inflammation () (). Use them exactly as directed. For example, GoodRx notes that after common eye surgery, patients use antibiotic and anti-inflammatory drops to “prevent complications such as… eye infection” (). Similarly, a trabeculectomy post-op guideline stresses that antibiotic and steroid drops are fundamental to a successful recovery (). Avoid touching or rubbing: Never rub or press on the operated eye for at least the first week (). Even after that, be gentle. If you need to clean around the eye, do so very carefully. One care sheet reminds patients to keep water, soap, shampoo and other products out of the eye, especially for the first week (). When showering, wash above the eyes with closed lids or use a gentle spray away from the face. Avoid swimming pools, hot tubs, or anything that might expose your eye to bacteria for at least a month (). No makeup or lotions: Do not wear eye makeup (mascara, eyeliner, eye shadow) for about 2 weeks after surgery (). Also, avoid applying perfumes or skincare creams near the eyes during this time. Keeping the eye area clean and free from potential irritants helps prevent infection. Sun and Light Protection Wear UV-blocking sunglasses: Your eye may be light-sensitive after surgery. Protect it outdoors with wraparound sunglasses that block 100% of UVA/UVB rays (). The American Academy of Ophthalmology recommends UV400 sunglasses – these block all harmful rays – for outdoor use (). In the first week especially, wear sunglasses any time you go outside (). This shields your eye from glaring light, wind, dust and pollen (which can burn or irritate a fresh surgical site). The Southwest Eye Institute notes that sunglasses “make [the light sensitivity] transition far more comfortable, and protect healing eyes from UV and debris” (). Use clean shields: Keep your sunglasses clean. A Brazilian clinic suggests washing post-op protective eyewear with soap and water, and putting them on by the arms (rather than touching the lenses) (). Clean, well-fitting sunglasses or a plastic shield (often provided by your doctor) can also be used indoors or at night to prevent accidental rubbing while sleeping. If an eye shield was given at night, continue wearing it for the first week or as instructed (). Reducing Eye Strain Even while recovering, digital screens are often necessary for work or leisure. To prevent digital eye strain, follow these tips: 20-20-20 breaks: Every 20 minutes, take a 20-second break and look at something about 20 feet away (). This simple “20-20-20 rule” is recommended by eye doctors to relax the eyes (). Setting a silent timer or using a break reminder app can help you remember. Blink often: Remind yourself to blink fully, especially if you feel dry. Blinking refreshes the tear film and keeps your eye lubricated. Optimize your screen: Use larger text and higher contrast on your computer or phone so you don’t have to squint. Position your device so you can sit upright, with the screen at or below eye level (this also helps keep your neck relaxed). Reduce glare by using curtains or an anti-glare filter on the screen. Voice/personal assistants: Take advantage of speech-to-text or voice assistant features. For example, you can dictate emails or documents instead of typing and reading long passages. On smartphones, voice commands (like Siri or Google Assistant) can control basic functions hands-free. For extensive reading, consider text-to-speech apps or built-in screen readers. Scheduled microbreaks: Throughout your day, stand up, stretch, and rest your eyes for a minute or two. Simple neck rolls and gentle shoulder stretches help you relax and improve circulation (just avoid bending forward deeply while stretching). Conclusion By week two, many patients find they can cautiously increase activities while still taking precautions for their healing eye. The key is moderation and protection. Stick to light housework and taking short stints of remote work with frequent breaks () (). Continue to follow your surgeon’s instructions on drops and follow-up visits. Avoid lifting heavy items or intense workouts for at least two more weeks () (). Always protect your eye – from infection and from UV/debris – by keeping hands clean, using your medications, and wearing sunglasses outside () (). Your eye is healing, but with these gentle guidelines and simple aids (like a lightweight vacuum or using voice dictation to rest your eyes), many normal activities can resume. If anything feels off – such as increasing eye redness, pain, or vision changes – contact your doctor promptly. Otherwise, implementing these care tips should help you recover comfortably and safely.... Continue reading at https://visualfieldtest.com/en/week-2-after-trabeculectomy-transitioning-to-light-chores-and-remote-workSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/days-5-7-after-trabeculectomy-completing-week-one-with-safer-routines-and-visual-comfortTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Days 5–7 After Trabeculectomy: Completing Week One With Safer Routines and Visual Comfort After a trabeculectomy (glaucoma surgery), the first week is all about gentle healing and carefully reintroducing normal tasks. By days 5–7, you’ll likely feel a bit better, but your eye is still fragile. It’s common to notice light sensitivity (you may find bright lights or sunlight harsh) and vision that goes from clear to fine to a bit blurry on different days. For example, one surgical recovery guide notes that “by the end of the first week, many patients notice gradual improvement in comfort and mild improvement in clarity, although vision may still fluctuate.” This means you might see better some hours, then foggy the next — this is normal as your eye pressure settles and the new drainage bleb (tiny fluid pocket) matures. You may also find your eye feels scratchy, watery, or a bit sore, especially from the tiny stitches (sutures). Malik and colleagues explain that the eye often feels like there’s a foreign body or scratchy sensation from stitches, but this usually causes only mild discomfort (). Your eye could be red and irritated, and it might water more than usual (). A common analogy surgeons use is that you’ve got a small, healing wound on your eye – some swelling and watering is expected. It’s important not to rub or press on the eye during this time, as even small jostles can disturb the healing. Medications continue in week one. Keep taking all prescribed eye drops exactly as directed – usually an antibiotic to prevent infection and a steroid to control inflammation. These are often used for several weeks and then gradually tapered (). If you have scheduled acetaminophen (Tylenol) or other mild pain medicine, you can use it for any soreness; Ibuprofen-type pain relievers are typically not needed. Most people find that over-the-counter acetaminophen is enough for the mild ache described by Greenwich Ophthalmology’s timeline (). By the end of day 7, you should be sleeping and waking with slightly less irritation than Midweek. Managing Comfort and Vision Even as the eye feels better, vision clarity can still change daily. It’s usual to have some blur or variability. The surgeon at Oracle Eye Physicians explains that in these first weeks “vision is quite variable,” sometimes almost normal and other times blurry, but it should slowly return to your previous level over several weeks (). In practice, this means some morning you wake up seeing very clearly, and another day everything might look fuzzy or cloudy. Don’t panic — this is part of normal recovery as your eye pressure stabilizes. To cope with light sensitivity and variable vision: Use sunglasses indoors and out. If lights feel bright or driving at dusk bothers you, wearing sunglasses can shield your eye from glare (). Many doctors recommend sunglasses especially when you’re outside or in brightly lit rooms. Minimize eye strain. In general, rest your eyes as much as possible. During days 1–3 most doctors advise resting your eyes and avoiding any extended reading or screen time (). By days 5–7 you can try short periods of reading or looking at a screen, but keep them brief and break often. Stay on your drop schedule. Continuing inflammation control is key for comfort. Every drop of steroid or antibiotic is important to prevent swelling and discomfort. Safer Screen Time and Reducing Eye Strain You might be wondering when you can get back to screens (phone, computer, TV). By days 5–7, light use is generally okay, but it’s wise to follow ergonomic and eyestrain-reducing practices. The American Academy of Ophthalmology (AAO) and other experts offer simple tips to protect healing eyes from digital strain: Take frequent breaks. Use the “20-20-20” rule: every 20 minutes, look at something 20 feet away for at least 20 seconds (). This rest lets your eyes refocus and blink normally. Maintain good distance and posture. Sit upright at a desk or table with the screen about an arm’s length away (~25 inches). Position the screen so your gaze is slightly downward (the top of the display just below eye level) (). This reduces eye strain and neck tension. Adjust light and contrast. Make sure room lighting isn’t too dim or too bright compared to the screen. Increase your screen contrast so text stands out; as one guide notes, ensure your screen’s brightness roughly matches the room light (). Use matte screen protectors or anti-glare filters if you’re in a bright room. Use large, clear text. On computers or phones, bump up the font size. Experts recommend at least a 12-point (or larger), dark text on a light background for easier reading (). High-contrast visual themes (dark mode vs light mode, etc.) that suit your comfort can help reduce squinting () (). Blink often and lubricate. We tend to blink less when staring at screens, so remind yourself to blink or look away. Keep preservative-free artificial tears handy during the day. If your eye feels dry, apply drops as needed – the AAO explicitly suggests keeping drops at hand to “help lubricate your eyes when they feel dry” (). A small room humidifier or steam (like from your shower) can also ease dryness in winter or air-conditioned environments. Follow any specific instructions from your doctor about screen use. There’s no strict “safe hours per day” rule, but many surgeons advise not pushing it in the first week. Instead of marathon sessions, do short bursts (5–10 minutes) and rest frequently. Regarding blue light, don’t fret too much: researchers have found that special blue-light blocking glasses or filters don’t reduce digital eye strain more than neutral (clear) filters (). However, using a device’s “night mode” or blue-light reduction setting in the evening can help with sleep even if it doesn’t directly prevent strain. So, if it’s easier on your eyes or helps you settle at bedtime, go ahead and use the blue-light filter—but focus more on all the other healthy screen habits above. Activity Restrictions Your doctor gave you rules for a reason: protect that fresh surgical site! In days 5–7, the main restrictions usually remain in place from day one, unless told otherwise: No swimming or submerging your face. Avoid pools, hot tubs, lakes, or even face-down baths for at least 2–4 weeks (). Bacteria in water can cause infection in the healing eye. Showering is allowed (starting the day after surgery), but be careful to keep water, soap, shampoo and conditioner out of the eye (). You can wash your hair, but tilt your head back and/or use gentle water flow so nothing runs into the eye. Avoid dusty or dirty environments. Skip gardening, yard work, dusting, or home renovation for now. Dirt and dust can irritate the eye or introduce germs. Kaiser’s guide specifically says to avoid gardening and dust for 1–2 weeks (). If someone else can do the chores, let them – or wear protective goggles if absolutely needed (but generally best to wait until clear). No heavy lifting or straining. Lifting heavy objects, straining (including heavy housework), and even bending forward can sharply raise pressure in the head and eye. For the first 2 weeks (and often longer), avoid lifting more than about 5–10 pounds, and do not bend over at the waist. Instead, bend your knees and lift with your legs if you must pick something up (). One surgeon’s instructions say, “Strenuous activity, heavy lifting, and bending over should be avoided for the first one to two weeks.” (). This also means no weightlifting, no exercise that makes your face red (like running or aerobics), and even avoid straining on the toilet: ask your doctor about using a stool softener if needed () (). Follow medication timing and precautions. Keep your eye shield or patch on at night for at least the first week (as your doctor recommended) to prevent you from accidentally rubbing your eye in sleep (). During the day, wear your regular eyeglasses if you have them, and don’t try to wear contact lenses for many weeks. Kaiser notes that patients usually need to avoid contacts for about 8 weeks after a trabeculectomy (). In short, take it very easy. If it’s strenuous for the body, it’s strenuous for the eye. Use assistance for any chores that involve bending, lifting above waist, or splashing of any kind. To make life easier, consider using prepared meals or meal kits. These ready-made or easy-prep dinner kits can cut down on time spent chopping, lifting pots, and bending over counters – lowering the strain on your eye during this vulnerable week. Follow-Up Care and Next Steps Your doctor will schedule follow-up visits to monitor healing. It’s typical to have an appointment the day after surgery, and then several visits in the first few weeks () (). Day 1 post-op: Wear your protective shield at night and have someone drive you in. At this visit, the surgeon will usually remove the patch, check your vision and pressure, and look at the new bleb (the little fluid-filled reservoir) (). They will give you any new drop instructions and be explicit about what activities to avoid. Week 1: You’ll likely return in about a week (day 5–7). The doctor will check how the bleb is working and may adjust sutures if needed. Kaiser PermanenteSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/days-3-4-after-trabeculectomy-calming-inflammation-while-staying-mobileTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Days 3–4 After Trabeculectomy: Calming Inflammation While Staying Mobile If you had trabeculectomy surgery for glaucoma, your body is now in the early healing phase. It’s common at this stage (around days 3–4) for your eye to be red and swollen and for your sight to be blurry or fluctuating. Don’t worry – this is usually normal. The eye’s natural response to surgery is to be a bit inflamed at first. Most patients still have some redness or a “bloodshot” look in the operated eye during the first 1–4 weeks (). Likewise, your vision may still be far from perfect. You might notice it going in and out of sharpness: one moment your sight seems nearly normal, the next it feels quite hazy () (). This happens as pressure and fluid levels in the eye adjust and as stitches and swelling settle. Typically, blurred vision after trabeculectomy starts to improve after a week or two and returns to its best over a few months () (). In short, expect ups and downs in comfort and clarity at this stage, but no need to be alarmed if each day brings a little better vision. To help calm inflammation, your surgeon will have prescribed anti-inflammatory eye drops. These are usually steroid drops (for example, dexamethasone) and sometimes a non-steroidal anti-inflammatory acetate drop. In the first days after surgery, you’ll likely use them very frequently. For instance, one clinic’s protocol is to put in steroid drops every 1–2 hours while awake for the first few days, then gradually taper to a few times per day over the next weeks (). Another guide recommends continuing steroid drops every 2 hours during the day for about the first month, then slowly reducing the dose over 2–3 months (). It’s vital to follow your exact drop schedule. These anti-inflammatory drops (and the prescribed antibiotic drops) prevent infection and control swelling so your new drainage “bleb” can form properly () (). Don’t stop them early, and try not to miss doses. Always wash your hands before touching your eye, and close your eye for a minute after each drop so it can soak in. Activity and Precautions While you should avoid strenuous activity or stress on the eye, it’s also good to stay as mobile as you safely can. In general, doctors advise moderate rest but not complete bed rest. You can sit up, walk around indoors, and do light tasks. For the first 1–2 weeks, however, be sure to avoid heavy lifting, bending, or anything strenuous. For example, avoid lifting anything heavier than about 10 pounds (a small bag of groceries) and refrain from jogging, weight-lifting, or intense housework () (). Bending forward (for example, to tie shoes or pick something from the floor) can temporarily raise eye pressure. To protect the eye, plan tasks ahead to minimize stooping. A reacher grabber tool can help pick up items without bending. If climbing a ladder or heavy lifting is part of a chore, wait until your doctor says it’s safe. According to guidelines, even ordinary housekeeping (dusting, vacuuming, cleaning) should be gentle or postponed for about a week or two (). These chores can stir up dust or require bending/straining, which could irritate the healing eye. Avoid dusty or smoky environments whenever possible. Airborne particles or smoke can irritate your eye’s surface or introduce germs. Health systems often advise using indoors air filters or masks if you must be in dusty areas. Also, don’t rub or press on the eye – even if it feels irritated, keep that reflex in check. Wear the prescribed eye shield at night (typically one week, or as directed) to prevent accidental rubbing while asleep (). If your eyes feel light-sensitive outdoors, use UV-blocking sunglasses or wraparound shades (preferably with side shields) to protect against wind, dust, and bright light () (). One often-overlooked step in recovery is preventing constipation. Straining on the toilet can significantly raise eye pressure, which you want to avoid while the eye heals (). Therefore, your doctor may recommend a high-fiber diet or a gentle stool softener. Keep your bowels easy-moving – for instance, consider fiber supplements or stool softener tablets each evening (but only if your doctor okays it) (). Drinking plenty of water also helps with this and supports healing overall. There are many mobile apps today to remind you to drink water regularly, which can be a handy tool during recovery. Warning Signs – When to Call Your Doctor While some redness and discomfort are expected, watch closely for any worsening symptoms. Alert your doctor immediately if you experience any of the following: Severe or increasing eye pain that doesn’t get better with your usual pain relievers. Some soreness is normal, but sharp or throbbing pain is not (). A pus-like (purulent) discharge: thick yellow or green fluid coming from the eye is a red flag for infection (). A rapid drop or change in vision beyond mild blurring. If your vision suddenly gets much worse or you see a new dark or “shadow” area, call urgently (). Halos or colored rings around lights, especially accompanied by a headache or eye pain. These can signal a dangerous rise in eye pressure (similar to an acute glaucoma attack) (). (If your eye also becomes very red or brownish, that is another warning sign.) Worsening redness or swelling that doesn’t start to improve after a few days. Persistent redness or a swollen eyelid might mean inflammation is not subsiding as expected (). Any signs of infection elsewhere: fever, chills, or feeling generally unwell. If you see any of these, it’s better to err on the side of caution. Many hospitals stress that infection and severe pressure problems can cause permanent vision loss if not treated promptly () (). Don’t wait – contact your eye surgeon or go to the emergency room if needed. Practical Tips for Comfort and Safety Eye shield or patch: Continue using an eye shield at night as directed. This prevents accidental rubbing. Some people keep a plastic shield taped over the eye at bedtime for the first few nights (). Pain management: Take over-the-counter acetaminophen (Tylenol) every 4–6 hours as needed for discomfort. Do not use aspirin or ibuprofen unless your doctor approves, since these can increase bleeding risk (). Stool softeners/fiber: As noted, take any recommended fiber supplement or stool softener to make bowel movements easy (). Hydration: Sip water throughout the day. Good hydration helps your body heal and keeps the eye moist. Setting reminders on your phone can help you drink regularly. Light activity: Short walks around the house are fine. You can read, watch TV, or do hobbies like knitting or light crafts – anything that doesn’t involve bending or heavy effort. Use caution if walking outside; wear your sunglasses. Reacher/grabber tools: Use a reaching tool for tasks that would otherwise require bending, like picking things off the floor or reaching low shelves. This avoids pressure spikes from bending. Eyedrop organizer or app: If you have a complicated drop schedule, use a pillbox-style drop organizer or a phone app (there are “eye drop reminder” apps) to track each dose. This helps ensure you don’t miss anti-inflammatory or antibiotic drops. Above all, follow your surgeon’s instructions. Attend all follow-up visits (often scheduled weekly at first) so the doctor can monitor your bleb (the filtering area) and eye pressure. They may adjust stitches or medications in the early weeks to keep your pressure in the safe range. Recovery can be a bit unpredictable, but staying on top of drops and restrictions will help everything settle down. Conclusion By days 3–4 after trabeculectomy, you should be gently resuming normal life while still taking good care of your eye. Some redness, mild soreness, and blurred vision are normal. Use your anti-inflammatory eye drops exactly as prescribed to calm swelling () (). Keep strenuous activities on hold, protect the eye from irritants (dust, smoke, bumps), and prevent any straining in daily tasks. Be mindful of any warning signs (worsening pain, pus, halos) and report them immediately. With these precautions – along with simple aids like stool softeners, sunglasses, hydration reminders, and reachers – you can support a smooth recovery and protect your vision. Always ask your surgeon or nurse if you have questions; good communication and safe habits are key to getting back to full strength.... Continue reading at https://visualfieldtest.com/en/days-3-4-after-trabeculectomy-calming-inflammation-while-staying-mobileSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/how-does-the-preserflo-microshunt-stack-up-against-trabeculectomy-and-other-drainage-devicesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction For people with open-angle glaucoma, surgical options aim to lower intraocular pressure (IOP) by creating a new drainage pathway for eye fluid (aqueous humor). The traditional gold-standard surgery is trabeculectomy, a technique that creates a small hole under a scleral flap, forming a filtering bleb under the conjunctiva. In recent years, newer implants have emerged. These include tube shunts (Ahmed, Baerveldt, Molteno implants) that channel fluid from the front of the eye to a plate under the conjunctiva, and minimally-invasive glaucoma surgeries (MIGS) such as the XEN Gel Stent and PreserFlo MicroShunt. The PreserFlo MicroShunt (formerly InnFocus MicroShunt) is a small, ab-externally implanted glaucoma device made of a soft polymer (poly(styrene-block-isobutylene-block-styrene), or SIBS). It drains fluid from the anterior chamber into a posterior subconjunctival bleb. This device is meant to be less invasive than trabeculectomy yet more effective than purely bleb-less MIGS. In this review, we compare PreserFlo to trabeculectomy and other drainage devices (Ahmed valve, Baerveldt and Molteno implants, XEN stent) in terms of how they work, clinical effectiveness, safety, practical use, and current access/cost issues. We use evidence from published trials and registries. When we report results, we note sample sizes and study years. If data are limited or mixed, we say so. Key findings are summarized in the concluding table. Background and Mechanism PreserFlo MicroShunt: The PreserFlo device is an 8.5 mm long tube with a 350 µm outer diameter and a very narrow 70 µm inner lumen (). It is made of SIBS, a biocompatible polymer that resists biodegradation (). The surgeon opens a small conjunctival/Tenon’s flap (much like for trabeculectomy) and uses mitomycin-C (an antifibrotic) under the flap. The MicroShunt is inserted ab externo: a tiny pocket is made in the sclera to accept the device fins, and a tunnel is made into the anterior chamber. The proximal tip sits inside the eye (just anterior to the iris) and the distal end drains fluid beneath the conjunctiva (see image below). Because the lumen is very small, it provides some flow resistance to help prevent severe postoperative hypotony (very low pressure). () Figure: The PreserFlo MicroShunt (red arrow) shunts aqueous humor from the anterior chamber (right) to a bleb under the conjunctiva (left) (). Trabeculectomy: In trabeculectomy, the surgeon creates a scleral flap and manually makes an opening under it (sometimes removing a small piece of iris) to connect the anterior chamber to the subconjunctival space. This creates a bleb. Mitomycin-C is often applied. Trabeculectomy is highly effective at lowering IOP, but it is invasive: it requires extensive dissection, sutures, and careful postoperative management. Tube Shunts (Ahmed, Baerveldt, Molteno): These are aqueous drainage implants. A silicone tube is inserted through the sclera into the anterior chamber. The tube drains fluid to a plate placed under the conjunctiva. The Ahmed Glaucoma Valve (AGV) includes a one-way valve designed to prevent early hypotony. The Baerveldt implant (typically 350 mm² plate) and Molteno implant (typically 275–350 mm²) are non-valved; surgeons ligate or occlude the tube temporarily to prevent immediate overdrainage. In general, valved shunts (Ahmed) cause less early hypotony but may end up at slightly higher pressures, while large non-valved shunts (Baerveldt, Molteno) can achieve lower long-term IOP but risk early overdrainage if not carefully tied off. XEN Gel Stent: The XEN 45 is a soft, gelatin-based 6 mm tube with a 45 µm lumen. It is implanted ab interno (from inside the eye) through a small corneal incision. It also drains to a subconjunctival bleb. No scleral dissection or removable flap is needed – only a gentle subconjunctival elevation of conjunctiva is done and mitomycin-C is often injected under the conjunctiva. Because the XEN lumen is slightly larger than the aqueous outflow resistance of normal trabecular pathways, it provides a controlled flow (and 45 µm lumen is internally limiting flow to avoid hypotony). However, like PreserFlo, it relies on bleb formation and often requires postoperative management (needling) of the bleb. MIGS vs Traditional Spectrum: Surgical options range from classic filtration surgery (trabeculectomy/tubes) at one end to ab interno MIGS at the other. MIGS are generally defined as procedures with an ab interno approach, minimal tissue trauma, faster recovery, and a good safety profile (). Examples of ab interno MIGS that do not form a bleb include stents in Schlemm’s canal (iStent, Hydrus) or suprachoroidal devices. PreserFlo, XEN, and older shunts are unique because they do create a bleb. These “bleb-forming MIGS” are sometimes considered intermediate: they are less invasive than trabeculectomy (especially XEN, which is minimally dissected) but not as simple as trabecular bypass stents. In practice, PreserFlo and XEN are often lumped into the MIGS group (despite ab externo steps in PreserFlo’s case) because they aim to reduce invasiveness and management burden. Efficacy Outcomes IOP Reduction and Success Rates: Clinical studies show that PreserFlo consistently reduces IOP into the mid-teens. In Baker et al. (2021), a large randomized trial of 527 eyes (395 PreserFlo, 132 trab) reported one-year IOP falls from 21.1±4.9 to 14.3±4.3 mmHg (–29% from baseline) after MicroShunt, versus 21.1±5.0 to 11.1±4.3 mmHg (–45%) after trabeculectomy (). Corresponding mean glaucoma medications dropped from 3.1 to 0.6 in the PreserFlo group and 3.0 to 0.3 in the trab group (). By Baker’s success criteria (≥20% IOP reduction without more meds), 53.9% of PreserFlo eyes and 72.7% of trabeculectomy eyes “succeeded” at 1 year (P<0.01) (). This shows that trabeculectomy gave a somewhat larger pressure drop and higher success per this definition. A single-center prospective study by Fili et al. (2022) also compared PreserFlo (150 eyes) vs trabeculectomy (150 eyes) in moderate-to-advanced glaucoma. At 12 months, 81.3% of MicroShunt eyes and 94.0% of trabeculectomy eyes achieved >20% IOP reduction without medications (). Mean IOP at 1 year was 12.9±3.4 mmHg (PreserFlo) and 11.4±4.5 mmHg (trab) (). Medications fell from ~2.5 to 0.4 in the PreserFlo group and to 0 in the trab group (). These results again favor trabeculectomy for lower final IOP, though both groups reached low teens pressures. Other PreserFlo series report similar IOP control. For example, Beckers et al. (2022) studied 81 eyes with PreserFlo at 2 years. Mean IOP fell from 21.7±3.4 mmHg at baseline to 14.5±4.6 mmHg at 1 year and 14.1±3.2 mmHg at 2 years (P<0.0001) (). Overall success (with or without meds) was 74.1% at 1 year (). Medications dropped from 2.1 to 0.5 (mean) by 2 years, with 73.8% of patients medication-free (). In their study, higher mitomycin-C (0.4 mg/ml) trended toward better pressure and med reduction than 0.2 mg/ml (). PreserFlo vs XEN: Available data suggest similar efficacy between these two bleb-based MIGS. In a 2-year comparative series, Scheres et al. (2022) found that mean IOP dropped from 20.1 to 12.1 mmHg (PreserFlo) and from 19.2 to 13.8 mmHg (XEN) at 2 years (p=0.19) (). The probability of “qualified success” (achieving target IOP with or without meds) was 79% for PreserFlo vs 73% for XEN at 24 months (). Both groups had substantial medication reduction. Thus, in this series the two devices gave nearly equivalent pressure outcomes. PreserFlo vs Tube Shunts (Ahmed/Baerveldt): There are no head-to-head trials of PreserFlo versus tube implants. For context, device trials provide a ballpark: The Ahmed vs Baerveldt ABC Study showed at 1 year mean IOP ~15.4 mmHg with Ahmed vs 13.2 mmHg with Baerveldt when starting from 31 mmHg (). Both used adjunctive medications. These results imply that large plate tube shunts can achieve very low pressures (down to ~13 mmHg) often slightly lower than PreserFlo’s typical outcome (low teens). On the other hand, tubes carry more serious surgery for difficult cases. In practice, PreserFlo tends to be used in mild-to-moderate glaucoma; Ahmed/Baerveldt in refractory or severe cases. Longer-Term Durability: Prestigious controlled data (like Baker et al.) reported only 1-year results so far. Longer follow-up is still needed. In the Beckers 2-year series, PreserFlo pressure control was sustained at ~14 mmHg through 2 years (). Fili’s study was only 1 year. The Scheres XEN vs PreserFlo study also had 2-year data (). Notably, Baker’s trial is designed for 2 years (NCT01881425), and longer-term data should clarify durability of the MicroShunt vs trabecular outcomes. Safety and Complications Hypotony (Low IOP): Shunt surgeries often have early postoperative hypotony. In Baker et al., transient IOP ≤5 mmHg occurred in 28.9% of PreserFlo eyes versus 49.6% of trabeculectomy eyes (P<0.01) (). Thus, while PreserFlo had less frequent shallow pressure than trab, more than a quarter of eyes did have an IOP hump to ≤5 mmHg after MicroShunt. Serious hypotony-related complications (maculopathy or required reformation) weSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/lowering-eye-pressure-the-lumigan-vs-roclanda-showdownTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Lowering Eye Pressure: The Lumigan vs Roclanda Showdown Open-angle glaucoma and ocular hypertension are conditions where intraocular pressure (IOP) is higher than normal, threatening vision. Eye drops that reduce IOP are the first-line defense. In this “showdown,” we compare Lumigan (brand of bimatoprost) and Roclanda (called Rocklatan in the US, a fixed-dose combo of latanoprost + netarsudil) – explaining how each works, how well it lowers pressure, side effects, dosing, cost, and which patients might benefit most. Mechanism of Action The two drops work differently. Lumigan (bimatoprost) is a prostaglandin analogue. Prostaglandin analogues act mainly by increasing the drainage of fluid out of the eye (especially via the uveoscleral outflow pathway). Bimatoprost is converted in the eye to a form that boosts outflow of aqueous humor, reducing pressure. For example, laboratory studies show bimatoprost lowers resistance in the trabecular meshwork by about 26% (). Clinically, bimatoprost and other prostaglandins (like latanoprost) share this main effect: more fluid drain leads to lower IOP () (). Roclanda (latanoprost + netarsudil) combines two actions. The latanoprost part is another prostaglandin, working like bimatoprost to improve outflow. On top of that, netarsudil is a Rho kinase (ROCK) inhibitor – a different class. Netarsudil’s unique action is to relax the eye’s conventional drainage meshwork (trabecular meshwork) and lower the pressure needed to push fluid out. It also has secondary effects: it can reduce pressure in the episcleral veins and even slightly reduce fluid production (). In short, while both drugs share the prostaglandin mechanism (increasing uveoscleral drainage ()), netarsudil adds a tug at the trabecular outflow route and venous side of things (). Efficacy Clinical trials show both Lumigan and the netarsudil/latanoprost combo can dramatically lower IOP, but the combo generally drops pressure further than latanoprost alone (and thus more than a single prostaglandin alone). Lumigan monotherapy typically reduces IOP by a large percentage. In trials of bimatoprost 0.03%, average drops of about 6–8 mmHg (roughly 25–35%) from baseline were seen (). For example, one analysis noted an average reduction around 7.7 mmHg. This means from a starting IOP in the mid-20s, many patients on Lumigan drop into the high teens. In fact, bimatoprost has consistently shown strong pressure-lowering: multiple studies and meta-analyses found it often lowers IOP slightly more than other prostaglandins like latanoprost (). For Roclanda/Rocklatan (netarsudil+latanoprost), phase-3 trials (the MERCURY studies) found even bigger drops compared to each drug alone. In those trials, adding netarsudil to latanoprost produced an extra 1.5–3 mmHg reduction in IOP beyond latanoprost alone (). In concrete terms, patients on the combination averaged IOPs around 15–16 mmHg at follow-up, compared to about 17–18 mmHg on latanoprost alone () (). Notably, at 3 months one study reported 42% of patients on the combo hit a mean pressure ≤15 mmHg, while only about 16–18% did so on latanoprost or netarsudil alone (). In pooled analyses, Roclanda patients had mean daytime IOP ~15–16 mmHg versus ~17–18 mmHg on latanoprost alone (). There are no direct head-to-head trials comparing Lumigan vs the netarsudil/latanoprost combo. (The recent MERCURY-3 trial compared the combo to bimatoprost/timolol rather than bimatoprost alone.) Thus we rely on separate data: prostaglandin drops like Lumigan give a strong single-agent effect, while the fixed combo can add on extra pressure reduction for those needing it. The combined drug is designed for patients not at target on a prostaglandin alone (). Side Effects and Tolerability Side effects of these drops are mostly well-known ocular reactions. Prostaglandin analogues (Lumigan’s bimatoprost and Roclanda’s latanoprost) commonly cause mild eye redness (conjunctival hyperemia), longer or thicker eyelashes, and gradual darkening of the iris color and surrounding skin () (). These changes come from the drug’s pharmacology – for example, Lumigan’s prescribing information notes pigmentation changes (iris, eyelid, lashes) and eyelash growth (). In practice, redness on Lumigan 0.01% affects about 30% of patients (); a higher 0.03% dose had more. Eyelash growth and iris darkening are not dangerous and can even be cosmetically welcome (they gave rise to Latisse eyelash formulation). However, the pigmentation changes tend to be permanent, and some patients dislike puffiness or deepening of the eye folds (“sunken eyes”) seen with prostaglandins. Overall, prostaglandin side effects are usually mild-to-moderate, but they lead many patients to notice their eyes look a bit different () (). Netarsudil, by contrast, has a distinctive side-effect profile. The most common issue is also redness – in fact, even higher than with prostaglandins. Clinical data report redness in over 50% of netarsudil-treated eyes () (). Netarsudil can also cause conjunctival hemorrhages (tiny red blood spots on the white of the eye) and corneal verticillata (whorl-like deposits on the cornea) in up to 10–20% of patients () (). For example, Rhopressa’s label notes ~53% hyperemia and about 20% cornea deposits or hemmorhages (). In Rocklatan trials, about 59% of combo patients had some hyperemia, and 11% had conjunctival bleeding and 15% had corneal deposits () (). Latanoprost’s own side effects (modest pigment/lash changes) can add to this but are relatively minor compared to the big difference in redness between netarsudil vs prostaglandin. In summary, Lumigan’s typical adverse effects: Eye redness (hyperemia) – very common (~31% on 0.01% ()). Eyelash and eyelid changes (growth, darkening) and possible eyelid fat loss () (). Iris color darkening (permanent) (). Roclanda’s common adverse effects (netarsudil + latanoprost): Hyperemia/redness – very common (~54–59% in trials) () (). Subconjunctival hemorrhage (small eye bleeds) – ~11% (). Corneal verticillata (deposits) – ~15% (). Eyelash or pigmentation changes (from the latanoprost) – generally milder than with bimatoprost. These side effects affect tolerability. In practice, up to ~40–45% of patients on a prostaglandin drop report some adverse event (), and redness is often the main complaint. The higher redness rate with netarsudil combinations can be uncomfortable – many patients describe mild stinging or a “bloodshot” eye that typically fades over time () (). Such effects do influence real-world use: patients bothered by redness or irritation may skip doses or switch drugs. (Interestingly, in the netarsudil vs latanoprost studies, some reported the red-eye of netarsudil tended to decrease after a month of nightly dosing.) Both drugs are usually given at bedtime in part to minimize noticing these effects during waking hours. Dosing and Convenience Both Lumigan and Roclanda are simple once-daily drops (usually one drop in the affected eye(s) each evening) () (). Lumigan 0.01–0.03% is instilled nightly, as is Rocklatan (netarsudil 0.02%/latanoprost 0.005%) () (). So neither requires multiple doses per day. A convenience point: Roclanda provides two active ingredients in one bottle. If a patient needs both a prostaglandin and netarsudil, using the fixed combo means only one dropper instead of two separate bottles. (For example, someone already on latanoprost who adds netarsudil could use Rocklatan and simplify their regimen.) By contrast, if a patient on Lumigan needs extra therapy, they would typically add a second bottle (another drug). The single-bottle combination can improve adherence for some patients by reducing the number of separate medications to juggle. Cost, Availability, and Approval Lumigan (bimatoprost) is a well-established medication. In the US it was originally approved in 2001 () (as 0.03%, and later 0.01%) and has parent-patent expiration spun off generics. Generic versions of bimatoprost 0.01% were approved around 2025 (). In practice, generic bimatoprost drops are now widely available, making this therapy relatively inexpensive with insurance or discount programs. (By contrast, the brand Lumigan without insurance can cost hundreds of dollars for a bottle, though coupons often reduce this.) Roclanda (latanoprost/netarsudil) is newer. The European Medicines Agency (EMA) gave approval in January 2021 (); it is marketed in the US as Rocklatan (FDA approval 2019). As a brand-name combination, it is pricier. There are currently no generic versions of the netarsudil/latanoprost combo; netarsudil itself is proprietary. Without insurance, Rocklatan’s cost is several hundred dollars for a month’s supply. Many insurance plans require patients to try simpler therapy first (for example, requiring failure of a prostaglandin drop before covering the combo). Regional differences apply: in Europe, Roclanda would be covered by national health systems similarly to other second-line glaucoma meds. Ideal Patient Profiles Lumigan (bimatoprost monotherapy) is often used as a first-choice eye drop for open-angle glaucoma or ocular hypertension () because it’s very effective and simple. It suits a patient whose target IOP is modesSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/glaucoma-drainage-implants-in-midlife-decoding-the-long-term-success-ratesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Glaucoma Drainage Implants in Midlife: Decoding the Long-Term Success Rates Glaucoma drainage implants – also called aqueous shunts or tube shunts – are filters placed in the eye to lower pressure by draining excess fluid. They are often used when standard surgery (trabeculectomy) is unlikely to succeed or has already failed. Common devices include the Ahmed Glaucoma Valve (a valved implant), the Baerveldt Glaucoma Implant (a larger, non-valved plate), and the older Molteno implant. Newer minimally invasive options (like the XEN stent or PreserFlo micro-shunt) exist, but they are generally for milder cases and have less long-term data. Trabeculectomy is the “classic” glaucoma surgery that creates a new drain in the eye without a device. A thin flap is made and often treated with an agent (mitomycin C) to prevent scarring. By contrast, a tube implant has an artificial tube leading to a small reservoir (plate) under the eye’s surface. In effect, both aim to create a “bleb” (a drainage pocket) but trabeculectomy relies on the body’s tissues alone, whereas a tube shunt uses foreign material. Each approach has pros and cons. Tubes usually are chosen when trabeculectomy may fail (for example, if the conjunctiva is scarred or in some secondary glaucomas). Studies often compare tube shunts versus trabeculectomy head-to-head because both lower pressure but with different mechanisms and healing tendencies () (). Defining Success and Failure How do researchers judge “success” after glaucoma surgery? There is no single definition, so results can look different across studies. In general: Complete success means the eye pressure is controlled without any glaucoma medications and remains in a safe range (for example, ≤21 mmHg, often with at least a 20% drop from baseline). We measure pressure with IOP (intraocular pressure). The exact target varies (some studies use ≤18 mmHg, some ≤21 mmHg, for instance) (). Common practice is to say IOP in the mid-teens or below is a success if it’s stable. Qualified success allows glaucoma medicines. In this case the IOP is still in the target range, but the patient is using eye drops or pills in addition to the surgery. Failure is defined when the pressure is too high (above the chosen cutoff) or not lowered enough (less than the required percentage drop), or if another glaucoma procedure becomes necessary. Some definitions also count vision loss (e.g. loss of light perception) or serious complications (like uncontrollable hypotony) as failure. In short, failure generally means the surgery did not solve the problem on its own (). Because different researchers pick different pressure goals, success rates can’t be compared directly unless the definitions match (). For example, some trials counted any IOP up to 21 mmHg as success, while others needed ≤18 mmHg. It is important to note whether a reported “success rate” was complete (no meds) or qualified (with meds). Many papers report both when data is available. Long-Term Outcomes: What Do the Numbers Show? Tube Shunts vs. Trabeculectomy (TVT Study) The landmark Tube Versus Trabeculectomy (TVT) Study was a randomized trial that followed patients for 5 years () (). It compared the Baerveldt tube (350 mm² plate) to trabeculectomy with mitomycin. Key findings at 5 years (212 eyes) were: Pressure control: Both groups had similar final IOP (around mid-teens), and a similar drop in medication use (). Success (no failure) rate: 70.2% in the tube group versus 53.1% in the trabeculectomy group at 5 years (). In other words, failure (meeting failure criteria) had occurred in 29.8% of tubes and 46.9% of trab outcomes (P=0.002), showing tubes held pressure more reliably over time. Reoperation: Additional glaucoma surgery was needed much less often in the tube group (9% versus 29% in the trabeculectomy group at 5 years) (). These results suggest that after 5 years, a tube shunt was more likely to maintain target pressure than trabeculectomy in this study (for eyes that had prior cataract or trab surgery history). The IOP reduction achieved by both surgeries was similar, but trabeculectomy more often required repeat surgery. Even at 3 years of follow-up, the study showed cumulative failure rates of 15.1% for tubes versus 30.7% for trabeculectomy () (i.e., 84.9% vs 69.3% success at 3 years). In practical terms, the TVT study implies that about 30–40% of tube shunts may fail or need reoperation within 5 years, whereas trabeculectomy failure was around 47% in that timeframe () (). (Note: failure here includes not only high pressure but also tube removal, vision loss, or need for more surgery.) The pattern seen was about a 5% failure per year for tubes (), so roughly half survive at 10 years (see below). Ahmed Valve vs. Baerveldt Implant (AVB and ABC Studies) Several trials have directly compared the Ahmed valve (Ahmed-FP7) to the Baerveldt implant (BGI). Both designs are common, and understanding their long-term outcomes is important. Briefly: Ahmed FP7 has a built-in valve that resists very low pressure (so-called “flow-restricting valve”). It often lowers IOP quickly but may allow higher long-term pressures. Baerveldt (non-valved) relies on a temporary ligature (until tissue capsule forms). It can achieve lower pressures but sometimes carries a small risk of low-pressure complications (hypotony) once the ligature dissolves. Key study findings at 3 and 5 years (several hundred eyes combined): Three-year outcomes: The AVB (Ahmed vs Baerveldt) Study reported that at 3 years the cumulative failure rate was 51% with Ahmed vs 34% with Baerveldt (P=0.03) (). Mean IOP was slightly lower in Baerveldt eyes (14.4 mmHg) than Ahmed (15.7 mmHg), and Baerveldt eyes needed fewer medications (1.1 vs 1.8, P=0.002) (). Complication rates were similar, though hypotony-related issues were more common with Baerveldt. Five-year outcomes (ADB study): In a later five-year report, the AVB trial showed 5-year failure of 53% with Ahmed and 40% with Baerveldt (significantly favoring Baerveldt, P=0.04) (). The average IOP at 5 years was 16.6 mmHg (Ahmed) vs 13.6 mmHg (Baerveldt), and final medication use was 1.8 vs 1.2 drops (). Hypotony failures were 0% in Ahmed vs 4% in Baerveldt (since only the non-valved can over-drain) (). Five-year outcomes (ABC study): The ABC (Ahmed-Baerveldt Comparison) Study (a different multicenter trial) found a 5-year failure rate of 44.7% (Ahmed) vs 39.4% (Baerveldt) (not statistically different, P=0.65) (). At 5 years the IOP was 14.7 mmHg (Ahmed) vs 12.7 mmHg (Baerveldt), with about 2.2 vs 1.8 medications (). Putting it together, most trials show moderately better control with the Baerveldt implant. Roughly half of Ahmed valves and about 40% of Baerveldt implants may fail by 5 years () (), meaning about half are still successful at that point. The differences aren’t enormous, but generally Baerveldt tends to reach lower pressures and needs slightly fewer pills, at the cost of a little more risk of very low pressure. Overall success rates (complete or qualified) at 5 years are on the order of 45–60% depending on the study and definition () (). (For example, if failure is 40%, success is 60%.) Other Implants The Molteno implant is an older design (non-valved). Long-term data is sparser, but historical series suggest intermediate success rates (roughly similar ballpark as Baerveldt). Since its design is similar to Baerveldt (just smaller plate per stage), we treat it similarly but it is not commonly used today. Newer minimally invasive implants (e.g. XEN gel stent, PreserFlo MicroShunt) are smaller tubes placed via ab interno approach. These have been marketed in the last decade but have less long-term evidence. Early results indicate they can lower IOP, but often not as much as traditional tubes, and they may still fail over time. For our purposes focused on long-term outcomes, the traditional Ahmed and Baerveldt implants provide the bulk of data. Age and Device Survival (Middle-age vs Older Patients) Age can influence healing. Younger eyes tend to heal more vigorously and scar more, which can cause drainage surgery to fail sooner. Indeed, analyses from large trials confirm younger age is a risk factor for failure of tube shunts. In a pooled study of hundreds of patients from major trials (TVT, AVB, ABC), each 10-year decrease in age raised failure risk by about 19% (). In simpler terms, for example, a 50-year-old tended to have better success than a 40-year-old with the same surgery. This mirrors findings in trabeculectomy: younger patients generally scar faster, undermining the bleb. However, most published trials have mean ages in the 60s or higher. There is very little data specifically on 35–55 year olds. We extrapolate from the broader studies. Overall, middle-aged adults (e.g. 40-year-olds) may be somewhat more prone to failure than the typical study participant (who might be retired and in their 70s). But the exact drop in success isn’t sorted out in age “subgroups” in the literature. Clinically, surgeons worry that a 40-year-old’s robust healing will encapsulate the plate sooner, so we tend to expect somewhat lower long-term success in mid-life thSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-hidden-eye-risk-in-athletes-understanding-pigment-dispersion-syndrome-and-pigmentary-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Imagine running a race and later noticing rainbow-­like halos around lights, a brief blurring of vision, or a dull ache in your eyes. For most people this would sound alarming – yet such symptoms are often painless and temporary in a hidden condition called Pigment Dispersion Syndrome (PDS). PDS tends to strike healthy, young, myopic (nearsighted) adults, especially men in their 20s–40s. These individuals are often active and otherwise feel fine. Yet their eyes carry a concealed risk: tiny dust-like pigment granules rubbing off the back of the iris and clogging the eye’s drainage system. Over time this can raise eye pressure and lead to Pigmentary Glaucoma (PG), a form of glaucomatous nerve damage. () (). This article dives deep into what PDS is, how it can progress, and what it means for athletes and fitness enthusiasts. We’ll explain the eye’s anatomy in plain language, give clear examples from real studies, and outline the latest evidence (up to 2026) on exercise and PDS. You’ll learn why PDS often feels “silent,” how doctors spot it, and – most importantly – how people with PDS/PG can safely stay active. What is Pigment Dispersion Syndrome? The Eye’s Pigment “Dust” The iris (the colored part of the eye) has a back layer called the iris pigment epithelium, rich in dark melanin granules. In a normal eye, these pigment cells stay put. In PDS, however, the iris is slightly bowed backward and rubs repeatedly against the lens zonules (tiny fibers holding the lens). This rubbing releases pigment particles into the eye’s fluid (the aqueous humor) () (). Reverse Pupillary Block: One big factor is a “reverse pupillary block” mechanism. Normally fluid flows from behind the iris, through the pupil, to the front of the eye and drains out. In PDS eyes, however, the iris bows back like a sail (often in myopic eyes with deep anterior chambers () ()). This can create a one-way “ball-valve” effect: fluid struggles to flow forward, causing pressure behind the iris and pushing the iris even more backward. This iris concavity greatly increases rubbing between the iris pigment and the underlying structures () (). The result is repeated bouts of pigment shedding – think of it like dust collecting on a car’s windshield wipers. Where Do the Pigments Go? Once free in the eye’s aqueous fluid, the pigment granules float around and deposit on various tissues in the front of the eye (). The most important deposit is in the trabecular meshwork (TM) – the eye’s drainage grate. Pigment accumulates in the meshwork, clogging it and reducing fluid outflow () (). Over time this backs up fluid and raises intraocular pressure (IOP). Other classic signs (often seen by doctors, not by patients) include: Krukenberg Spindle: A vertical spindle-shaped band of pigment on the central corneal endothelium (the inner lining of the clear cornea) (). Convection currents in the eye cause the pigment to line up like a spindle. Iris Trans-illumination Defects: The iris develops spoke-like, radial defects that look like little gaps in a wheel when light shines through (). These are where the iris pigment cells have been stripped away. Zentmayer (Scheie) Line: A line of pigment on the back surface of the lens equator (near the top/bottom of vision). Sampaolesi Line: Pigment just in front of the Schwalbe’s line (the edge of the drainage angle). Homogeneous Angle Pigmentation: On gonioscopic exam (special mirror view of the angle), the entire trabecular meshwork is stained darkly with pigment () (). These findings – pigment showering the cornea, iris defects, and a heavily pigmented drainage angle – form the classic triad of PDS/PG () (). > Analogy: Imagine your eye’s drainage as a sponge filter. Pigment granules are like fine sand tossing into the water you pour through. Over time, the sand clogs the sponge, slowing drainage (outflow) and causing pressure to build up behind the faucet. If the outflow obstruction is significant and chronic, eye pressure rises (ocular hypertension). When this pressure damages the optic nerve (seen as thinning of nerve fibers and vision field loss), it becomes Pigmentary Glaucoma (PG) () (). In the disease spectrum, PDS is the early stage (pigment release and high pressure risk) and PG is the later stage (actual glaucoma damage) (). PDS to Pigmentary Glaucoma: Risk and Progression How Likely is PDS to Become Glaucoma? Fortunately, most people with PDS do not immediately go blind. Estimates vary, but current evidence suggests only a subset progress to true glaucoma. In clinic-based studies, about 10–50% of PDS patients eventually develop PG () (). A recent 2026 review summarized one large observation: about 10% of PDS eyes converted to PG by 5 years, and 15% by 15 years (). Earlier reviews even cited up to 50%, but those older numbers likely come from biased samples (people already in eye clinics) () (). In the general population, progression is likely at the lower end of that range, roughly 10–20% over one or two decades () (). The key risk factors for progressing from PDS to glaucoma are well documented (): High Trabecular Pigment: Eyes with a very dark, crowded trabecular meshwork (seen on exam) are at greatest risk (the “filter is nearly plugged”). Elevated Pressure from the Start: Higher baseline IOP in a PDS eye means more stress on the nerve. Younger Age: Paradoxically, younger patients may have more vigorous pigment shedding, so PDS often appears in youth and can progress more quickly. Male Sex: Men with PDS convert more often than women () (). Myopia (Nearsightedness): Moderate myopes have deeper anterior chambers and more iris-lens contact, predisposing to PDS and PG () (). Race: PG is much more common in Caucasians than in darker-pigmented eyes () (). (Many African-American or Asian patients do not show the iris transillumination defects because their eyes produce less visible pigment release, though the risk patterns are less well studied outside white populations ().) Family History: A family history suggests a genetic susceptibility. Visible Signs: Detecting a Krukenberg spindle or other pigment signs in both eyes raises the odds that glaucoma may follow (). Chronicity: A longstanding PDS (multiple years) increases odds, as pigment has more time to accumulate. The European Glaucoma Society notes that overall PDS accounts for only about 1–1.5% of all glaucoma cases, underscoring that it’s a minority form of glaucoma () (). Nonetheless, for each PDS patient, vigilance is crucial. PG tends to affect a younger population (often diagnosed in the 30–50 year range () ()) and any vision loss at that age is significant, even if total blindness is rare (). > Statistics to Note: PDS appears in about 1–2% of people (), whereas typical open-angle glaucoma is 3–4% in older adults. Of those with PDS, roughly 10–20% may develop glaucoma over time () (). There is also an age-related “burn-out” phenomenon described: as patients grow older (past 50–60), the iris often becomes less concave and sheds less pigment () (). This means PDS may slow or even abate with age. Studies have observed that older PDS patients tend to have lower IOP and slower progression (). However, any nerve damage already done is permanent, so earlier cases must be managed proactively. The Exercise Connection: What Does the Research Say? Jogging and Jumping: Triggering Pigment Release A striking theme in PDS research is the effect of physical activity. Since the 1980s, doctors have noted that jarring or high-impact exercise can provoke pigment showers and IOP spikes in PDS eyes. In a classic 1992 study, Haynes et al. had 14 PDS patients, 10 PG patients, and 10 healthy controls all do 45 minutes of jogging. They found that eyes with PDS/PG were significantly more likely to spit out pigment into the front chamber after exercise, compared to controls (). Some PDS eyes had suddenly clouded aqueous with pigment granules immediately post-run. The pressure often rose as a result, though in that small study it was modest. Interestingly, eyes on the miotic drug pilocarpine (which constricts pupils and pulls the iris taut) showed much less pigment release: in fact, pre-treatment with pilocarpine “appeared to inhibit exercise-induced pigment dispersion” (). Based on these findings, the authors concluded that not all PDS patients need to avoid exercise, but anyone who jogs or does similarly strenuous activity should get checked before and after. If heavy pigment release occurs, one strategy is starting pilocarpine drops rather than giving up the exercise (). Earlier, in 1980, Schenker et al. reported two cases of PDS patients who each had sudden painful IOP spikes after vigorous exercise (in one case, heavy lifting triggered a painful “attack” ()). These were isolated case reports, but they raised the alarm that exercise can aggravate PDS. In the late 1980s, a larger study by Smith et al. deliberately tested exercise in 10 PG patients using movements meant to jostle the lens-iris. Surprisingly, on average these glaucoma patients did not show a significant IOP rise over the two hours after exercise (). Only 2 eyes (out of 100+) had a 6–7 mmHg spike at 15 minutes, which then fell back to baseline bySupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/patient-reported-outcomes-and-quality-of-life-after-glaucoma-proceduresTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Patient-Reported Outcome Instruments in Glaucoma Surgery Glaucoma surgery can lower eye pressure and slow vision loss, but patients care most about how their vision and daily life feel afterward. Patient-reported outcomes (PROs) capture what matters to patients – for example, how well they see, whether their eyes feel dry or irritated, and how easy it is to manage treatment. To understand these effects, researchers use questionnaires and surveys. Common vision-related questionnaires include the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and glaucoma-specific tools like the Glaucoma Quality of Life-15 (GQL-15), which ask about difficulty with reading, driving, and performing everyday tasks (). Ocular surface symptoms (dryness, burning, grittiness) are often measured with tools such as the Ocular Surface Disease Index (OSDI) (). Treatment burden and convenience can be assessed by treatment satisfaction surveys (for example, the Treatment Satisfaction Survey for Intraocular Pressure or newer instruments like the Allergan Satisfaction with Treatment Experience Questionnaire), and some glaucoma-specific instruments now include “treatment convenience” or “ocular comfort” domains (). For instance, an adaptive GlaucomaCAT tool (GlauCAT) measures 12 domains of glaucoma quality-of-life, including visual symptoms, ocular comfort, and general convenience () (). These validated PROMs ensure we listen to patients’ perspectives after surgery. Quality of Life After Different Glaucoma Surgeries Glaucoma procedures vary widely in their effectiveness and recovery, and this shows up in patient-reported outcomes. Minimally invasive glaucoma surgeries (MIGS), often done at the same time as cataract surgery, tend to have a modest pressure-lowering effect but a gentle recovery. For example, one study of patients receiving combined cataract surgery plus a MIGS device (Hydrus or iStent) found significant improvements in patient-reported visual symptoms, ocular comfort, and general convenience (). These patients also used fewer glaucoma eye drops after surgery (an average drop count fell from about 1.8 to 1.1) and showed better tear-film tests on exam (). In other words, by relieving pressure and clearing the vision (from the cataract removal), MIGS patients reported better vision-related quality of life and fewer symptoms of dry or irritated eyes () (). In contrast, traditional filtering surgeries – trabeculectomy (making a new drainage channel) and glaucoma drainage implants (tube shunts) – usually achieve greater pressure reduction and bigger drops in medication. These bring their own trade-offs. Trabeculectomy often eliminates or greatly reduces the need for daily eye drops, but it involves a longer healing course and possible side effects (e.g. low pressure, bleb management). A large UK trial (TAGS) found that two years after surgery, patients who had trabeculectomy used about 1 drop per day on average, versus about 1.6 drops in patients managed with medications only () (). However, the same trial showed no significant difference in overall vision-specific quality of life (NEI VFQ-25 scores) between the surgical and medical groups up to 24 months (). In clinical practice and smaller studies, patients who undergo trabeculectomy often report more eye irritation (redness, foreign body sensation) and longer periods of blurred vision than those having MIGS or simpler procedures. For example, one study found that about 1–2 weeks after trabeculectomy many patients still needed patching or activity restrictions, and vision could remain blurry for up to 6 weeks () (). Comparisons among surgeries have shown meaningful differences. In one quality-of-life survey comparing trabeculectomy vs. non-penetrating canaloplasty, canaloplasty patients reported higher overall satisfaction and mood, and far fewer non-visual symptoms (like glare, burning, or stinging) than trabeculectomy patients (). Importantly, daily activities (reading, driving, socializing) were much less disrupted after canaloplasty; patients rated interference almost nonexistent, while trabeculectomy patients often needed longer recovery (). A small study of MIGS vs trabeculectomy found no significant difference in quality-of-life scores at 6 months (), but the trabeculectomy group did achieve lower pressures and larger medication drops. Glaucoma drainage implants (tubes) have a different PRO profile. Patients typically experience a slower functional recovery and more discomfort than trabeculectomy patients. One study using daily diaries reported that tube shunt implantations caused greater short-term post-op difficulty than trabeculectomy, and both glaucoma surgeries had a slower recovery of function over the following weeks compared to routine cataract surgery (). Tube patients often continue some drops afterward and may worry more about future surgeries, but objective QoL measures (NEI VFQ-25) tend to be similar between trabeculectomy and tube in cross-sectional studies (). In summary, MIGS tend to give patients a quicker, more comfortable recovery with fewer symptoms (especially when combined with cataract surgery), at the cost of somewhat less dramatic pressure lowering. Trabeculectomy and tube shunts offer powerful pressure control and often eliminate eye drops, but with longer downtime, monitoring, and more eye irritation in the short term () (). Canaloplasty provides good pressure control with a very patient-friendly profile (no bleb, minimal symptoms) (). These differences in recovery and comfort are important for patients to understand when choosing a surgery. Linking Clinical Outcomes with Patient Experience Clinical measures (eye pressure, visual acuity, visual field tests) do not tell the whole story of how patients feel. Several studies have explicitly linked patient-reported outcomes to these clinical changes. For example, after MIGS with cataract surgery, improvements in patient-reported visual symptoms and ocular comfort were driven largely by measurable gains – specifically, the better eye’s visual acuity (from the cataract removal) and lower intraocular pressure () (). In other words, when the cataract was cleared and pressure came down, patients reported less blur and dryness. Even so, recovery of daily function (answering how soon patients can read or drive) can’t be fully predicted by vision or pain alone. In a study tracking daily recovery, researchers found that after cataract, trabeculectomy, or tube surgery, early post-op vision and pain only partly explained how patients rated their functional ability (). (Patients still felt limited in activity even when acuity had returned or pain was gone.) This implies that asking patients directly about their daily activities is crucial – it uncovers issues that eye charts and pressure gauges miss. For shared decision-making, clinicians should discuss outcomes that matter most to patients. Qualitative studies consistently show patients care about practical vision goals – being able to drive, read fine print, see at night – and about treatment burden (how many drops they must use, eye discomfort from medications or surgery) () (). For instance, in interviews patients often spontaneously mentioned that continued need for eye drops was inconvenient and that they feared not being able to read or see well while driving at night. These patient-derived priorities suggest that, when choosing a surgery, doctors should explain not just the expected pressure drop but also how vision for daily tasks and comfort in the eyes are likely to improve. For example: “MIGS plus cataract surgery may not lower pressure as much as trabeculectomy, but it often clears up vision from the cataract and lets people use fewer drops () (). Trabeculectomy might mean months of careful follow-up (patches, adjustments) but can eliminate most medications () (). Together, patients and doctors can weigh these trade-offs based on what the patient values: medication freedom, clear vision, fast recovery, or maximal pressure drops.” Gaps in Long-Term PRO Data and Future Directions Despite growing interest, long-term patient-reported data on glaucoma surgeries are still limited. Many studies follow patients only a few months after surgery. For example, recent data on MIGS quality-of-life improvements typically extend only 6–12 months follow-up (). Longer-term outcomes (years after surgery) are largely unknown. It will be important to study whether early PRO gains – like improved comfort and independence – persist over time, and how they relate to maintaining vision years later. Another gap is consistency of measurement. There is no single standard PRO instrument for glaucoma surgery, and studies use a mix of general and disease-specific tools. New instruments like the GlauCAT (Computerized Adaptive Testing) show promise by covering many vision and comfort domains (), but they need more validation in diverse populations and different surgical contexts. Notably, most validated PROMs have been developed or tested in certain regions, so we need more data in underrepresented groups. Moreover, few randomized trials of glaucoma surgery include PROs as core endpoints. For example, MIGS trials focus on intraocular pressure and vSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-glaucoma-shunt-journey-what-to-expect-before-during-and-after-surgeryTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction: The “Why” and “What” Imagine your eye as a sink that constantly produces fluid. Normally, this fluid drains out through tiny channels to keep the pressure inside your eye (intraocular pressure) in a healthy range. In glaucoma, those channels are blocked or not working well, so pressure builds up and can damage your vision. To fix this, doctors sometimes install a tiny drainpipe called a glaucoma shunt (also known as a tube shunt or aqueous shunt) in your eye. Think of it like adding a safety valve or an extra drain in the sink to let fluid out. Kaiser Permanente’s health encyclopedia describes this as placing a small plastic tube with a miniature silicone pouch in the eye to help drain fluid (). Why would a doctor suggest this? Usually, tube shunt surgery is a backup plan when more common treatments aren’t enough. If eye drops and laser surgeries can’t lower your eye pressure, or if a prior surgery has scarred over, an ophthalmologist may recommend a shunt () (). Some cases of glaucoma are extra difficult – for example, when new blood vessels grow on the iris (neovascular glaucoma) or after earlier surgeries – and a drainage implant gives another way to control the pressure () (). Remember: the goal here is not to cure glaucoma or restore lost vision, but to prevent further damage by keeping pressure low () (). In short, a glaucoma shunt is a tiny drainage device for your eye, and doctors choose it when keeping pressure low is critical and other methods aren’t doing the job () (). Preparation: Getting Ready for Surgery What should you do before the big day? First, follow your doctor’s instructions on medications. Usually, you should keep taking your glaucoma eye drops and pills exactly as prescribed until they tell you to stop. Often they even add an extra drop regimen a few weeks before surgery to get ready. For example, a UK eye hospital leaflet advises patients to continue their glaucoma medications until the time of surgery, and tells them about using a new eye drop four times a day in the lead-up () (). If you’re on blood thinners (like aspirin, warfarin, or similar), discuss this with your surgeon. Many eye teams ask patients to stop these a week before surgery to reduce bleeding risk, but only if it’s safe for your overall health (). Don’t make this decision on your own – your eye doctor will coordinate with your GP or cardiologist. Your hospital or surgical center will send you fasting instructions (for example, “no food or drink after midnight”) if you’ll be under general anesthesia (). Wear comfortable clothes and don’t bring jewelry. Importantly, arrange a ride and a helper: you will not be able to drive yourself home. You’ll likely be sedated, so plan for an adult friend or family member to escort you. As Wills Eye Hospital notes, most patients get sedation or “twilight anesthesia” during surgery and will need an adult to drive them home afterward (). Lastly, take care of yourself mentally and physically: get a good night’s sleep before, eat healthy meals up to the permitted time, and try some deep breathing or light exercise (like a short walk) the day before. Having a loved one accompany you to the hospital can ease nerves, and knowing the steps ahead can give you confidence. When you’re well prepared – both practically (meds, ride, paperwork) and mentally – you help the whole process go smoothly. The Procedure: What Actually Happens So, what happens during the surgery itself? First, you’ll go to the operating room on the scheduled day. This is usually an outpatient procedure, meaning you can go home the same day () (). You’ll lie on the surgical bed and get either local anesthesia with sedation or general anesthesia. Local anesthesia means numbing drops and injections around the eye, often combined with IV sedation (“twilight anesthesia”) so you’re relaxed and sleepy. Sometimes, especially in certain clinics, full general anesthesia (going completely to sleep) is used. The Cure Glaucoma Foundation notes that most tube-shunt surgeries use numbing injections around the eye and sedation (). In either case, you’ll feel comfortable and should not feel pain. Once you’re numb and relaxed, your eye is cleaned and covered with a sterile drape, leaving only the eye exposed. A tiny speculum (a spring-loaded clip) holds your eyelids open, so you don’t have to worry about blinking (). At this point, you may notice a bright light in your vision. Wills Eye reassures that patients often see bright lights during the operation, but because of the numbing and sedation, you should not feel any pain (). You also shouldn’t feel the surgeon’s instruments moving around. Now for the main part: the surgeon creates a small incision in the white part of your eye (the sclera). They carefully insert one end of the silicone tube into the front chamber of your eye (usually just in front of the colored iris). The other end of the tube is attached to a small plate or reservoir that sits under the conjunctiva (the thin lining over the white of the eye) under your upper eyelid () (). The device is very tiny – about 0.6 mm in diameter – and usually made of silicone or plastic (). Once in place, fluid from inside the eye can drain out through the tube to collect around the plate, then slowly seep into the body’s natural tissues. Because it sits under your eyelid, you will not see it, and you won’t feel it either () (). Often, the surgeon partially ties or fills the tube at first to prevent too much fluid from escaping too quickly. The Dudley NHS leaflet explains that a special stitch (sometimes with a material called Supramid) is used to temporarily slow flow. The stitch can later be adjusted or dissolved as needed to balance the pressure (). The surgeon then closes up the tiny incision with dissolvable stitches, and covers the part of the tube outside your eye with a patch graft (often a thin piece of donor tissue or processed tissue) so it stays covered and secure (). Finally, an eye patch and a sturdy plastic shield are taped over your eye to protect it (). In total, the surgery usually takes a couple of hours. The Cure Glaucoma Foundation notes that the surgeon’s work is about an hour, but including prep and recovery process, expect to be at the surgery center for 3–4 hours (). When it’s all done, you’ll be moved to recovery. Remember: at no point should you feel pain. If you feel discomfort or pressure, the anesthesia team can give extra numbing or sedation. Right After Surgery: The First 24–48 Hours When you wake up in the recovery room, you may feel a bit groggy (especially if you had general anesthesia) or just calm and relaxed (if you had sedation). Nursing staff will be checking your blood pressure and pulse and can give you a pain pill if needed. After surgery, your eye will still be covered by an eye pad and a hard plastic shield (). Your vision in the operated eye will be blurry at first – it’s very normal. In fact, in the first day or two, vision can be worse than before surgery (). Most people only use their unaffected eye to see clearly until the new eye heals a bit. Your other eye will still have the old vision, so rely on it for seeing while the patched eye recovers. You might feel your eye is gritty or as if something (like an eyelash) is in it () (). This scratchy/foreign-body sensation is common. The eyelid might feel heavy from the patch, and your eye will likely be red. Your doctor has given you a shield to protect that eye – you should wear it, especially if lying down or walking around at home, to avoid accidentally rubbing or bumping it. Pain is usually mild, but everyone’s tolerance differs. Your eye may ache or throb a bit as the numbing wears off. Tylenol (acetaminophen) is often recommended for discomfort (). Take any pain meds as prescribed, and don’t hesitate to call your doctor for stronger pain relief if needed. If you experience severe pain or a sudden catastrophic loss of vision, contact your doctor immediately. But mild soreness and ache are expected, and they generally improve day by day. After surgery, doctors usually restart any eye drops or medicines needed. You’ve probably been given antibiotic drops (to prevent infection) and steroid drops (to reduce inflammation). The Cure Glaucoma guide confirms you will use prescription eye drops to prevent infection and calm swelling (). Use them exactly as directed – skipping drops can increase infection risk or scarring. Rest is key. Keep your head elevated (propped up on pillows) to reduce swelling. Avoid any activity that jolts or strains the eyes. In fact, nurses might suggest taking a laxative to avoid constipation and straining (because straining at the bathroom can push pressure up in your eyes) (). Your doctor may also recommend you wear the eye shield for a few nights while sleeping to prevent you from rolling onto the eye () (). Take it easy: lie back, watch TV or listen to music, and let others help you with tasks. You did a lot – give your eye time to start healing. Short-Term Expectations: The First Few Weeks Here’s what to expect as you move into the weeks after surgery: Vision. In the days following surgery, your vision will likely remain blurry. This is totally normal. A hurried eye doctor at Wills Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/targeting-very-low-iops-achieving-single-digit-pressures-safelyTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction In advanced glaucoma, doctors often set very low target pressures (often 10 mmHg or lower) to protect remaining vision () (). “Single-digit” pressures mean an eye pressure under 10 mmHg (normal pressure is 12–22 mmHg). Achieving such low pressure can slow or stop glaucoma damage, but requires strong surgery. This article explains the main surgical approaches—trabeculectomy with antimetabolites, tube shunts with flow restriction, and cyclodestruction—along with how doctors balance the benefits against risks like hypotony (too-low pressure) and vision problems. We will also cover what factors predict a surgery’s success or failure, how surgeons fine-tune eye pressure after surgery, and how to spot and treat complications early. Surgical Strategies to Achieve Low IOP Trabeculectomy with Tailored Antimetabolites Trabeculectomy (filtering surgery) creates a new drainage path for fluid (aqueous humor) to leave the eye under the eyelid. Surgeons remove a small piece of the eye’s internal drainage tissue (trabecular meshwork) and make a tiny hole into the white of the eye. A flap of tissue is sewn loosely over this opening so fluid can seep out gradually. As the fluid drains, it forms a bubble or “bleb” under the conjunctiva (the transparent tissue covering the eye). To keep this new drainage channel open long-term, surgeons often use antimetabolites (anti-scarring drugs) like mitomycin C (MMC) or 5-fluorouracil (5-FU) at the time of surgery. These drugs slow down healing so scar tissue doesn’t seal the flap shut. By carefully choosing the dose and duration of MMC, doctors can tailor how much drainage occurs. Stronger or longer MMC treatment generally increases the chance of a very low pressure, but also raises the risk of over-drainage. For example, using a high concentration of MMC (0.4 mg/ml for 4 minutes) led to hypotony (dangerously low pressure) in about 13% of cases (), whereas a lower dose (0.2 mg/ml) in a similar setting reduced that risk to 3–5% (). Modern techniques (such as injecting MMC under the conjunctiva instead of placing sponges) can achieve low pressures without excessively high hypotony rates (). Key points about trabeculectomy: It can often achieve mid-to-low single-digit pressures, especially in experienced hands () (). Surgeons use antimetabolites (usually MMC) to prevent scarring. Tuning the concentration and time of application helps find the balance between pressure lowering and safety (). The surgery can include adjustable or releasable sutures in the scleral flap. This means sutures (stitches) can be loosened or removed after surgery to increase drainage if IOP is still high, or they can be partially cut with a laser (suture lysis) if pressure is too low () (). Tube Shunts with Flow Restriction Glaucoma drainage devices (tube shunts) are small implants comprising a drainage tube and a plate. The tube is placed into the front chamber of the eye, and the plate sits under the conjunctiva on the outside. Fluid flows through the tube into a reservoir (the plate) where it is absorbed by surrounding tissues. Tube shunts are often used when previous surgeries have failed or in severe secondary glaucomas, but they can also achieve very low pressures when carefully managed. There are two main types of shunts: Valved shunts (e.g., Ahmed valve) have a built-in mechanism that partially blocks flow when pressure is low. This means they limit how low the pressure can drop automatically. Ahmed valves typically control pressure into the mid-teens. They often still require glaucoma drops after surgery. Because of the valve, deep hypotony is rare (), but extreme low targets (<10 mmHg) often need additional medications or procedures. Non-valved shunts (e.g., Baerveldt, Molteno) have no built-in valve, so by default they would drain too much fluid at first. To prevent early hypotony, surgeons temporarily occlude these tubes. The standard method is to tie (ligate) the tube shut with an absorbable suture (like 6-0 or 7-0 Vicryl) around the outside of the tube. Some also place an internal stent (a thick nylon thread called Supramid®) inside the tube. As time passes (weeks to months), the ligature dissolves or the stent is removed, gradually allowing fluid out. This staged approach yields very low pressures once the eye has formed a capsule around the plate. Flow restriction techniques for tube shunts: External ligature: Tying the tube with a dissolvable suture (typically Vicryl) prevents flow for the first 4–6 weeks until the ligature softens. Some surgeons leave multiple fine sutures inside or outside that can be cut with a laser in clinic to increase flow gradually later (). Internal stent: A nylon or prolene suture (3-0 “Supramid”) is placed inside the tube lumen. This blocks most flow but can be left protruding so it can be pulled out or lasered when needed (). Fenestrations: Some surgeons create tiny slits (“Sherwood slits”) in the tube before it enters the eye. These allow a small amount of fluid to bypass the ligature early on. Because non-valved shunts ultimately allow higher flow (once fully open), they can reach lower pressures than valves, but they require careful follow-up to adjust flow. For example, one technique is to tie a Baerveldt with a loose nylon suture (10-0) that provides just ~10% occlusion on top of the main ligature. In clinic, the physician can then use a laser to cut one nylon suture at a time and “stage” the drop in pressure (). Key points about tube shunts: Valved devices (Ahmed) limit extra-low pressures but are easier to control; they often result in moderate pressure (high-teens) and usually need glaucoma drops after surgery (). Non-valved devices (Baerveldt/Molteno) can achieve very low single-digit pressures after the occluding ligature dissolves, but require temporary blocking to keep pressure safe early on () (). Post-surgical adjustments (cutting sutures, pulling stents) allow fine-tuning of IOP without major surgery. Adjunctive Cyclodestruction Cyclodestructive procedures use energy (laser or ultrasound) to partially destroy the ciliary body – the tissue that produces aqueous fluid. By reducing fluid production, these treatments help lower eye pressure. Cyclodestruction is generally used in advanced, refractory glaucoma or when other surgeries have failed or are not possible. Newer methods (like micropulse cyclophotocoagulation) aim to reduce side effects by delivering short, repeated laser pulses that heat the tissue gently (). Common cyclodestructive techniques include: Transscleral cyclodiode laser: A diode laser probe is applied on the white of the eye (sclera) over the ciliary body. It delivers burns through the sclera, shrinking fluid-producing cells (). Patients often get topical or general anesthesia for comfort. Micropulse cyclophotocoagulation: Delivers the same diode laser energy in very brief pulses, allowing the tissue to cool between bursts. This tends to cause less inflammation and pain () (). Endoscopic cyclophotocoagulation (ECP): Performed during cataract or other eye surgery, a tiny camera and laser are inserted into the eye via a small incision to directly target ciliary processes. Cyclodestruction is less predictable and generally less powerful than filtration surgery. It often lowers IOP by 20–30% on average, and is not usually enough to reach very low single digits by itself, but it can supplement other treatments. For eyes with remaining vision, doctors typically use conservative settings or micropulse to balance efficacy and safety. Key points about cyclodestruction: It is a non-incisional approach that “turns down the tap” by reducing fluid production () (). Micropulse methods cause less inflammation and usually fewer complications like pain or damage than traditional continuous-wave cyclodiode () (). Common side effects include inflammation (iritis) and potential vision loss if overtreatment occurs. Severe complications (retinal detachment, vision loss, or even phthisis) are rare with modern protocols, especially micropulse. Nonetheless, cyclodestruction is often reserved for eyes where vision is already limited or other surgeries have failed. Balancing Safety, Risks, and Follow-up Lowering eye pressure to single digits can protect vision in progressing glaucoma, but it also raises the chances of complications. Each procedure has trade-offs: Trabeculectomy: Can achieve low IOP without long-term implants, but it carries risks of overfiltration. Wounds can leak, and blebs can become too thin. Hypotony (too low pressure) after trabeculectomy can cause hypotony maculopathy – retinal folds and distorted vision (). There is also a lifelong risk of bleb-related infection (blebitis or endophthalmitis) if bacteria enter the eye through the bleb. On the plus side, trabeculectomy often achieves the lowest pressures of all procedures, especially with MMC (). Tube shunts: Generally have a safer early postoperative course regarding hypotony, especially valved implants. They also avoid an external bleb (so no bleb infection, though tubes have other risks like corneal touch or tube blockage). Non-valved shunts, once open, can still over-drain, but the staged occlusion techniques help prevent catastrophic hypotony early ().Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/slt-s-evolving-role-relative-to-migs-and-surgeryTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Selective Laser Trabeculoplasty (SLT) in Modern Glaucoma Care Glaucoma treatment has evolved beyond just daily eye drops or major surgery. Selective laser trabeculoplasty (SLT) is a gentle office laser procedure that helps lower eye pressure by improving fluid drainage through the eye’s natural pathway. In recent years, SLT’s role has grown – sometimes used as an initial therapy, other times added later – especially alongside newer minimally invasive glaucoma surgeries (MIGS). Patient-friendly studies now suggest SLT can safely reduce or delay the need for medications and surgery. For example, a large trial (the LiGHT study) found that when open-angle glaucoma patients started treatment with SLT instead of drops, 74% of them remained off all medications three years later and none needed incisional surgery (). Leading eye care organizations (like NICE in the UK and the American Glaucoma Society) now list SLT as an option for first-line treatment, recognizing its benefit in early glaucoma care (). SLT as Primary or Adjunct Therapy SLT is often recommended either before starting drops or after medications alone can’t reach the target pressure. Being “selective,” the laser targets pigment cells in the drainage meshwork without scarring it, so it leaves the drainage pathway intact. As a result, SLT can be repeated if needed (). Per the Glaucoma Research Foundation, a single SLT session typically lowers pressure for about 2–3 years (often longer), and then can be repeated (). Many patients on multiple eye drops can do very well with SLT: it often allows them to reduce or stop medications. In contrast, MIGS procedures (such as tiny stents or implants like the iStent or Hydrus) are newer surgical methods done in the operating room, often together with cataract surgery. MIGS also aim to drop pressure or cut down medications, and are especially used in mild-to-moderate glaucoma. For example, one study found that combining a Hydrus microstent with cataract surgery gave the same IOP drop as SLT alone, but allowed many more patients to go medication-free (47% versus only 4% with SLT) (). However, that MIGS group did have a few more short-term issues (temporary blurred vision or IOP spikes) that weren’t seen in the SLT group (). In practice, doctors may choose MIGS when slightly lower pressures are needed than SLT can usually achieve, or when a patient is already getting cataract surgery. MIGS generally have a good safety profile and modest pressure drops (), filling a gap between simple drops/laser and major glaucoma surgery. SLT can also be used after a MIGS or vice versa. Notably, SLT still helps even if a stent is already in place. One study showed that glaucoma patients who had an iStent implant and then received SLT got about the same eye-pressure reduction as others – but importantly, the previous stent group ended up on fewer medications afterwards (). (This suggests SLT adds benefit in terms of med reduction even after MIGS.) In all cases, SLT is a quick outpatient procedure and may be tried first in suitable patients because it has minimal downsides. If it does not achieve the needed pressure, doctors can then consider stepping up to MIGS or traditional surgery. Durability and Retreatment SLT’s effects wear off over time. In general, about half to three-quarters of eyes have successful pressure control at one year, but many lose enough effect by 3–5 years that retreatment is needed. A review of studies reported SLT success rates ranging roughly 45–87% at 1 year, falling to only ~25% by five years (). In practice, nearly 44–45% of eyes in a 3-year study eventually needed a second SLT treatment (). Fortunately, SLT is repeatable because it does not scar the meshwork. A repeated SLT (often covering 360° of the angle) can regain pressure control and typically gives another 1–2 years of effect (). However, each time tends to give a slightly smaller drop, so the benefit diminishes with more repeats (). Several factors predict how well SLT will work for a patient. The baseline eye pressure is the strongest predictor: patients with higher starting pressures tend to get bigger pressure drops and higher success rates, simply because there’s more to reduce (). In fact, eyes with very low pressure to start (such as normal-tension glaucoma) may see little benefit at all (). Other features like pigment in the drainage angle or pseudoexfoliation may slightly alter response, but results are quite individual (). Age, race, or severity do not strongly predict outcomes beyond their effect on baseline IOP. In short, entering SLT with a pressure well above target usually means a better absolute drop, while eyes already very low may need more aggressive treatment. When monitoring SLT, doctors watch for pressure creep. If target pressure is lost or disease progresses (for example, worsening visual field loss), it’s time to step up therapy. Modern guidelines emphasize not waiting for a very high pressure before acting: any sign of glaucoma worsening warrants additional treatment, whether that is repeating SLT, adding MIGS, or moving to incisional surgery (). Importantly, data show that patients started on SLT often avoid surgeries longer: in the LiGHT trial, none of the SLT-first patients needed glaucoma surgery by year 3 (versus several who started on drops) (). Safety and Side Effects SLT is exceptionally safe for patients. It is done in the clinic under topical anesthesia and causes minimal discomfort. The most common side effects are mild and short-lived. Nearly all patients have some mild eye inflammation (seen as a few cells in the front chamber) for a day or two after the laser, which usually helps the pressure drop before it resolves (). Many patients also take a few anti-inflammatory drops for a week. Some people might notice a bit of redness or eye irritation right after. A known effect is a transient pressure spike: in roughly 20–30% of eyes, the IOP temporarily rises by about 5 mmHg or more in the first few hours (especially if a lot of angle pigment is present) (). This spike usually takes a day to 48 hours to go away, and doctors often give a preventive drop (like brimonidine or acetazolamide) to blunt it. Rarely, a spike can be higher and take a few days to settle. Serious complications from SLT are very rare. There have been isolated reports of extended inflammation or even cystoid macular swelling, especially in patients with other eye problems, but these are exceptional cases. By contrast, incisional surgeries (trabeculectomy or tube shunts) carry risks like infection, chronic hypotony, or bleb complications. MIGS are generally safer than classic surgery, but they still involve incisions inside the eye and have their own issues (transient blood or fluid in the eye, needling revisions of stents, etc.). In one head-to-head comparison, a Hydrus MIGS implant and SLT gave similar IOP-lowering, but the MIGS eyes had a few more side effects (temporary blurred vision or early pressure spikes) that did not happen with SLT (). In summary, SLT’s advantages are its simplicity and safety: it carries none of the risks of a later trabeculectomy (no bleb to worry about) and can be done as often as needed. Its limitations are that it typically cannot achieve very low “target” pressures (often only into the mid-teens) and it may need repeating. MIGS falls in between: it is more invasive, so has somewhat more risk, but it can sometimes reach a bit lower pressure and substantially reduce medications (). The choice between them depends on how much pressure lowering is needed and patient preferences. Sequencing SLT and MIGS: Proposed Treatment Pathways The best order of treatments depends on disease severity, resource goals, and patient wishes. Here are evidence-based approaches to lining them up: Early (mild) glaucoma: Consider SLT first to delay drops. A patient with newly diagnosed mild open-angle glaucoma and a target pressure in the mid-teens can often do well with one SLT treatment (). If the patient is already undergoing cataract surgery, a surgeon might instead or additionally place a MIGS stent during the same operation (for example, an iStent or Hydrus). If SLT is used and later pressure rises, re-treat SLT once or twice more before moving on. If additional lowering is needed, MIGS procedures or adding a single medication may be the next step. Several guidelines now endorse using laser early exactly for these patients. Moderate glaucoma or patients on multiple drops: Many surgeons consider MIGS (with cataract if indicated) at this stage, especially if target IOP is not reached by medicines and lens changes allow. For example, an eye needing to go from 18 to 15 mmHg might handle SLT, but an eye needing 12–13 mmHg may require a stent or micro-shunt. SLT can still be done either before or after MIGS to shave off a few more points or reduce meds. Indeed, even after an unsuccessful MIGS, applying SLT later can add some benefit (). If MIGS itself is insufficient, the patient may ultimately need a full trabeculectomy or tube shunt, especially if disease is progressing. Advanced glaucoma: Here the target pressure is very low (often mid-teens or below). Neither SLT nor most MIGS will reliably hit those levels. In such cases, many doctors proceed directly to traSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/trabeculectomy-vs-tube-shunts-in-the-modern-era-long-term-safety-and-durabilityTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Trabeculectomy vs Tube Shunts in the Modern Era: Long-Term Safety and Durability Glaucoma is often treated surgically by creating a new pathway for fluid to drain out of the eye. Two main approaches exist: trabeculectomy (making a new small flap/“bleb” in the eye’s wall) and tube shunt implants (silicone tubes that divert fluid to a distant reservoir). Over the past decades, doctors have shifted increasingly toward tube shunts, especially in complex cases (). However, patients and surgeons still debate which is safer and more durable in the long run. Large clinical trials and patient series have compared these surgeries. In general, tubes tend to be more reliable at keeping pressure from jumping up, whereas trabeculectomies often achieve lower pressure with less medication. Each method has different risks: for instance, trabeculectomy blebs can leak or get infected, while tubes can cause double vision or corneal problems. Importantly, how the surgery is done – the dose of antifibrotic medication, suture techniques, and careful follow-up – can greatly affect outcomes. This article will summarize the key long-term findings from major studies, detail typical complications, and explain how technique and postoperative care influence safety. We will also offer guidance on which procedure may be best suited for eyes needing very low target pressure or eyes with “refractory” glaucoma (e.g. after failed prior surgery). Comparing Long-Term Results of Trabeculectomy and Tube Shunts Tube versus Trabeculectomy (TVT) Study – Eyes with Prior Surgery An important trial known as the Tube Versus Trabeculectomy (TVT) Study looked at patients who had already had cataract or glaucoma surgery that failed () (). Here, one group received a large Baerveldt tube implant (350 mm² endplate), and the other had a trabeculectomy with mitomycin C (MMC). In the first year, both surgeries lowered eye pressure (intraocular pressure, IOP) similarly. However, tubes were more likely to maintain good pressure control long-term and needed fewer repeat surgeries. For example, at 1 year the failure rate (by strict criteria including high IOP, very low IOP, or need for more surgery) was significantly lower with tubes (3.9%) than with trabeculectomy (13.5%) (). In practical terms, tube patients were less likely to need another glaucoma surgery or to have dangerously low pressure. Both groups lost vision at similar rates (about 32–33% lost ≥2 lines of vision, usually due to non-surgical causes) (). Over longer follow-up, the advantage for tubes continued. At 3 years, IOPs were effectively the same (around 13 mmHg on average) between the groups, and use of glaucoma medicines was similar (). But tubes failed less often: the 3-year chance of failure was 15% with tube versus 31% with trabeculectomy (a statistically significant difference) (). Postoperative complications (mostly mild and transient) were also more common after trabeculectomy. In the first year 60% of trabeculectomy patients had some complication versus 39% with a tube (). Notably though, severe complications harming vision occurred at about the same rate (~20–27%) in both groups (). Key findings of the TVT Studies can thus be summarized as: Both surgeries significantly lowered IOP long-term, but tubes required slightly more medical therapy initially (). Tube shunts had higher success rates (fewer failures and reoperations) in eyes with prior surgery (). Trabeculectomy achieved lower IOP without meds, but had more postoperative problems like bleb leaks (). Over 5 years, there was no clear winner for vision loss or glaucoma control – other factors like patient/doctor preference and follow-up patterns matter (). (For completeness, a more recent “Primary Tube vs Trabeculectomy (PTVT)” trial in eyes without prior surgery found somewhat different results. At 1 year in that trial, trabeculectomy with MMC actually had a higher success rate and lower IOP (mean 12.4 mmHg vs 13.8 mmHg) than tubes (). However, most serious complications occurred in the trabeculectomy group (7% vs 1% for tubes) (). This suggests that in eyes where healing is normal, trabeculectomy can give a lower pressure but may carry more risk. By contrast, in complex eyes (like in TVT), tubes had the edge.) Ahmed vs Baerveldt (Tube versus Tube) There have also been head-to-head trials comparing different types of tube shunts. The two most common are the Ahmed valve (flow-restricted device) and the Baerveldt plate (non-valved, larger plate). The Ahmed Versus Baerveldt (AVB) Study randomized hundreds of refractory glaucoma patients to one of these devices. At 3 years, both implants had similar pressure control (mean IOP ~15 mmHg) (), but Baerveldt eyes needed fewer medicines (1.1 vs 1.8 meds on average) (). More importantly, failure (defined as inadequate IOP or vision loss) was lower with the Baerveldt (34% failure) than Ahmed (51% failure) at 3 years (). The main difference was pressure: the Baerveldt produced lower IOP (mean ~14.4 mmHg) than the Ahmed (~15.7 mmHg), though this just missed statistical significance (P=0.09) (). However, hypotony (too-low pressure) was more of an issue with the Baerveldt: by 3 years, 6% of Baerveldt patients had a vision-threatening hypotony complication, whereas none of the Ahmed patients did (P=0.005) (). At 5 years (follow-up of the same study), the pattern was similar: Baerveldt eyes continued to have lower IOP (mean 13.6 vs 16.6 mmHg, P=0.001) and fewer medications (). Cumulative failure at 5 years was 40% for Baerveldt vs 53% for Ahmed (P=0.04) (). Again, hypotony was seen only in Baerveldt eyes (4% of patients) while none of the Ahmed eyes failed due to hypotony (). Overall: Both Ahmed and Baerveldt implants effectively lower IOP, but Baerveldt typically achieves slightly better long-term pressure and medication reduction (). Baerveldt has a small risk of hypotony, whereas the Ahmed valve’s built-in resistor prevents this (none in Ahmed group) (). Serious complication rates were similar (around 60–69% had some complication, mostly minor, in either group) (). In one analysis, Ahmed eyes had about twice the risk of needing reoperation compared to Baerveldt by 3 years (). (However, note that definitions and patient mix vary between studies.) Other analyses and systematic reviews generally confirm that large plates (Baerveldt or Molteno) yield lower pressures than valved devices (Ahmed) or trabeculectomy, at the cost of slightly higher early hypotony rate. Common Complications and How to Manage Them Both trabeculectomy and tube shunts can cause complications. Understanding these helps patients and doctors avoid or treat them early. Four important issues are hypotony maculopathy, bleb leaks/infections, diplopia (double vision), and corneal endothelial loss. Hypotony and Hypotony Maculopathy What it is: Hypotony means an abnormally low IOP (often ≤5 mmHg). When pressure is too low, the back of the eye can wrinkle and the optic nerve can swell, a situation called hypotony maculopathy. This can permanently damage vision if not recognized. Modern use of anti-scarring drugs (like MMC) in trabeculectomies has made hypotony maculopathy more common than in the old days (). How often it happens: In general, hypotony is more associated with trabeculectomy (especially with high MMC dose) than with valved tubes. CIGTS (a glaucoma study) found a 5-year hypotony risk of about 1.5% after trabeculectomy (). Tube shunts (Baerveldt or Ahmed) rarely cause persistent hypotony because tubes have restricted flow (Ahmed) or require flow ligation (Baerveldt is often tied off initially). In the AVB study above, 4% of Baerveldt eyes failed from hypotony at 5 years, while Ahmed had none (). Risk factors: Young, myopic males with pliable sclera and first-time filtering surgery are at highest risk (). High doses of MMC (longer time or higher concentration) make the bleb “thinner” and prone to over-drain. Early overfiltration (for example from too-loose sutures or a large drainage) is also a big factor. Prevention strategies: Surgeons take several precautions: Titrating MMC dose: Use the lowest effective exposure (often 0.2 mg/ml for 1–2 minutes) in primary cases. Very high MMC doses increase hypotony risk (). Careful flap suturing: Place tight sutures on the scleral flap so it doesn't over-drain. Adjustable or releasable sutures allow gradual loosening in clinic. Staged release: Delay full flow in tubes (e.g. Baerveldt tubes are ligated at surgery and only released later, often with ripcord or tie suture removal) to prevent a huge pressure drop when scarring has occurred around the plate. Safety-valve techniques: Some surgeons add small “vent” incisions or partial thickness flaps that slow flow if necessary (). Controlled suture lysis: If laser suture lysis is needed post-op, do it gradually to avoid a sudden pressure crash (). If hypotony does occur, treating it promptly is crucial (). For example, one can apply a pressure patch or bandage contact lens to close leaks, inject autologous blood or fibrin glue under the bleb, or even revise the flap surgically (adding sutures or conjunctival stitches) (). The goal is to raise IOP and allow the eye tissues to re-expand. A number of techniques like conjunctivalSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/do-orally-ingested-collagen-peptides-reach-the-eyeTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Do Oral Collagen Supplements Reach the Eye? Many people take hydrolyzed collagen (collagen broken into small pieces) to support their joints, skin, and even eye health. Collagen is a structural protein found in the skin, bones, cartilage – and the eye’s connective tissues (like the cornea and sclera). A key question is whether collagen fragments eaten by mouth can travel through the body’s blood and actually get into eye tissues. This article reviews what we know about how collagen peptides behave in the body (their “pharmacokinetics”), whether small collagen pieces can cross the blood-aqueous and blood-retinal barriers, and what evidence animal or human studies provide. We also suggest how future experiments could directly test for collagen peptides in eye fluids and tissues. How Collagen Peptides Enter the Blood When you swallow hydrolyzed collagen (often from supplements or certain foods), your digestive system breaks it into very short chains of amino acids – mainly dipeptides and tripeptides (two or three amino acids linked together). Two common collagen dipeptides are Proline-Hydroxyproline (Pro-Hyp) and Hydroxyproline-Glycine (Hyp-Gly). These small peptides are unusually resistant to digestion because their amino acids (proline and hydroxyproline) form a rigid ring structure. Studies in humans show that after eating collagen hydrolysate, these collagen-derived peptides do appear in the blood. For example, Virgilio et al. (2024) gave people a collagen supplement and found high blood levels of Pro-Hyp, Hyp-Gly, and related collagen peptides within 1–2 hours (). In fact, they reported that “all collagen products yielded relevant plasma concentrations of the investigated metabolites” (meaning collagen breakdown products) (). In practical terms, this means that when you ingest collagen hydrolysate, enzymes in the gut produce a mix of small peptides (and free amino acids), some of which enter the bloodstream intact. The peak blood levels of peptides like Pro-Hyp typically occur around 60–120 minutes after ingestion, according to multiple studies (). After peaking, these peptide levels fall over the next few hours. For instance, one study found that Pro-Hyp (which contains the common hydroxyproline, 4Hyp) returned to its baseline (undetectable) level by about 4 hours after ingestion (). In contrast, a more unusual collagen peptide (Gly-3Hyp-4Hyp, containing 3-hydroxyproline and 4-hydroxyproline) stayed at its peak blood concentration through around 4 hours due to exceptional stability (). In summary, collagen peptides appear in the blood quickly and then are cleared within a few hours () (). What Happens to Collagen Peptides in the Body Once in circulation, collagen peptides distribute to various tissues. Animal tracer studies using radio-labeled collagen fragments show that ingested collagen tends to accumulate in collagen-rich tissues. For example, Kawaguchi et al. (2012) gave rats an oral dose of radioactively labeled Pro-Hyp and found it widely distributed in the body after 30 minutes. The highest radioactivity was in the digestive tract (stomach and intestines, understandable as the site of absorption) and surprisingly also in skin and cartilage – tissues built of collagen (). Cells like skin fibroblasts, cartilage cells, bone cells, and others that normally respond to collagen peptides actually took up these labeled fragments (). This suggests that after absorption, collagen peptides can travel through blood to reach collagen-containing tissues. Another rat study found that collagen tripeptides like Gly-Pro-Hyp remained in the blood and deposited mainly in the kidney (for excretion) and skin for days after dosing (). Importantly, these animal studies did not examine the eye. They show that collagen fragments in blood can end up in tissues with high collagen content (bone, cartilage, skin), but eyes were not tested. This leaves a data gap on whether any of the orally derived collagen peptides reach the eye. The Eye’s Protective Barriers Before considering if collagen peptides reach the eye, it helps to understand the eye’s blood-barrier systems. The eye has two major “blood-ocular” barriers: Blood-Aqueous Barrier (BAB): This is at the front of the eye (between the blood and the fluid in the front chamber called the aqueous humor). It is formed by the lining of the iris and ciliary body. The BAB restricts entry of many substances from the bloodstream into the anterior chamber (). Blood-Retinal Barrier (BRB): This is at the back of the eye (between blood and the retina/vitreous). The BRB is formed by tight junctions in the retinal blood vessels (inner BRB) and by the retinal pigment epithelium (outer BRB). It severely limits movement of molecules from the blood into the retina (). These barriers block large molecules (like most proteins) and many drugs. Only small, lipid-soluble, or actively transported molecules cross easily. In fact, drug delivery reviews stress that the BRB’s limited permeability is a major challenge for systemic eye treatments (). Could collagen peptides cross these barriers? Collagen peptides are small (di- or tri-peptides), but they are hydrophilic, so they usually would not passively diffuse through these barriers. However, the body does have specialized peptide transporters. In the gut and kidneys, transporters PepT1 and PepT2 carry di- and tri-peptides. There is evidence that similar carriers exist on ocular barriers. Notably, Atluri et al. (2004) showed in rabbits that a model dipeptide (glycylsarcosine) injected into the blood did reach the vitreous, retina, and aqueous humor within minutes (). The uptake was time-dependent and could be blocked by other peptides, indicating a carrier-mediated transport. In other words, the rabbit eye has peptide transporters at its blood barriers that can shuttle small peptides from blood into ocular fluids (). In summary, small collagen-derived dipeptides could cross into the eye if they fit those transporters. This has been shown with model substrates (like glycylsarcosine); natural collagen peptides like Pro-Hyp may also use the same pathways. However, direct evidence that oral collagen peptides enter the eye is still missing. What Studies Show (and Don’t Show) About Eye Uptake To date, no published human or animal study has directly measured collagen peptides in eye tissues or fluids after oral dosing. We have hints but no definitive tracking for the eye itself. The earliest evidence comes from the rabbit glycylsarcosine experiment (): it proves an oligopeptide can cross both anterior (blood-aqueous) and posterior (blood-retinal) barriers in healthy eyes. But glycylsarcosine is a simple model peptide, not derived from collagen. For actual collagen fragments, we only have general distribution studies (like Kawaguchi’s rat autoradiography ()). Those showed radioactivity in skin, cartilage, bone marrow, etc., but made no mention of eyes. It may mean the eye’s radioactivity was low or unmeasured, or simply not reported. If collagen peptides did not accumulate in the eye as much as in skin, the study might not have noted it. Because of the blood-ocular barriers, it seems unlikely that large fractions of orally ingested collagen peptides get into eye fluids. But we cannot rule it out. For example, any collagen peptides in the blood will eventually pass through the blood vessels of the choroid and iris; some fraction might slip through transporters into the sclera, retina, or aqueous. We just lack measurements. In short, evidence is very limited. No study has given people labeled collagen and then sampled their aqueous humor, vitreous, or optic nerve tissue to look for peptides. This is a key data gap. We can only infer from related work that entry is biochemically possible but probably low in quantity. Designing Experiments to Find Collagen Peptides in the Eye Future experiments could directly answer the question by measuring peptide levels in ocular compartments after tracer dosing. For example: Animal Tracer Studies: Give animals (e.g. rabbits or mice) collagen hydrolysate labeled with a heavy isotope or a radioactive tag (such as ^14C or ^3H on an amino acid). After dosing, at various times collect samples of aqueous humor (via needle tap), vitreous humor, and dissect tissues like the trabecular meshwork, sclera, retina, and optic nerve head. Measure radioactivity or use sensitive mass spectrometry to detect labeled peptides in those samples. Autoradiography (exposing eye sections to film) could visually show peptide distribution in ocular tissues. This would directly test if any collagen-derived peptides cross into the eye. Ocular Microdialysis: In larger animals (rabbits or dogs), tiny probes called microdialysis fibers can sample fluid from inside the eye over time. If animals are fed labeled collagen, the microdialysis samples from anterior or posterior chamber could be analyzed for labeled peptides. This technique has been used in ocular drug studies and could reveal time-courses of any peptide reaching the eye fluid. Human Surgical Sampling: Make use of eye operations to sample fluids. For example, prior to routine cataract surgery, a patient could take a dose of collagen hydrolysate containing a non-radioactive stable isotope label. Just before surgery, the surgeonSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/collagen-peptides-and-the-trabecular-meshwork-mechanistic-links-to-intraocular-pressureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Glaucoma and Intraocular Pressure: The Role of the Outflow Pathway Glaucoma is a group of eye diseases that can cause vision loss by damaging the optic nerve. High intraocular pressure (IOP) – the fluid pressure inside the eye – is a major risk factor for glaucoma. Normally, fluid made inside the eye (aqueous humor) drains out through the trabecular meshwork (TM) and Schlemm’s canal (SC) at the front (anterior segment) of the eye. When this drainage becomes blocked or restricted, fluid builds up and pressure rises. In many forms of glaucoma, doctors see extra extracellular matrix (ECM) – the network of proteins and structural components outside cells – accumulating in the TM and SC. This thickened ECM acts like extra “debris” in the drainage channels, making it harder for fluid to exit. Over time, this increased resistance to outflow causes IOP to climb, which can damage the optic nerve and lead to loss of vision (). In a healthy eye, the TM and SC work together like a plumbing system. The TM is a spongy, porous tissue lined by endothelial cells, and it sits just in front of Schlemm’s canal (see illustration below). Fluid flows out through pores in the TM and the inner wall of SC into a blood vessel-like channel (Schlemm’s canal) to exit the eye. Research shows that most of the normal resistance to fluid outflow comes from the juxtacanalicular TM region (the deepest part of the TM right next to Schlemm’s canal) and from the basement membrane of the inner wall of Schlemm’s canal (). In glaucoma, the TM and SC basement membrane become abnormally thick and stiff, filled with extra collagen, fibronectin, and other ECM proteins (). These changes make the outflow paths narrower, like clogging a drain, which raises IOP. () Figure: Fluid drains from the anterior chamber through the trabecular meshwork (TM) and inner wall of Schlemm’s canal (SC). Most outflow resistance – the “bottleneck” – is in the deep TM and inner SC wall (). ECM Remodeling in the Trabecular Meshwork In glaucoma, the TM cells (which behave somewhat like fibroblasts, the connective tissue cells found in skin and other organs) produce extra matrix and fail to break it down properly. The balance of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) shifts so that more ECM is deposited. At the same time, powerful signaling proteins are at play. A key culprit is transforming growth factor-beta (TGF-β). Both TGF-β1 and TGF-β2 are growth factors that normally help tissues heal and regulate ECM, but in glaucoma the level of TGF-β2 in the eye’s fluid (aqueous humor) is abnormally high (). Experiments show that TGF-β2 stimulates TM cells to make more collagen and other matrix molecules, and to cross-link the fibers (via lysyl oxidase enzymes) (). This creates a fibrotic phenotype (like a scar) where the TM is filled with solid matrix and becomes stiffer. Another important factor is connective tissue growth factor (CTGF), also called CCN2. CTGF is induced by TGF-β and further promotes matrix production. Studies in human TM cells found that TGF-β increases CTGF, and that adding CTGF to TM cells causes them to deposit much more ECM (). Blocking CTGF (for example with an antibody) prevents these fibrosis-like changes (). In glaucoma patients, CTGF levels are elevated in the TM, and research suggests CTGF may create a positive feedback loop: as collagen builds up, CTGF drives even more collagen to be made (). In other words, thinner, normal TM becomes thicker and scarred. Integrins are surface receptors that let TM cells sense and bind to the ECM around them. When integrins bind to collagens or fibronectin, they send signals inside the cell that affect its shape, survival, and function. In the TM and Schlemm’s canal cells, many integrins connect to ECM proteins like collagen and laminin (). This “outside-in” signaling can, for example, activate enzymes like FAK (focal adhesion kinase) that influence the actin cytoskeleton. Abnormal ECM (like extra fibronectin or collagen) can therefore trigger inside-out signals too. For instance, when fibronectin is high in glaucoma, it may bind to RGD-recognizing integrins on TM cells, altering their behavior (). However, how collagen fragments or peptides might directly affect integrins in eye cells specifically is still being studied. Overall, the TM and Schlemm’s canal become more fibrotic in glaucoma due to a combination of excess ECM, increased cross-linking, and profibrotic signals (TGF-β, CTGF, cytokines) () (). This fibrotic remodeling raises outflow resistance and IOP. (For more details on TM pathophysiology, see reviews by Vranka et al. and others () ().) Collagen Peptides: Effects on Fibroblasts and ECM Collagen peptides are short chains of amino acids (small protein fragments) derived from collagen. They are commonly taken as dietary supplements for skin, joint, or bone health. In the lab, scientists have tested collagen peptides on various cell types (especially skin fibroblasts) to see what they do at the molecular level. Recent studies suggest that collagen peptides can stimulate fibroblasts and influence key pathways like integrins, TGF-β, CTGF, and MMPs. While data on ocular cells is limited, findings from skin and other tissues provide clues. Fibroblast proliferation and matrix production. Multiple studies have found that collagen peptides can make skin fibroblasts multiply and produce more collagen. For example, Brandão-Rangel et al. (2022) showed that adding collagen peptides to human dermal fibroblasts caused a significant increase in cell proliferation and in the expression of pro-collagen type I (the main collagen of skin) (). Similarly, another in vitro study found that collagen peptides at moderate concentrations boosted the genes for collagen type I (COL1A1), elastin (ELN), and proteoglycan versican (VCAN) in dermal fibroblasts (). In both cases, fibroblasts made more of the building blocks of the connective tissue matrix. A systematic review of studies on hydrolyzed collagen reported that doses of about 50–500 µg/mL of collagen peptides are enough to stimulate fibroblast activity and collagen synthesis in human cells (). In short, collagen peptides appear to help rebuild and strengthen the extracellular scaffolding by prompting fibroblasts to grow and make more matrix. Anti-inflammatory effects and TGF-β. Surprisingly, collagen peptides also have anti-inflammatory actions. In the Brandão-Rangel study, collagen peptides not only spurred collagen production but also suppressed inflammatory markers. When skin cells were exposed to a bacterial toxin (LPS), adding collagen peptides greatly lowered the induced levels of cytokines IL-6, IL-8, TNF-α and others (). At the same time, the peptides raised the levels of TGF-β (and VEGF) in the fibroblasts (). In other words, collagen peptides acted like a signal to calm inflammation and shift cells into a growth/repair mode. Because TGF-β is both anti-inflammatory and pro-fibrotic, this could be a double-edged sword: more TGF-β may help healing, but it could also drive fibrosis if unchecked. Indeed, in the same study the highest dose of collagen peptides (10 mg/mL) was needed to upregulate pro-collagen and TGF-β (). Another report in skin cells found that certain collagen-derived dipeptides (like ile-hydroxyproline) activated the TGF-β/Smad pathway, promoting collagen synthesis (). Thus, collagen peptides can engage the very pathways (TGF-β signaling, Smad) that normally control ECM production. Integrin signaling. Collagen is a natural ligand for certain integrins (notably α2β1 integrin binds collagen). Recent work in skin models shows that collagen peptides can increase the expression of collagen-binding integrins and activate associated signals. Mistry et al. (2024) found that porcine collagen peptides applied to skin cells significantly raised integrin α2β1 levels and triggered downstream signaling via ERK and FAK pathways (). (These pathways normally respond to the cell binding to the ECM.) In those experiments, blocking the β1 integrin subunit prevented the collagen peptide effects in keratinocytes, although fibroblasts still responded, suggesting multiple routes of activation (). The take-home is that collagen peptides can “prime” cells to sense and adhere to collagen. In a trabecular meshwork context, integrin α2β1 is present and mediates collagen binding (). If collagen peptides similarly boost α2β1 on TM cells, that might increase adhesion to the surrounding matrix, potentially influencing outflow. MMPs and TIMPs (matrix remodeling). The matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) control how fast the ECM is broken down. Excess MMP activity leads to ECM degradation, while too much TIMP can preserve ECM and lead to fibrosis. In skin models, collagen peptides seem to reduce the expression of some MMPs. Liu et al. (2019) showed that certain collagen peptide metabolites in culture suppressed activation of AP-1, lowered the protein levels of MMP-1 and MMP-3, and thereby depressed collagen degradation (). Another study noted that increased collagen accumulation in fibroblasts was linked not only to more collagen synthesis but also to Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-ferroptosis-supplements-protect-vision-in-glaucoma-what-the-new-dnajb14-discovery-really-meansTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:The Ferroptosis Hype in Glaucoma: Hope or Hype? Imagine reading about a magic pill that could stop glaucoma by blocking a new form of cell death called ferroptosis. Some reports even mention a recent gene finding (DNAJB14) that sounds like a cure-in-the-making. It’s a captivating idea – protect your vision with a supplement! But before you start popping supplements, let’s break it down. We’ll look at what the science actually says, what’s only been shown in lab animals, and what claims are likely misleading or risky. In the end, we’ll give you clear takeaways on what really can help your eyesight. What Is Ferroptosis, Anyway? Ferroptosis is not a household word, but it’s essentially a newly recognized way cells can die. Unlike typical cell death (like old cells dying normally), ferroptosis is driven by iron and oxidative stress. When tiny cell parts (like membranes) get overloaded with iron and reactive oxygen species (chemicals that cause damage), they literally rust themselves to death. In simple terms: imagine your cells corroding from the inside out. It’s been studied in basic science (cells in dishes and animals), and researchers think it might happen in eye diseases. In the context of glaucoma, the cells of concern are retinal ganglion cells (RGCs), the nerve cells in your eye that send visual signals to the brain. These cells die off in glaucoma, which causes gradual vision loss. Scientists have found signs of ferroptosis in animal models of glaucoma. For example, high eye pressure and other distress signals trigger iron release and oxidative stress, which then cause RGC death by ferroptosis (). In animal studies, blocking ferroptosis chemically (using experimental drugs like ferrostatin-1) can protect these neurons from dying (). These findings suggest the idea is biologically plausible – oxidative damage and iron overload do seem to be part of glaucoma-related cell death. Yet it’s crucial to note: most of this evidence is from lab experiments and animal models, not from people. The human eye is much more complex than an isolated cell or a mouse. So far, we lack clinical trials in humans proving ferroptosis inhibitors help glaucoma patients. In fact, in glaucoma patients doctors have observed higher levels of oxidative stress markers (like malondialdehyde, a sign of lipid peroxidation) and lower natural antioxidants (like glutathione) (). These observations are consistent with ferroptosis happening. But observation is not the same as proof that a supplement can stop it. Supplements and Claims: Separating Plausible from Pointless or Risky Because ferroptosis involves free radicals (oxidative stress) and iron, many people jump to the idea of taking antioxidants or iron binders as “ferroptosis supplements.” You may have seen products or advice suggesting things like melatonin, vitamin E, or herbal extracts to protect your eyes. Here’s what we know: Biologically plausible ideas: Antioxidants can neutralize free radicals, and indeed, some studies show antioxidant-like substances protect retinal cells in lab tests. For example, the hormone melatonin (also a mild antioxidant) protected retinal ganglion cells in mice under high eye pressure by blocking ferroptosis (). Similarly, N-acetylcysteine (NAC) can boost the cell’s own antioxidant glutathione, and in animal studies led to more glutathione in eye cells and less cell death (). These are promising signals: in theory, strengthening antioxidant defenses could help. What’s only lab evidence: However, both examples above are in animals or cells. Melatonin’s effect was in a controlled mouse model, not human glaucoma. NAC showed benefit in reducing macular degeneration risk in a cohort and in animal eyes (), but not specifically in glaucoma patients. Animal and cell studies matter – they show a mechanism is possible. But they are not enough to say a human supplement will work. We still need clinical trials in people. Common supplements studied: Some clinical research on vitamins and glaucoma (not specifically ferroptosis) has been done. For instance, vitamins C and A might slightly reduce glaucoma risk in some population studies (), but most vitamin trials have not proven meaningful effects. A 2025 review found Ginkgo biloba (often touted for eye health) did not significantly improve eye pressure or visual field outcomes in glaucoma patients (). Other herbs like green tea or ginkgo sometimes slow progression in small studies, but overall the evidence is weak () (). The bottom line: no supplements have been proven to prevent or reverse glaucoma. Risky or misleading ideas: Beware of claims that a supplement can “cure” or reverse glaucoma. The Mayo Clinic (via Augusta Health) clearly states: “little evidence supports using [eye vitamins/supplements] for preventing glaucoma or reversing vision loss ().” Supplements might seem harmless, but without strong evidence they can give false hope. There’s also risk if people think supplements replace standard care. Always continue your prescribed glaucoma treatments (eye drops or surgery) first. Never stop treatments aiming to lower intraocular pressure in favor of unproven pills. Also, key idea: Higher dose isn’t always better. For example, mice needed very high doses of vitamin B3 (nicotinamide) to see a benefit (). That doesn’t mean popping B3 vitamins will have the same effect in people (and too much B3 can have side effects). Similarly, while antioxidant supplements are generally safe, mega-doses could have risks or interfere with other medications. So talk to your doctor. The Mayo Clinic advice is spot on: “If you're interested in trying eye vitamins or supplements, discuss the benefits and risks with your eye doctor” (). What about iron chelators or specialized “ferroptosis inhibitors”? Some lab drugs (like ferrostatin-1 or liproxstatin) can block ferroptosis in cells (). But these are experimental chemicals, not available to patients. Any actual iron-chelating strategy (like prescription deferoxamine) would be risky if misused and has not been tested for glaucoma. Right now they are research tools, not supplements. Don’t attempt to chelate iron in your diet or body without medical supervision. The DNAJB14 Discovery: A Word of Caution You may have heard about “DNAJB14” – a newly reported gene that supposedly protects against retinal stress. DNAJB14 is a heat-shock protein gene (one of the Hsp40 family) that helps cells deal with stress. A very recent study found that altering this gene in a lab model affected retinal neuron survival under stress conditions. Some news or blog posts might have sensationalized this as “gene therapy for glaucoma arrives!” or linked it to supplement claims. Here’s what’s really happening: Researchers discovered a piece in the complex biology of retinal cell death. In a mouse or cell experiment, they may have turned DNAJB14 on or off and saw differences in how ganglion cells survived. It’s an interesting research clue, but it is early-stage science. Plausible element: It’s biologically plausible that proteins like DNAJB14, which help cells manage stress, could influence ferroptosis or other cell death pathways. Understanding this gene might eventually lead to new targets. Laboratory evidence only: So far, this discovery is in lab models. No human data exists yet. There is certainly no dietary supplement or pill that can “enhance DNAJB14”. Any claims that a nutrient will mimic this gene’s effect have no proof. Risk of misunderstanding: It would be misleading to take this discovery as proof that some off-the-shelf supplement can give the same benefit. Changing gene activity in people would require advanced therapies (like gene therapy) that are not available for glaucoma. Supplements on store shelves simply can’t target a specific human gene arm yet. We often see new genetic findings get hyped. For patients, the key is to recognize the difference between lab research and practical treatments. Just because something is found in a lab does not mean you can buy it as a supplement. The path from gene discovery to an actual drug (if one ever comes) takes many years of trials. Until then, Dnajb14 is an exciting clue for scientists, not a new treatment you can buy. Keep this in mind when you hear headlines saying “New gene cures glaucoma!” – it’s much too early for that. Practical Takeaways for Patients Keep up proven treatments. The only proven way to slow glaucoma right now is lowering your eye pressure (with drops, laser or surgery) and regular eye exams. Supplements should never replace those. No miracle supplement exists (yet). Currently, no supplement has strong evidence to prevent glaucoma damage or restore lost vision (). Nutrients like vitamin A, C, B-complex are healthy, but taking extra pills won’t reverse glaucoma. At best, they might support overall health. Antioxidant foods are fine. Eating a balanced diet rich in fruits (vitamin C), leafy greens (some B vitamins), and other antioxidants is good for general health. But remember, pilot studies are not proof. Don’t rely on diet alone to protect your eyes. Be skeptical of “ferroptosis” products. If a product claims it targets ferroptosis to saveSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/is-glaucoma-an-energy-failure-disease-mitochondria-aging-and-the-optic-nerveTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a leading cause of irreversible blindness worldwide, affecting tens of millions of people (). It is traditionally linked to high eye pressure (intraocular pressure), but many patients continue to lose vision even when pressure is controlled. Scientists now think that pressure is only part of the story. Inside each retinal ganglion cell (RGC) – the neurons whose long fibers form the optic nerve – a complex energy crisis may arise over years. In this scenario, glaucoma becomes an “energy failure” disease: if an RGC cannot make enough energy, its axons and connections slowly fail, damaging vision. This article explores why optic nerve cells need so much energy, how aging and stress may starve them, and what researchers are trying – often by boosting cell power – to save the nerve. We’ll also connect these ideas to other brain diseases and early experimental treatments that aim to shore up cellular energy. Why Retinal Ganglion Cells Need Huge Energy Retinal ganglion cells are the nerve cells in the eye that send visual signals from the retina to the brain. They have an especially high energy demand. Unlike most neurons, RGC axons (the nerve fibers) travel a long distance without the usual insulating sheath called myelin. In fact, all along the length of the retina and optic nerve head, RGC axons are unmyelinated (). Each electrical signal (“action potential”) must be actively regenerated step by step, which uses a lot of energy. To meet this demand, RGCs pack in mitochondria – the cell’s “power plants” – along their axons, especially at the optic nerve head where the fibers take a sharp turn out of the eye (). The region just inside the optic nerve is mechanically stressful (squeezed by eye pressure and movement), so RGCs concentrate mitochondria there to keep energy up under strain. In short, RGCs are among the most energy-hungry cells: they “never stop,” and their unique structure means they are built with dense fuel-supplies () (). In practice, this means any problem that reduces their fuel can quickly hurt RGCs. Neurons rely on two main pathways to turn nutrients into ATP (cellular energy): glycolysis (using sugar) and oxidative phosphorylation (using oxygen in mitochondria) (). RGCs ride a delicate balance between these, and they depend on continuous delivery of oxygen and nutrients through tiny blood vessels. Even slight disruptions – like slower blood flow or extra pressure – can tip the balance. Glaucoma Stressors: Pressure, Blood Flow, and Aging Glaucoma stresses RGCs in several ways, any of which can hurt mitochondria (and thus energy supply). Eye Pressure and Blood Flow Elevated eye pressure makes it physically harder for blood to reach the retina and optic nerve. Imagine pinching a hose: reduced blood (and oxygen) supply starves cells of fuel. In glaucoma, this can create brief “ischemia-reperfusion” injury – a kind of mini-stroke where blood flow drops and then suddenly returns. During this process, mitochondria produce extra reactive oxygen species (ROS) that act like toxic sparks inside cells (). Indeed, animal studies show that high pressure causes a surge of oxidative stress in the retina. For example, when researchers raised eye pressure in rats, levels of glutathione (the cell’s natural antioxidant) plummeted while markers of superoxide (a damaging oxygen molecule) rose in the retinal ganglion cell layer (). In other words, high pressure literally starves RGCs and floods them with damaging free radicals () (). Over time, this “chemical stress” weakens RGC mitochondria, making them less able to make energy. Aging and NAD Decline Age is the other big risk factor. As we grow older, all our cells lose some ability to fight stress. In RGCs, a key change is a drop in NAD (nicotinamide adenine dinucleotide) – a molecule that cells use like currency in energy production. Multiple studies in glaucoma models report that retinal NAD levels fall with age (and with pressure) () (). This makes a perfect storm: older RGCs have less raw fuel (NAD) to run their mitochondria, so they are already close to energy failure. The consequences are clear in experiments. In a mouse study, the researchers found that boosting NAD by giving nicotinamide (a form of vitamin B3) protected RGCs starkly. At the highest dose, 93% of treated eyes had no glaucoma damage at all, even though eye pressure still rose (). This shows that simply “refilling the battery” can nip the damage in the bud. In other work, aging mice given high-dose nicotinamide kept their NAD levels high long-term and resisted vision loss (). Conversely, human glaucoma patients have been found to have lower blood levels of vitamin B3 compared to people without glaucoma (). All together, the evidence suggests that age-related NAD loss tips some RGCs into an energy crisis () (). Oxidative Stress: When Cells Burn Too Much Oxidative stress is a term you will hear often in glaucoma studies. It simply means the balance between harmful oxygen molecules (like free radicals) and the cell’s antioxidants is tipped so far that damage occurs. Mitochondria naturally leak some reactive oxygen during energy production, and small amounts are normal. But when pressure, poor blood flow, or aging disrupts the system, RGCs generate excess radicals faster than they can clean them up. One review explains: reactive oxygen are “essential participants” in cell signaling, but when production overwhelms the antioxidant capacity, damage to cellular molecules ensues – a state of oxidative stress (). In glaucoma, oxidative stress is seen in multiple ways. Studies have found oxidative modifications of proteins in dying RGCs, and loss of antioxidants in the eye’s fluids () (). In experimental models, artificially raising eye pressure causes spikes of oxidative markers in the retina () (). Oxidative stress itself can damage mitochondria and other cell parts. Proteins, DNA, and membrane fats get “shot” by these reactive species, making mitochondria less efficient and cells more prone to self-destruct. This is why antioxidants are considered for therapy (see below): by bolstering the cell’s cleanup crew, we hope to prevent the energy machinery from self-immolating. Mitochondrial Dysfunction and Optic Nerve Damage When mitochondria start failing, an RGC can’t make enough ATP, its essential energy packets. The results are profound: the nerve fiber (axon) can no longer transport cellular cargo (like proteins and organelles) up and down its long length. Researchers describe this as a breakdown of axonal transport – think of it like cargo trucks stuck on a road because there’s no fuel. In glaucoma models, impaired axonal transport is one of the earliest signs of trouble (). This eventually leads to thinning of the optic nerve and failure of synapses in the brain – and the visual field loss patients see. Microscopic examinations confirm that mitochondria look abnormal long before RGCs die. For example, in one glaucoma model, the tiny folds inside mitochondria (“cristae”) become reduced on electron microscopy, signaling collapse of energy factories even before any cell loss (). The cells also lose internal structure: in DBA/2J mice (a glaucoma strain), RGCs start retracting branches and pruning connections once energy falters (). Bursting these processes of energy shortfall and structural damage is a vicious cycle: more oxidative stress impairs mitochondrial function, and bad mitochondria create more oxidative stress, along with activating cell death programs () (). Thus, by the time clinical signs appear, the RGCs have already lost much of their support. This energy-starvation model helps explain why some glaucoma patients (especially the elderly) continue to worsen even with normal eye pressure – their cells simply can’t keep up. Neuroinflammation and the Eye’s Immune Storm Another layer is neuroinflammation. The optic nerve is supported by glial cells (like astrocytes and microglia) that normally help neurons. But when RGCs struggle, they send distress signals that activate these glial cells. At the same time, damaged mitochondria themselves release inflammatory cues. For instance, fragments of mitochondrial DNA can act as “danger signals” that trigger the cell’s immune sensors (e.g. the NLRP3 inflammasome), causing release of inflammatory cytokines like IL-1β (). Once inflammation kicks in, it further robs cells of energy (it takes fuel for immune reactions) and can directly damage neurons. In fact, a recent review noted that in glaucoma, “crosstalk” between mitochondria and inflammation accelerates damage: injured mitochondria amp up immune signals and, in turn, immune signals further drown the cell’s power production (). Practically, this means that high pressure or oxidative stress in the optic nerve can lead to an immune reaction similar to what we see in Alzheimer’s or Parkinson’s disease, contributing to a downward spiral in RGC health () (). While our technology is still catching up in mapping inflammation in the eye, it’s clear that metabolic failure and immune activation go hand in hand. Imaging of human glaucomatous optic nerves shows markers of inflammation, and many immune-related genes are switched on in stressed optic nerve tissue. ThSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-future-of-glaucoma-care-may-be-personal-matching-treatment-to-each-patient-s-riskTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:The Future of Glaucoma Care May Be Personal: Matching Treatment to Each Patient’s Risk Glaucoma is a chronic optic nerve disease and a leading cause of irreversible blindness. Traditionally, doctors have focused on one main factor – eye pressure – to diagnose and treat glaucoma. But in recent years experts have realized that glaucoma behaves very differently from person to person. In fact, two patients with the same eye pressure can have very different outcomes. For example, one patient might slowly lose vision despite moderate pressure, while another with high pressure stays stable for years. This is because many hidden factors – genetic traits, eye anatomy, blood flow, lifestyle habits and more – all influence glaucoma risk () (). Today we are on the brink of truly personalized glaucoma care, where doctors will tailor follow-up plans and treatments to each person’s unique risk profile. In this article we’ll explore how clinicians estimate glaucoma risk now, and how future tools like advanced imaging, genetics and artificial intelligence (AI) may change things. We’ll give examples of different patient profiles and imagine what glaucoma care might look like in 2030. We’ll also consider possible pitfalls, like too many tests or unequal access to new technology. Why Two Patients with the Same Pressure Can Have Different Outcomes A key reason is that glaucoma is multifactorial. High eye pressure (intraocular pressure, IOP) is the best-known risk factor, but it is far from the only one. Some people’s optic nerves are simply more vulnerable than others’. For example, one large study (the Ocular Hypertension Treatment Study) found that people who went on to develop glaucoma tended to be older, already have larger “cup-to-disc” ratios in their optic nerve, and have thinner corneas than those who did not (). In other words, an older person with a fragile optic nerve and a very thin cornea might suffer damage at a given pressure level that a younger person with a robust nerve might tolerate. Similarly, about half of glaucoma patients never have very high pressure – so-called normal-tension glaucoma – but still lose vision because of other problems like poor blood flow or genetic factors (). The European Glaucoma Society even emphasizes that “IOP is not the only factor” in glaucoma risk (). To put it another way: imagine two people, both with an eye pressure of 25 mmHg. Patient A has a thin cornea (which actually masks higher true pressure) and a family history of glaucoma. Patient B has a thick cornea and no family history. Patient A’s optic nerve may already be stressed from years of even slightly elevated pressure and blood flow issues, so glaucoma damage can progress more quickly. Patient B’s healthier eyes and strong corneas might tolerate that pressure without harm for much longer. In short, each eye is different – like a unique machine with its own weak points – so identical pressures don’t guarantee identical outcomes () (). How Doctors Estimate Glaucoma Progression Risk Today Currently, eye doctors (ophthalmologists) piece together many clues to judge each patient’s risk of vision loss. There’s no single “glaucoma paint-by-numbers” formula used for everyone, but clinicians pay attention to known risk factors and test results. Some key elements include: Baseline eye pressure (IOP): Even if pressure isn’t the whole story, higher IOP generally raises glaucoma risk. Yet doctors also consider pressure fluctuations over time, not just one reading (). Optic nerve appearance: A large or asymmetric cup-to-disc ratio (the hollow in the optic nerve head) suggests more damage or susceptibility (). If one eye’s nerve shows more cupping, that eye may need stricter control. Visual field tests: A standard visual field test maps what areas a person can see. Early loss in these tests indicates glaucoma onset. Doctors look at field results over time – a faster rate of field loss means higher risk. Retinal imaging (OCT): Technologies like Optical Coherence Tomography (OCT) give high-resolution scans of the optic nerve and its retinal nerve fiber layer. Thin or thinning fiber layers can signal higher progression risk even before fields are affected. Corneal thickness (pachymetry): The central cornea’s thickness is measured because it affects pressure readings. A thin cornea not only underestimates true IOP, it also independently correlates with nerve vulnerability (). In fact, the Ocular Hypertension Study found people with corneas ≤555 µm had three times the risk of glaucoma compared to those with thicker corneas (). Age: Older patients generally have higher risk. Each additional decade of age slightly increases the odds of progression. Myopia (nearsightedness): Being very nearsighted stretches the eye and optic nerve, raising glaucoma risk (). Family history: A strong clue – a first-degree relative (parent, sibling) with glaucoma boosts risk dramatically. One review found relatives of glaucoma patients had a 22% lifetime risk, versus only about 2–3% for relatives of people without glaucoma (). Race/ethnicity: People of African descent have higher rates of open-angle glaucoma, and those of Asian descent have more angle-closure forms (). Certain genetic backgrounds color risks. Systemic health: Conditions like diabetes and high or low blood pressure [L557–560] can worsen optic nerve health. For instance, very low blood pressure at night (“nocturnal hypotension”) or sleep apnea may starve the eye of blood, adding risk () (). Lifestyle factors: Smoking, for example, damages tiny blood vessels and is linked to glaucoma progression (). Migraine and systemic vasospastic issues can also hint at vulnerable optic nerve perfusion (). Medication adherence: Known modifiable factor – if a patient doesn’t stick to treatments, risk climbs. Often, doctors will use risk calculators or scoring systems. For example, the Ocular Hypertension Treatment Study (OHTS) provided a calculator for patients with high pressure but no glaucoma. It combines age, pressure, corneal thickness, optic disc measurements and more to estimate a 5-year glaucoma risk () (). Such tools quantify how multiple factors interplay. In practice, doctors integrate all these clues. If most signs point to low risk (thick corneas, no family history, only slight optic changes), a patient might only need mild treatment or routine monitoring. But high-risk patients – say, an older person with very cupped optic nerves and thin corneas – would likely get aggressive treatment to lower pressure promptly () (). The Role of Key Tests: OCT, Visual Fields, Pachymetry and More Two tests are especially important today: Visual Field Testing: This functional test charts a person’s field of vision (often using a computerized device). It detects visual field loss from glaucoma – for example, small scotomas (blind spots) that develop in peripheral vision. Tracking changes in the field over months or years lets doctors calculate how fast vision is worsening. Faster loss means a higher risk profile and need for stronger therapy. Optical Coherence Tomography (OCT): This is an imaging “CAT scan” of the eye. OCT gives a high-resolution cross-section of the retina and optic nerve. It measures the thickness of retinal nerve fibers and shows structural damage. Thinning on OCT often precedes visible field loss. By comparing OCT images over time, doctors spot subtle nerve fiber decline. This helps them catch progression earlier and tailor treatment. (Emerging OCT angiography can even image blood flow around the optic nerve.) Other measurements round out the picture: Pachymetry for corneal thickness, as noted. Gonioscopy to check the iris and angle (to rule out angle-closure threat). Photography of the optic nerve to record appearance. Intraocular Pressure Checks (often at different times of day or after posture changes). Together, these tests help classify each patient. One might say: “Our patient has moderately damaged fields and moderately thin nerve fiber layers, with IOP usually in the mid-20s. Given her thin corneas and a family history of glaucoma, her risk is above average.” Another patient with similar pressures but normal OCT and no family risk might be classified as lower risk. AI for Tailoring Follow-Up and Treatment Artificial Intelligence (AI) is starting to enter glaucoma care, promising to personalize decisions further. Advanced AI systems can analyze large amounts of data – images, test histories, even genetics – to spot patterns a human might miss. For example, a recent review of over 150 studies found that deep-learning AI on fundus photos or OCT scans can match or even exceed specialist accuracy for glaucoma detection (). More impressively, some sequence-based AI models could detect subtle worsening of visual fields up to 1.7 years earlier than traditional trend analysis (). In other words, an AI algorithm looking at a series of fields and OCTs could warn a doctor long before visual acuity worsens visibly. Other AI models have been trained to predict which patients are likely to need surgery – one multi-modal network combining OCT, field tests and clinical data achieved an accuracy (ROC AUC ~0.92) in forecasting eventual need for incisional surgery ().Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-the-optic-nerve-be-protected-the-new-neuroprotection-era-in-glaucoma-researchTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Can the Optic Nerve Be Protected? The New Neuroprotection Era in Glaucoma Research Glaucoma has long been called the “silent thief of sight” – historically treated by focusing on intraocular pressure (the fluid pressure in the eye). But a growing body of research shows that glaucoma is not just a plumbing problem. It is also a neurodegenerative disease that gradually destroys the eye’s nerve cells. Imagine your eye as a camera and the optic nerve as the cable that carries its images to your brain. In glaucoma, this cable gets frayed and rusty over time, not only from high pressure but from an internal “wear-and-tear” process. In this article, we’ll explain why that matters, and how new treatments are trying to protect the neural wiring of the eye. We’ll use simple metaphors – nothing too technical – so you can follow along easily. Retinal Ganglion Cells: The Eye’s Messengers Inside the eye’s retina, special nerve cells called retinal ganglion cells (RGCs) work like telephone wires, carrying visual signals from the eye to the brain. Each eye has about 1.5 million of these cells, whose long fibers bundle together into the optic nerve (). Think of RGCs like millions of tiny light bulbs along a cable: when light hits the retina, RGCs convert that information into electrical signals that zoom up the optic nerve to the brain. RGCs are crucial. Once they die, our vision is lost in those areas – they do not regenerate on their own. As one review bluntly puts it, glaucoma is marked by the “irreversible loss of retinal ganglion cells (RGCs)” (). In other words, if these cells “burn out,” the damage is permanent. A 2021 study of lab-transplanted RGCs emphasizes that because RGCs “transmit visual information from the retina to the brain, their progressive loss results in fading vision and, ultimately, blindness” (). In everyday terms, losing RGCs is like cutting fibers in a cable – the signal can’t get through, and you get a blind spot or fair-sized dark area in your vision. Because RGCs do so much work, they burn a lot of energy. They’re packed with tiny power plants called mitochondria, and they need good blood flow and nutrients. This makes them shinny glass in a storm: delicate and easily damaged. In glaucoma, anything that weakens RGCs – from starvation of blood to chemical “rust” – can cause them to die. Glaucoma: More Than Just High Eye Pressure Traditionally, doctors have measured eye pressure as the key glaucoma risk. High pressure can physically squeeze the optic nerve fibers as they exit the eye (like pressing on a cable at the wall). This pressure can block roads for nutrients, slow down the traffic of essential chemicals, and trigger cell damage (). But scientists now understand that high pressure is only one piece of the puzzle. In many patients, something else is at work hurting those nerve cells, even when pressure is normal. Neurodegeneration and the Brain In fact, glaucoma is increasingly seen as similar to other nerve diseases like Alzheimer’s or Parkinson’s, but focused on the eye and its brain connection. Studies have found that damaging glaucoma can spread beyond the eye all the way into the brain’s visual centers (). For example, a recent review explains that people with glaucoma often show changes in their brain, such as thinning of visual cortex or altered neural connections – much like early Alzheimer's patients (). This hints that glaucoma triggers a kind of “domino effect” of damage along the visual pathways, not unlike what happens with other neurodegenerative diseases. Mechanistically, researchers are finding shared culprits between glaucoma and brain diseases: things like broken mitochondria, chronic inflammation, and clogged nerve transport systems (). In simple terms, if Alzheimer’s is a problem of aging brain cells, glaucoma may be a related problem of aging eye cells (RGCs) and their brain links. Beyond Pressure: Inflammation, Oxidative Stress, and Vascular Factors Because glaucoma is more than just “too much fluid,” other harmful processes are blamed when we see vision worsen despite good pressure control. One key factor is inflammation. The eye – like the brain – has immune-support cells (glia) that can overreact when stressed. Stressed RGCs send out danger signals such as reactive oxygen species (free radicals), nitric oxide, and inflammatory proteins (like TNF-α and interleukins) (). This can trigger chronic inflammation that ironically damages the very neurons it was meant to protect. Here’s an analogy: imagine RGCs as factories. When something goes wrong (like machinery overheating), the factory alarms (inflammatory signals) go off. If the alarm system is too sensitive or stuck on, it can end up hurting the factory itself, not helping it. In glaucoma, exhausted RGC mitochondria may flood the retina with reactive oxygen (oxidative stress) that activates this “alarm,” causing friendly fire against nerves (). One review on glaucoma neuroinflammation describes how broken mitochondria in RGCs can set off the immune system, leading to a sustained damaging response (). In short: when RGC energy centers fail, they trigger a damaging inflammation loop within the eye. Vascular factors also play a role. The tiny blood vessels that feed the optic nerve can be sensitive. Eyedrops that raise heart rate or conditions like diabetes and high blood pressure can affect blood flow to the eye. Low blood pressure (especially at night) or vascular “spasms” are linked to worse glaucoma because they temporarily starve RGCs of oxygen (). For instance, one comprehensive review notes that reduced blood perfusion pressure and faulty blood vessel regulation likely help drive RGC damage (). In our cable analogy, this is like having power fluctuations in the electrical grid; even if the cable and camera are fine, if the power supply is shaky, the system falters. This is why glaucoma specialists often pay attention to cardiovascular health and sometimes even advice moderating certain blood pressure medications at night. Why Pressure Control Isn’t Always Enough All these factors explain why some patients keep losing vision even when their eye pressure is low or normal. For example, “normal-tension glaucoma” is a common scenario where eye pressure never gets high, yet RGC damage and optic nerve cupping progress (). Conversely, in some patients with high pressure, lowering it stops further damage. But in many others, damage creeps on. As one expert noted, despite “apparently good” pressure readings, disease can worsen in a number of patients (). In other words, lowering pressure is necessary but sometimes not sufficient. A meta-analysis of patient studies put it starkly: doctors have observed that RGC loss often “continues despite lowering IOP,” meaning that treatments only focused on pressure “may not be beneficial for some glaucoma patients” (). Think of blood pressure for analogy: lowering blood pressure helps most high-risk people, but if someone is still leaking cholesterol plaques or has other heart risks, they may still have a heart problem despite normal pressure. Similarly, in glaucoma we must also target the nerve itself, not just the fluid pressure. The Search for Neuroprotective Treatments Since RGCs are dying by many causes, scientists have searched for neuroprotective strategies: treatments that can keep these nerve cells alive longer or healthier. In simple terms, neuroprotection means anything aimed at preventing nerve damage or death (). This new era of research looks beyond pressure: it asks, “How can we shield the optic nerve from harm, regardless of the pressure?” Researchers are exploring many avenues, from drugs to diet to bioengineering. Here are some current and emerging strategies being studied: Neuroprotective Eye Medications: Some existing glaucoma drugs might have nerve-saving effects. For example, brimonidine (an eye drop that lowers pressure) was hoped to strengthen RGC survival. Lab studies in animals showed promise, but human trials have so far been disappointing (). An evidence review reports that to date, clinical trials of such “neuroprotectors” have failed to show clear benefits in people (). Another drug, memantine (used in Alzheimer’s), was tested in large glaucoma trials but did not prove effective. At present, manufacturers have not reported any significant vision benefit, so memantine is not part of glaucoma care. In short, while drugs like these are studied, none are yet a proven neuroprotective cure. Growth Factors and Gene Therapy: Scientists have tried giving eyes extra “growth factors” – proteins that help nerves survive and grow. For example, nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF) can keep RGCs from dying in animals. Experiments involving viral gene therapy are in early stages: for instance, researchers can inject a harmless virus carrying genes for protective proteins into the eye. One phase-1 trial (GVB-2001) is even testing a gene treatment to relax eye muscles for pressure control (), and similar approaches might deliver neuroprotective genes later on. These techniques are still experimental. The hope is to one day use gene vectors to make the eye produce its own protective agents, but it is deSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/sustained-release-glaucoma-implantsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Sustained-Release Glaucoma Implants Imagine having glaucoma and relying on daily eye drops to protect your vision – but every night, whether out of fatigue or busy schedule, you forget or skip them. Many patients know this drill: missing eye-drop doses, administering them poorly, or giving up because the drops sting or irritate. Glaucoma often feels like a hidden disease – vision can worsen silently when pressure stays high – so skipping medication can be dangerous. Studies show that roughly one in three glaucoma patients admit they do not use their eye drops consistently (). Side effects like burning, redness or dry eyes make matters worse: patients who experience side effects are much more likely to stop or skip treatments (). In short, relying on daily eye drops is a major problem – many people simply do not take them as prescribed, meaning real-world glaucoma control suffers () (). Ophthalmologists and researchers have long noted these challenges. Topical drops can work well if used perfectly, but in reality poor adherence and side effects are common (). Recognizing this, scientists have developed sustained-release alternatives. The idea is to deliver glaucoma medicine inside or near the eye once, so it slowly bathes the eye with medication for months – eliminating the need for a patient to remember daily drops. These new approaches include small intracameral implants (placed inside the eye), drug-eluting devices (like medicated spacers or rings), and long-acting prostaglandin delivery systems. By continuously releasing medication over time, these technologies promise steadier eye pressure control and far fewer missed doses, potentially reshaping glaucoma care () (). Why Eye Drops Are So Hard Glaucoma treatment often starts with eye-drop medications that lower intraocular pressure (IOP). But using drops correctly isn't easy. Many patients struggle with arm or neck stiffness, shaky hands, or poor vision that makes self-instilling drops difficult. People sometimes miss the eye entirely, or blink the drop out. Even simply remembering to take an oftentimes twice-daily dose can be a challenge amid busy lives. Surveys and studies confirm this: a review found that 30–50% of patients with chronic diseases in general do not adhere perfectly to their treatments (), and in glaucoma specifically roughly 30% admit missing enough drops to be considered “non-adherent” () (). Side effects add another hurdle. Glaucoma drops often contain preservatives or strong active drugs, which can cause stinging, redness, or eye dryness. For example, one study noted that about 38% of patients who had any side effects at all admitted poor use, compared to only 18% of those without side effects (). Preservatives in drops (like benzalkonium chloride) can irritate sensitive eyes, worsening comfort. Over time, patients may decide that putting drops in each day is “too unpleasant,” leading them to skip doses or stop the medication entirely. All this adds up to a hidden but serious real-world problem. In the controlled setting of a clinical trial, patients may dutifully use every drop and achieve excellent IOP control, but in everyday life “the patient-independent” issues – forgetfulness, dexterity, discomfort – often mean glaucoma is undertreated. Doctors ring alarm bells: poor adherence is a leading cause of glaucoma progression and vision loss. As one glaucoma review put it, conventional drops suffer from “poor patient adherence” and “local side effects”, which spurs the search for better delivery systems (). How Sustained-Release Systems Work Sustained-release glaucoma devices are built to solve these adherence issues. Instead of relying on a patient to administer a drug every day, the medication is encapsulated inside an implant or insert. These can be placed in or around the eye in a simple procedure, and then they continuously leach small doses of medicine over weeks to months. Intracameral implants: These are tiny drug-packed rods or reservoirs placed in the anterior chamber (front part) of the eye. For example, a biodegradable polymer rod can be injected through a needle into the eye; once inside, the polymer slowly breaks down, releasing the drug inside the eye over time (). Some devices, like the newly FDA-approved iDose® TR, use a tiny titanium reservoir anchored in the eye’s drainage angle, dispensing travoprost around the clock () (). Drug-eluting inserts or depots: Other ideas include punctal plugs or ocular rings: think of a soft plug placed in the tear duct or a ring in the eyelid that slowly releases prostaglandin analogs. These sit in the eye’s drainage or surface and diffuse medication gradually. Some specialty contact lenses have been tested that soak up a prostaglandin and sit on the eye, giving off drug slowly over days. Biodegradable implants: Many approaches use biopolymers (like PLGA or PEA) that safely dissolve in the eye. For instance, the Travoprost XR (ENV515) implant is made of a biodegradable material designed to release travoprost evenly for 6–12 months (). After that period, it has fully dissolved, and if needed a new one can be injected. Other implants may need manual removal or replacement. The common theme is “set it and forget it.” A doctor or specialist places the device in the eye during a visit. The patient then goes home and in the background (literally behind their eyeball) the medication is continuously supplied, day and night, without any effort from the patient. It’s like having a mini medication pump inside the eye. Researchers often describe this as “continuous drug delivery” – a stark contrast to the ups and downs of dosing with drops (). Example: Bimatoprost Sustained-Release (Durysta) One real-world example is Durysta® (bimatoprost SR) – the first FDA-approved implant (March 2020) for glaucoma treatment (). This tiny cylindrical implant contains 10 micrograms of bimatoprost (a prostaglandin analog) embedded in a solid polymer. It is injected with a fine needle into the front of the eye in a quick office procedure. Once inside, the polymer slowly dissolves, sending steady bimatoprost to the eye tissues over about 4–6 months. In clinical trials, Durysta’s single injection lowered eye pressure about as well as a daily bimatoprost drop would have, but for many patients it lasted significantly longer. Because it is biodegradable, no device removal is needed – it simply disappears over time. After one Durysta implant, many patients achieve target IOP for 6 months or more without any drops. However, the FDA label notes a key precaution: Durysta is currently approved for only one injection per eye, due to some concerns about corneal safety if repeated (). (In a few trial patients, multiple Durysta implants led to too much stress on the cornea’s cells, so repeated use is not allowed at present.) Example: Travoprost Implant (iDose® TR and Others) Travoprost, a common eye-drop medication, is also being delivered by implants. The new iDose® TR (by Glaukos) received FDA approval in December 2023 (). This device is a tiny, non-degradable pill made of titanium with 75 micrograms of travoprost inside. A surgeon places it in the drainage angle of the eye, and a thin membrane slowly releases travoprost 24/7 for about three years () (). Once that time’s up, the implant can be removed or replaced. In pivotal trials, a single iDose implant lowered pressure effectively for years, matching the effect of daily travoprost drops. Most people in the trials were able to reduce or stop additional glaucoma drops after the implantation. Another travoprost implant under study is Travoprost XR (ENV515) – a biodegradable rod similar in concept to Durysta but with travoprost. Preclinical tests in dogs and early human trials show that a single ENV515 injection lowers eye pressure significantly for many months (). In one trial, by Day 25 the implanted eye had a 30%+ drop in IOP, comparable to someone using daily travoprost eye drops (). Later in that study, most patients on the implant achieved target pressure control for a year or more. ENV515 is still going through clinical testing and awaits FDA approval (). Other Investigational Systems Research is ongoing on many other sustained-release systems. For instance, researchers have tested medicated contact lenses that slowly release latanoprost for a week, and punctal plugs that release travoprost or latanoprost. Some labs are developing long-acting injections (like microscopic particles) placed under the conjunctiva that dissolve over time. These are not yet in mainstream use, but they illustrate the wide interest in “drop alternatives.” Benefits of Sustained-Release Implants These new technologies offer several clear advantages over daily drops: Steady IOP control: Instead of daily peaks and troughs from each drop, the eye is bathed in a constant low-dose stream of medication. This can keep pressure very stable. Some trials have found that implant patients have more consistent IOPs and less fluctuation than those on drops. No missed doses: Because the patient doesn’t have to apply a drop, there’s virtually no chance of forgetting or misusing the medication. In a large travoprost implant trial, about 80–84% of patients using an implant reduced or eliminSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/disease-modifying-glaucoma-drugsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a chronic eye disease where nerve cells in the retina and optic nerve gradually die, often causing blindness if untreated. For decades, the main proven treatment has been lowering intraocular pressure (IOP) – the fluid pressure inside the eye – to slow damage (). This is done with eye drops, laser or surgery. But pressure isn’t the whole story. Many patients still lose vision even when their pressure is well-controlled. In fact, about one-third of treated patients eventually go blind in one eye (). And some people (so-called “normal-tension” glaucoma) get damage even with normal pressure. These facts tell us that simply draining fluid is not enough. Glaucoma is fundamentally a neurodegenerative disease – nerves are dying. Scientists are now exploring whether new drugs can modify the disease itself rather than just treating pressure, by protecting the nerves and improving the eye’s blood supply. In this article, we’ll explain what “disease-modifying” means in glaucoma and why it’s exciting. We’ll look at the importance of ocular blood flow and the endothelin pathway (which can choke blood vessels), and how improving blood flow or cell health might save vision. We’ll also cover PER-001, a new drug in development by Perfuse Therapeutics (now owned by Bayer), which targets endothelin. We’ll weigh the evidence – what’s been shown so far in small trials, what’s still uncertain – and discuss what the future might hold in 3–10 years. The tone is hopeful but realistic: disease-modifying therapies could change how we treat glaucoma, but they are not cures (at least not yet). What “Disease-Modifying” Means in Glaucoma A disease-modifying therapy is one that changes the course of the disease itself, instead of just relieving symptoms. In glaucoma, that would mean a drug that actually slows or stops the nerve-cell death in the eye, not just reduces pressure. It’s a bit like how some arthritis drugs do more than just mask pain by slowing joint damage. For glaucoma, the idea is often called “neuroprotection” – protecting the retinal ganglion cells (RGCs), the neurons that carry vision signals from the eye to the brain. A classic definition says neuroprotection is treating glaucoma “by a mechanism independent of lowering IOP” (). Right now, no therapy has been proven to do this in patients. In large, decades-long studies only pressure lowering showed a clear benefit. In fact, a 2023 review in Molecular Aspects of Medicine notes that “current strategies only target intraocular pressure… and do not directly target the neurodegenerative processes” of glaucoma (). It adds that up to 40% of patients still progress to blindness in at least one eye despite strict pressure control (). So researchers say we urgently need therapies that go beyond pressure. In plain terms: imagine the optic nerve as a plant that not only needs the right water pressure but also good soil and light. Pressure drops help water travel (good!), but if the root cells are sick or starved, the plant will still die. Disease-modifying treatments aim to brighten the light or improve the soil – directly helping the cells survive and function. Blood Flow and Endothelin: Why They Matter One big area of research is improving ocular blood flow. The retina is one of the body’s hungriest tissues for oxygen and nutrients. It’s like a high-performance engine needing constant fuel. If blood flow to the retina or optic nerve is compromised, cells can suffer from ischemia (lack of oxygen). Over time, even shortfalls in blood supply can kill retinal ganglion cells. Many people with glaucoma have vascular issues: for example, some have a condition called Flammer syndrome (blood vessels that over-react) or low blood pressure at night, which can worsen eye blood flow. In normal-tension glaucoma (glaucoma at normal pressures), poor blood flow is thought to be a key culprit. Scientific studies support this. For example, an experiment showed that giving endothelin-1 (a natural chemical) to animals reduced blood flow in the retina and optic nerve, causing ischemic damage (). The same molecule, endothelin-1, also raises pressure and promotes optic nerve injury (). Endothelin is perhaps the most potent vasoconstrictor in the human body () – imagine it like a very strong clamping of blood vessels. In glaucoma patients, blood levels of endothelin-1 tend to be higher than normal. Researchers even found that blocking endothelin receptors in healthy animals had no effect on normal flow, but giving extra endothelin caused a big drop in blood flow (). In other words, endothelin ramps up only when things are already bad. Why is this important? If endothelin-1 is high in glaucoma, it could constrict the small vessels in the eye, depriving nerve cells of oxygen. A 2011 review on endothelin in glaucoma put it neatly: increased endothelin can “lead to pathological changes in the retina and optic nerve head which is assumed to contribute to the degeneration of retinal ganglion cells” (). In simpler terms, high endothelin is like turning down the road supply to the optic nerve while also turning up the pressure, double-whammying the nerve. Therefore, drugs that block endothelin (called endothelin receptor antagonists) could in theory keep vessels open and protect nerves. Is there evidence OBF (ocular blood flow) matters in patients? Measurements of blood flow in glaucoma eyes often show abnormalities, and the risk of glaucoma goes up if perfusion pressure (blood pressure minus IOP) is too low (). Clinically, some glaucoma patients benefit from treatments that improve ocular perfusion (for example, some doctors manage blood pressure or use calcium channel blockers off-label). But so far, there is no approved glaucoma drug whose main action is boosting blood flow. That’s changing in research: the idea is that if we can safely open up the eye’s blood vessels or correct vascular dysregulation, we might protect the optic nerve from ischemic damage. Mitochondria and Retinal Cell Survival Another cutting-edge concept is mitochondrial protection. Mitochondria are the “power plants” of cells, and retinal ganglion cells have extremely high energy demands. They need a lot of ATP to maintain their long axons and signaling in the retina. In glaucoma, several stresses (high pressure, free radicals, inflammation) can damage mitochondria, leading to energy failure and eventually cell death. Some genetic forms of optic neuropathy (like Leber’s hereditary optic neuropathy) show that mitochondrial DNA problems cause RGC death. In glaucoma, even without a genetic mutation, chronic stress may overload the mitochondria. Researchers are testing ways to keep mitochondria healthy in glaucoma. For instance, nicotinamide (vitamin B3), which boosts the mitochondrial energy molecule NAD+, has shown promise. In a small phase 2 trial, giving glaucoma patients a combination of nicotinamide and pyruvate (another metabolic fuel) led to a short-term improvement in visual function for many participants (). The treated patients had more visual field test points that got better (not just stopped worsening) over a couple of months compared to placebo (). Although this was a very short-term result and not yet evidence that visual loss is permanently slowed, it suggests that helping RGCs with extra fuel can improve how well they work. There are other mitochondrial and cell-targeting strategies under study. Some are antioxidants (to mop up free radicals) and others are drugs that block programs of cell death. For example, experimental treatments that pre-condition cells (using mild stress like low oxygen) can activate built-in survival genes () – this “stress response” can make RGCs temporarily more resilient. Another approach is using neurotrophic factors (like brain-derived neurotrophic factor or BDNF) or growth factors to encourage cell survival. In fact, an eye drop containing nerve growth factor (rhNGF) is now in early trials for glaucoma (), aiming to block the signal that tells RGCs to die. However, it’s important to note that most of these strategies are experimental. For instance, memantine (an Alzheimer’s drug thought to protect nerve cells by blocking glutamate toxicity) underwent large clinical trials but did not significantly slow glaucoma compared to placebo (). So, while metabolic and protective approaches are very promising in concept, proof of lasting benefit in patients is still pending. PER-001 and Other Disease-Modifying Approaches A big hope in the field right now is a drug called PER-001 (from Perfuse Therapeutics, soon to be Bayer) – an intravitreal (inside-the-eye) implant of an endothelin receptor antagonist. This is exactly the strategy of blocking endothelin discussed above. PER-001 slowly releases a small molecule that blocks endothelin receptors in the eye every six months or so (). The idea is to keep eye blood vessels open, reduce inflammation, and protect retinal cells, in addition to helping lower pressure through better outflow. What do we know about PER-001 so far? Perfuse and Bayer have released encouraging early results. In a phase 1/2a study presented in 2025, a single PER-001 injection improved visual function and retinal structure compared to control overSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-copper-peptide-and-the-optic-nerve-a-deep-look-at-ghk-cu-oxidative-stress-and-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a group of eye diseases where nerve cells in the retina (retinal ganglion cells, or RGCs) slowly die, causing vision loss (). In most cases, high intraocular pressure (IOP, the fluid pressure inside the eye) is a major risk factor (). Treatments currently focus on lowering IOP, but this may not always stop nerve loss (). Indeed, some patients continue to worsen despite well-controlled pressure, suggesting other factors are at work () (). Glaucoma is now understood as a multifactorial optic neuropathy – age, blood flow, immune signals, cellular stress and genetics all play roles () (). In simple terms, glaucoma damages the optic nerve (the bundle of RGC axons connecting the eye to the brain) over time, often starting in mid-life or later. While lowering eye pressure is the only proven therapy now (), scientists are looking at other pathways because vision loss can continue from aging, reduced blood supply, oxidative damage, inflammation, and other cell-level problems () (). Plain-language summary: Glaucoma is a complex disease: it usually involves high eye pressure, but also aging, blood flow problems, and damage to retinal nerve cells. Treatments lower pressure, but they don’t always protect these cells fully. What is GHK-Cu? GHK-Cu stands for a small peptide (three amino acids: glycine-histidine-lysine) bound to a copper ion. It is a natural molecule found in the body (in blood plasma and wound fluid) () (). Doctors first discovered GHK in the 1970s as a “growth factor” in human plasma that could boost tissue repair (). GHK-Cu is much studied in dermatology and wound healing: it stimulates collagen and new tissue growth in experiments () (). Its levels normally decline with age (), and people have become interested in it for its anti-aging and repair signals. Overall, GHK-Cu is considered a normal human peptide, often cited as safe and well-tolerated (). It can be applied to the skin or taken systemically in research, but there is no approved medical use yet. In this article, “systemic effects” of GHK-Cu means effects throughout the body (bloodstream, organs), not just local skin or eye treatments. Plain-language summary: GHK-Cu is a naturally occurring protein fragment that carries copper. It is known to help wounds heal and may influence genes. People study it for anti-aging, but it is not a proven medicine for anything. Overlapping Biology of GHK-Cu and Glaucoma Oxidative Stress Oxidative stress is the damage that happens when harmful oxygen molecules (free radicals) build up and overwhelm the body’s defenses. It is like cellular “rust.” High levels of oxidative stress are found in glaucoma and other nerve diseases () (). Retinal ganglion cells have very high energy needs and rich fatty membranes, making them especially vulnerable to free radicals (). Research notes that when oxidative damage occurs (for example from high pressure or aging), it can trigger inflammation and nerve injury in the optic nerve () (). GHK-Cu has multiple antioxidant actions in lab studies. In wound experiments, GHK-Cu treatment boosted levels of antioxidant enzymes and molecules like glutathione and vitamin C (). It also directly neutralizes toxic lipid-byproducts. For example, GHK-Cu can bind and inactivate harmful breakdown products of fats (like acrolein and 4-HNE) that would otherwise damage cells (). In cultured cells, GHK alone (with or without copper) has been shown to reduce reactive oxygen species (). Computer analyses suggest GHK-Cu turns on many genes for antioxidant defense. For instance, one review notes GHK-Cu helps support enzymes like superoxide dismutase (SOD) and modulates iron levels to fight oxidative stress (). All together, these findings suggest that GHK-Cu could, in principle, boost the body’s antioxidant responses. However, antioxidant effects in cell or skin models do not guarantee protection of eye nerves. The eye has barriers and specialized chemistry. Simply taking an “antioxidant peptide” does not automatically cure glaucoma. Also, the body’s redox balance is complex – you can’t assume more antioxidants always help. For example, some large clinical trials of generic antioxidants in glaucoma have not clearly stopped progression (). Summary: GHK-Cu activates many antioxidant pathways and so might, in theory, help cells fight “rust.” But convincing evidence that it would specifically shield optic nerve cells in glaucoma is lacking. Mitochondrial Function Mitochondria are the cell’s energy factories. They use oxygen to produce ATP, the fuel cells need. Neurons like RGCs have huge energy demands, so healthy mitochondria are critical for their survival. Numerous studies link glaucoma to mitochondrial dysfunction (). In fact, glaucoma risk rises with age and with failing mitochondria – both and RGCs rely heavily on mitochondrial energy (). Conditions that hit mitochondria (low oxygen, metabolic stress) can trigger RGC damage in glaucoma. For example, in glaucoma models, high pressure or oxidative stress can impair mitochondrial function in RGCs and even form harmful protein clumps () (). In human optic nerve diseases like Leber’s hereditary optic neuropathy, a pure mitochondrial disorder, only the RGCs die (), highlighting this vulnerability. What about GHK-Cu? There’s no direct evidence on GHK-Cu and mitochondria in retinal cells. However, we can note some related points. Copper (delivered by GHK-Cu) is a cofactor for key mitochondrial enzymes. In particular, cytochrome c oxidase (complex IV of the electron transport chain) requires copper (). Thus, if GHK safely delivers copper, it might support mitochondrial energy production by supplying this element. (But this is purely hypothetical – it’s not proven that orally or topically given GHK-Cu ends up in mitochondria of RGCs.) Another idea is that by reducing inflammation or oxidative damage (as above), GHK-Cu could indirectly protect mitochondria. For now, this is speculative: we simply don’t have experiments showing GHK-Cu restores mitochondrial function in glaucoma. Plain-language summary: Retinal neurons need a lot of energy. In glaucoma, energy factories (mitochondria) in these cells can fail (). GHK-Cu may deliver copper needed by those factories (), but nobody knows if it actually helps RGCs make energy. There’s no direct proof GHK-Cu fixes mitochondrial issues in glaucoma. Neuroinflammation Glaucoma is increasingly seen as a brain-like neurodegenerative disease, with chronic inflammation in the retina and optic nerve. When RGCs are stressed or injured (by pressure, lack of blood, etc.), they release danger signals that activate immune cells (microglia and astrocytes) in the eye (). This neuroinflammatory response can help at first, but if it goes on too long it can harm RGCs and neighboring cells. In animal models of glaucoma, blocking certain inflammatory pathways (like IL-1β or TNFα signaling) protects RGCs (). Postmortem studies of human glaucoma eyes also show signs of chronic inflammation: activated inflammasomes and elevated inflammatory markers have been found in the optic nerve and retina () (). GHK-Cu has reported anti-inflammatory effects in other contexts. Wound studies noted that GHK-Cu treatment not only boosted antioxidants but also dampened inflammation (). GHK-Cu (and even GHK peptide alone) can lower pro-inflammatory molecules in skin cells after UV damage and in lung models of smoke injury. In cell studies, GHK orphaned deleterious oxidized lipids and prevented them from triggering inflammation (). In plain words, GHK-Cu seems to smooth out overactive immune responses in tissues like skin and lung. But it’s a big leap to assume the same would happen in glaucoma. The eye’s immune environment is very specialized. We have no experiments on GHK-Cu reducing microglial activation or retinal cytokines. Still, as a hypothesis: if GHK-Cu reduced chronic inflammation systemically, it could help protect nerves. This idea overlaps with general neuroprotection research (many studies look for anti-inflammatory treatments in glaucoma), but nothing specific links GHK-Cu to ocular neuroinflammation yet. Plain-language summary: Chronic inflammation in the eye damages nerve cells in glaucoma (). GHK-Cu is known to reduce inflammation in skin and other tissues (), so it might help calm the eye’s immune response – but this is only speculation because we have no direct data for glaucoma. Copper Biology Copper is a tricky element in biology: essential in trace amounts but toxic if unbalanced. It is an important cofactor for enzymes that protect cells. For example, copper is needed by superoxide dismutase (SOD) and ceruloplasmin – enzymes that break down reactive oxygen species (). Copper also helps regulate blood vessel growth and connective tissue enzymes. In fact, a deficiency of copper can impair normal repair and antioxidant defenses. However, free copper ions can trigger more oxidative stress through Fenton chemistry, so the body normally keeps copper tightly bound to carrier proteins. GHK-Cu is interesting because it tightly binds copper in a small peptide complex. In theory, GHKSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/brain-imaging-biomarkers-and-plasticity-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Glaucoma affects more than the eye Glaucoma is best known as a disease of the optic nerve and retina, but modern brain scans show it also involves the brain’s vision centers. Studies using MRI have found that people with glaucoma often have smaller brain structures and weaker connections in visual areas compared to healthy people () (). For example, a review in Frontiers in Neuroscience (2018) found thinner cortex in visual brain regions (lower volume in V1 and other visual areas) and abnormal blood-oxygen signals on fMRI in glaucoma patients (). These findings suggest that damage in the eye can travel “backwards” along the visual pathway, a process known as trans-synaptic degeneration. In other words, when retinal ganglion cells die in glaucoma, connected neurons in the lateral geniculate nucleus (LGN) and visual cortex can shrink or lose function too () (). Doctors and researchers use advanced MRI techniques to track these changes. One method is diffusion tensor imaging (DTI), which traces the brain’s white-matter fiber tracts. DTI has revealed rarefaction (thinning) of the optic radiations (the fibers from the LGN to visual cortex) in glaucoma patients, reflecting loss of nerve fibers (). Graph-theory analysis of DTI data even shows wide-range network changes: glaucoma patients have altered connectivity not just in visual areas but also in regions for movement and emotion (). In functional MRI (fMRI) scans, which measure brain activity, glaucoma patients often show reduced activation in the primary visual cortex (V1) when viewing images, and weaker functional connections between visual areas () (). In short, the brain imaging paints a consistent picture: glaucoma is associated with degeneration of the central visual pathway and disruption of normal network activity. MRI studies also measure cortical thickness – the thickness of the gray-matter surface. Several studies report that glaucoma patients have a thinner visual cortex. For instance, one MRI study found that people with open-angle glaucoma had significantly lower V1 thickness and smaller LGN volumes compared to controls (). These structural losses correlated with vision: in that study, thinner V1 and smaller LGN were tied to worse visual field scores (larger cup-to-disc ratio) (). Interestingly, brain changes are not limited to vision areas; some patients show thinning in non-visual regions like the frontal pole and amygdala (), which may relate to the stress or cognitive aspects of living with glaucoma. All together, these results confirm that eye damage in glaucoma leads to measurable brain atrophy and thinning, especially in visual pathways () (). Brain plasticity and reorganization The brain is not completely helpless in glaucoma – there is evidence of neuroplasticity (reorganization) that can help preserve function. When retinal cells die, nearby neurons or other pathways may adapt. Research in animals and patients shows that some retinal ganglion cells can recover function if treated early, and that the brain can adjust its wiring after long-term vision loss () (). For example, one study of mice found young animals could regain full retinal nerve function days after a pressure-induced injury, whereas older mice took much longer (). In humans, vision tests often improve after lowering eye pressure in mild glaucoma, suggesting surviving neurons ramp up activity (). On a brain level, functional MRI and connectivity studies hint that undamaged parts of the visual network may increase their connectivity to compensate for lost input () (). Specialized analyses (“AI analysis” or advanced computational modeling) are helping to spot subtle reorganization. For example, DTI-based network models found that glaucoma patients show higher clustering (stronger local connectivity) in certain occipital regions, perhaps reflecting an attempt to reroute visual information (). Overall, imaging suggests the adult visual cortex retains some flexibility: it can partially reorganize blood flow and synaptic connections after injury () (). However, this plasticity has limits. If the retinal loss is too severe or the disease is advanced, many neurons are gone and the cortex thinning becomes irreversible () (). MRI biomarkers of resilience Researchers are now eager to find which brain changes predict better or worse outcomes. The hope is to identify biomarkers — MRI features that indicate who is resilient (maintains vision) versus who might benefit most from therapy. For instance, if a patient’s visual cortex is still relatively thick and its connections largely intact on DTI/MRI, they may have a reserve that could support recovery with treatment. Conversely, early signs of LGN shrinkage or optic radiation damage might signal rapid progression. Some candidate biomarkers have emerged from studies. One approach is to correlate brain metrics with vision tests. The network/connectivity study mentioned above found that thinner retinal nerve fiber layer (from OCT eye scans) was linked to abnormal connectivity in the amygdala and temporal lobe on MRI (). This suggests combining retinal imaging and brain scans could flag patients whose brains are “keeping up” with the damage. Another study showed a tight correlation: eyes with worse visual field loss had thinner V1 cortex and smaller LGN on MRI (). In practice, a patient with preserved V1 thickness or high-fidelity DTI pathways might be more likely to maintain vision if treated. These ideas are still being tested, but the principle is that MRI measures of visual pathway integrity could one day help predict individual outcomes () (). Fusion of eye and brain imaging To get the best picture of glaucoma, experts advocate multimodal imaging – combining eye tests and brain scans. For example, optical coherence tomography (OCT) can precisely measure the retina’s nerve layers, while MRI assesses the brain. One recent study explicitly linked these: it found associations between OCT measures (like macular ganglion cell layer thickness) and brain connectivity. In that work, weaker connectivity in certain brain nodes went along with thinner retinal layers (). This kind of fusion could improve disease staging (knowing how advanced it is) and help select patients for neuroprotective treatments or rehabilitation. In future clinical trials, doctors might require both OCT and brain MRI to choose patients whose brains have enough intact wiring to benefit from therapy () (). Another practical example: combining visual field tests (functional eye exam) with MRI-based biomarkers. If a patient shows stable visual fields but MRI reveals worsening LGN atrophy, that might prompt earlier intervention. Conversely, some patients with significant field loss might still have relatively strong brain networks and be good candidates for neuroenhancement techniques. By bringing together ocular data (OCT, field tests) and neuroimaging, clinicians aim for a fuller assessment than either can provide alone. Future directions: longitudinal studies and rehabilitation Most MRI studies so far are “snapshots” of patients at one time. The next big step is longitudinal research – following the same patients over months or years. Such studies would track how brain imaging markers change over time, especially after interventions. For instance, if a glaucoma patient undergoes a visual training program or starts a neuroprotective drug, we could see whether their MRI markers (like V1 thickness or connectivity) show positive changes. Researchers suggest linking plasticity markers to rehab outcomes: do patients who show early signs of brain reorganization on fMRI end up gaining more vision with therapy? Some clues are emerging. A 2023 trial used virtual-reality visual training in glaucoma patients. After three months, the patients showed a slight increase in the thickness of the macular ganglion cell layer (measured by OCT) and improved sensitivity in the trained visual field area (). This provides proof-of-concept that training can induce structural and functional recovery. The next question is whether MRI could predict or monitor such gains. For example, one could imagine an fMRI before and after visual training: patients whose brain response in V1 improves might also have better vision outcomes. Another angle is lifestyle: preliminary evidence (mostly from animal studies) suggests exercise and diet can boost retinal recovery (). It would be valuable to see if these general measures reflect in brain scans (e.g. preserved visual cortex thickness in exercising patients). In short, doctors and scientists see a path forward: use advanced imaging over time to identify early brain plasticity signals, and link them to vision test results. This could validate targets for rehabilitation and guide personalized therapy. Ultimately, the goal is a feedback loop: measure MRI biomarkers, apply a treatment or training, re-measure MRI and vision, and optimize recovery strategies based on what the brain imaging shows. Conclusion Growing evidence shows that glaucoma is a neurodegenerative disease affecting the entire visual pathway, not just the eye. State-of-the-art MRI methods (DTI, fMRI, cortical thickness mapping) reveal retrograde degeneration from the eye back to the bSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/glaucoma-and-glutamine-is-there-a-real-link-through-glutamate-retinal-metabolism-and-neurodegenerationTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Executive Summary Glutamine is a common amino acid in the body, but current evidence does not show that glutamine itself causes or treats glaucoma. Instead, glutamine is part of the normal glutamate–glutamine cycle in the nervous system, including the retina (). In glaucoma (a disease where retinal ganglion cells and the optic nerve degenerate), researchers have wondered whether excitotoxic damage from too much glutamate may play a role. Since glutamine is the main precursor for glutamate, it is studied as an indirect marker of this process. Some experimental studies (mostly in animals or lab models) show changes in glutamine handling by retinal glial cells when pressure or blood flow is disturbed. A few small human studies found glaucoma patients had slightly higher glutamine in the eye’s fluids (), while others found no difference () (). Overall the human data are limited and inconsistent. Glutamine supplements have not been shown to help glaucoma, and no clinical trial has tested this. There is also no evidence that taking or avoiding glutamine changes eye pressure or disease. In practical terms, the main proven treatment for glaucoma remains lowering eye pressure (with drops, laser, or surgery), not dietary changes. What is Glutamine? Glutamine (Gln) is one of the body’s most abundant free amino acids. It serves many roles: a building block for proteins, a fuel for immune and gut cells, and a carrier of nitrogen between tissues (). Under stress or illness, cells use glutamine quickly and it can become “conditionally essential” (meaning we may need more from food or supplements) (). Glutamate (Glu) is a closely related amino acid that acts as a major excitatory neurotransmitter in the brain and retina. In contrast, glutamine itself is not an excitatory neurotransmitter. Instead, it is a “converter” or storage form. Neurons use glutamine mostly to re-synthesize glutamate. High extracellular glutamate can be toxic to neurons (a process called excitotoxicity), but glutamine is not toxic and does not directly activate glutamate receptors (). The glutamate–glutamine cycle: In the retina (and brain), neurons and glial cells recycle glutamate and glutamine in a tight loop (). For example: A neuron (such as a retinal ganglion cell) releases glutamate at its synapse. Nearby Müller glial cells (the main support cells in the retina) quickly take up this glutamate and convert it into glutamine (). The Müller cell then releases glutamine back to neurons. Neurons take up glutamine and convert it back into glutamate for future signaling. In effect, glutamine is a “safe” way to mop up excess glutamate. It keeps the fast-acting glutamate neurotransmitter within neurons and prevents glutamate from lingering too long outside cells, which could be harmful (). The cycle is illustrated conceptually below: Neuron releases glutamate → Glial cell converts glutamate → glutamine → Glial cell sends glutamine back → Neuron converts glutamine back to glutamate. () This recycling ensures that neurotransmitter levels remain balanced. Importantly, disturbances in this cycle (for example if glial cells fail to clear glutamate) can allow glutamate buildup and potentially cause excitotoxic damage to neurons. Why Could Glutamine Matter in Glaucoma? Glaucoma basics: Glaucoma is a group of eye diseases leading to optic nerve damage and vision loss, usually by death of retinal ganglion cells (RGCs). The most common form is primary open-angle glaucoma (POAG), often associated with elevated intraocular pressure (IOP). Another form is normal-tension glaucoma, where nerve damage occurs at normal pressures. Regardless of pressure, glaucoma involves progressive RGC loss. The National Eye Institute and others describe glaucoma as an optic neuropathy (nerve disease) that leads to peripheral vision loss and eventual blindness if untreated () (). Excitotoxicity hypothesis: Because glutamate is known to kill retinal neurons in lab studies (for example, injecting glutamate into the eye causes RGC death), scientists have long hypothesized that elevated glutamate could contribute to glaucoma damage. Some early studies reported higher vitreous (eye fluid) glutamate in glaucomatous eyes, suggesting an “excitotoxic” mechanism () (). In one review, it was noted that glaucoma patients had about 27 μM glutamate in vitreous vs 11 μM in controls, enough to harm RGCs (). However, other studies (including Honkanen et al. 2003) found no significant increase in ocular glutamate or glutamine in glaucoma patients () (). The role of glutamate excitotoxicity in human glaucoma remains unproven. Glutamine’s indirect role: Because glutamine is the precursor and breakdown product of glutamate, it is studied indirectly. If glutamate were accumulating, one might see changes in glutamine too. For example, one recent hypothesis is that in glaucoma, Müller glial cells may raise glutamine production in order to keep free glutamate levels low and protect neurons (). In effect, more glutamine in eye fluids might reflect an attempt to buffer glutamate. This is only speculative. The frontiers study (Lillo et al.) mentions that higher aqueous glutamine in glaucoma “could be a means of keeping the concentration of glutamate under control, thus avoiding [neuron] death” (). But whether this happens or matters in patients is unknown. Müller cell and astrocyte changes: Glial cells (Müller cells in retina, astrocytes in optic nerve head) normally regulate glutamate-glutamine recycling. In animal glaucoma models, these glial cells sometimes become reactive or dysfunctional. For instance, experimental glaucoma in monkeys led to higher glutamine labeling in Müller cells (), suggesting they were still converting extra glutamate to glutamine. In rat studies, raising intraocular pressure briefly actually blocked the increase in glial glutamine-synthetase (GS) that would normally follow glutamate exposure (). Only after one week of continued pressure did Müller cells resume raising GS as before. This hints that acute pressure spikes might temporarily impair glial glutamate clearance (). Such mechanistic findings show that the glutamate–glutamine cycle can be altered by glaucoma-like conditions, but they do not prove that glutamine itself is toxic or protective. They simply underscore that late-stage RGC death in glaucoma could involve metabolic stress in glial cells. Human Research: Glutamine/Glutamate Levels in Glaucoma Studies in humans have looked for differences in glutamine or related metabolites in the eye or blood of glaucoma patients. The results are mixed and generally not definitive: Aqueous humor (eye fluid) studies: New metabolomics analyses of aqueous humor (the fluid in the front of the eye) found that glaucoma patients had higher glutamine levels than controls. For example, a 2022 Frontiers in Medicine study reported median glutamine ~697 μM in glaucoma patients vs ~563 μM in cataract controls (). This was statistically significant and the authors noted glutamine (but not glutamate) was elevated in treated glaucoma. They suggested this might help keep glutamate low in the eye (). However, older analyses of aqueous humor (and vitreous) have not consistently confirmed this. A systematic review of glaucoma metabolomics noted that some studies found glutamine increased (e.g. Buisset et al. 2019; Tang et al. 2021) while others saw it decreased or unchanged (e.g. Myer et al. 2020) (). In meta-analysis of multiple aqueous humor studies in open-angle glaucoma, glutamine was often reported as an affected metabolite, but the findings went in opposite directions in different studies (). Overall, aqueous humor data suggest there are metabolic changes in glaucoma, but the specific role of glutamine is uncertain. Vitreous humor (eye gel) studies: Vitreous samples from glaucoma eyes have been measured in a few small studies. Honkanen et al. (2003) measured 16 amino acids (including glutamate and glutamine) in vitreous from glaucoma patients undergoing vitrectomy (usually for other eye problems) versus controls. They found no significant difference in glutamine (and no significant difference in glutamate) between groups (). The average glutamine was ~1200 μM in both glaucoma and control eyes, with p>.99 (). This argues against a large buildup of glutamate or its precursor glutamine in human glaucoma vitreous. (Earlier, Dreyer 1996 had reported higher glutamate in vitreous of glaucoma patients (), but that finding was not replicated by Honkanen.) In experimental eyes, a rabbit model of optic nerve ischemia (simulating glaucoma) also showed no change in vitreous glutamine, even though glutamate tripled (). So human vitreous data to date do not support a glutamine difference. Blood/serum studies: There is little data on glutamine in the blood of glaucoma patients. Metabolomics studies of patient plasma have identified many molecules altered in glaucoma, but glutamine specifically has not emerged as a clear marker in blood. For example, Tang et al. (2021) profiled plasma metabolites in POAG versus cataract controls and found some energy-related changes (like purine metabSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/nocturnal-hypotension-sleep-apnea-and-ocular-perfusion-continuous-monitoring-studiesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Our eyes depend on a steady blood flow and pressure balance to stay healthy. During sleep, changes in blood pressure, breathing, and even eye pressure can affect vision. In particular, a drop in blood pressure at night (nocturnal hypotension) and episodes of stopped breathing (sleep apnea) may reduce ocular perfusion pressure – the difference between blood pressure and eye pressure – and stress the optic nerve. Researchers are now using 24-hour monitoring of blood pressure, oxygen levels, and eye pressure to see how these factors line up with subtle changes in vision. This article explains how nighttime blood pressure dips and sleep apnea can influence eye health, how we can measure them, and what can be done to protect the eyes. Nighttime Blood Pressure Dips and Eye Health Most people experience a normal “dip” in blood pressure during sleep – typically a 10–20% fall compared to daytime levels. However, some individuals, especially those on blood pressure medications, experience a larger drop. When blood pressure falls too far, the ocular perfusion pressure (OPP) can become too low. The OPP is essentially the driving pressure pushing blood into the eye (roughly blood pressure minus eye pressure). If OPP drops too much, the optic nerve may not get enough blood. In fact, experts believe that the balance between intraocular pressure (IOP) and blood pressure is key to optic nerve health (). Studies confirm the danger of extreme nighttime dips. For example, glaucoma patients whose blood pressure fell far below daytime levels at night tended to have more progression of vision loss. In one long-term study of normal-tension glaucoma patients, the duration and magnitude of nocturnal blood pressure below daytime pressure predicted the rate of visual field loss (). In practical terms, this means if your nighttime blood pressure stays significantly (e.g. 10 mmHg or more) below your daytime average for many hours, your risk of glaucoma worsening is higher. Another study found that glaucoma patients who had unusual large dips in night blood pressure (so-called over-dippers) showed larger swings in ocular perfusion pressure and worse visual field test results (). Importantly, body position and sleep also matter. Normally, when you lie down, intraocular pressure (IOP) tends to rise (by 10–20%) because eye fluid drains more slowly (). So at night you may have higher IOP and lower blood pressure at the same time – a “double whammy” that can lower OPP. In simple terms, the nighttime balance of pressures can leave the optic nerve vulnerable if blood pressure drops too much or eye pressure rises too much. Sleep Apnea and Oxygen Supply Obstructive sleep apnea (OSA) is a condition where the upper airway repeatedly collapses during sleep, causing breathing to stop briefly and oxygen levels to fall. During an apnea event, the body may experience low oxygen (hypoxia) and sudden surges in blood pressure when breathing resumes. Over time, untreated sleep apnea has many health effects, including on the eyes. Research shows that patients with glaucoma have a higher chance of having sleep apnea. For instance, one study found 20% of glaucoma patients screened positive for sleep apnea (higher than in similar people without glaucoma) (). A large meta-analysis reported that sleep apnea is significSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/economics-of-high-frequency-home-monitoring-versus-clinic-based-perimetryTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Economics of High-Frequency Home Monitoring vs Clinic-Based Perimetry Glaucoma is a chronic eye condition that gradually shrinks side (peripheral) vision. It requires ongoing visual field testing (perimetry) to track disease progression and prevent vision loss. Traditionally, these tests are done in the clinic about every 6–12 months (). However, new home perimetry technologies (tablet apps or headsets) allow patients to test more often at home () (). Home testing could be much more convenient – saving travel and wait time – and might catch changes earlier. For example, in a remote-care model for glaucoma, patients saved an average of 61 travel hours compared to in-person exams (). Yet home tests also have costs (devices and data review) and performance uncertainties. Early reviews point out that while many home and portable perimeters are promising, their real-world accuracy and value still need validation (). Clinic-Based vs Home Perimetry Clinic perimetry is very reliable but requires specialized equipment (like a Humphrey Field Analyzer) and trained staff. It can be costly and burdensome – patients must take time off and possibly travel far for tests. In contrast, home monitoring offers comfort and flexibility. Patients can test on a personal tablet at home, often with simple apps that guide the procedure (). Users and eye doctors alike are optimistic: one UK study found patients and clinicians were cautiously positive about home glaucoma checks, citing potential convenience and cost-savings () (). In that study, most patients were able to use home devices regularly – 95% completed follow-up visits and 55% maintained ~80% or better adherence over 3 months (). However, home tests can be less controlled. For example, one trial of an iPad perimeter found about 44% of the unsupervised tests were flagged as unreliable (often due to distraction or fatigue), versus only 18% in the clinic (). Nevertheless, well-designed home tests have shown results closely matching clinic tests when done correctly. In fact, home testing had similar false-positive error rates to the clinic test (~14% in both cases) (). The bottom line is that home perimetry can free patients from some clinic visits (and save on travel and wait time) (), but it also depends on patient tech skills and diligence. Building Economic Models: Costs and Outcomes To compare home monitoring with clinic testing, researchers use decision-analytic models (often Markov models) that simulate patient health over many years () (). These models assign patients to vision states (no vision loss, moderate loss, severe loss) and simulate transitions between them each year. They tally up all costs (device, staff, clinic visits, treatments) and all health outcomes (measured in quality-adjusted life years or QALYs – a combination of length and quality of life). A QALY of 1 equals one year in perfect vision-health. For example, if home monitoring helps preserve vision and adds 0.1 QALY per patient (about 1.2 extra vision-quality months), and it costs an extra \$1,000 per patient, then the cost per QALY is \$10,000. Interventions below a country’s cost-effectiveness threshold (often \$50,000/QALY in the US or ~£20–30k in the UK) are generally considered good value () (). Key Factors in the Models Several real-world factors hugely affect the cost-effectiveness of home teSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/color-and-contrast-specific-perimetry-to-probe-retinal-ganglion-cell-subtype-vulnerabilityTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Vision relies on many kinds of retinal ganglion cells (RGCs), each tuned to different color or contrast signals. Standard visual field tests use white-on-white (achromatic) stimuli and measure overall sensitivity, but early or selective damage in diseases like glaucoma can hide behind normal full-field results. Specialized perimetry tests now probe specific pathways by using color or temporal contrast stimuli. For example, blue-on-yellow perimetry (Short-Wavelength Automated Perimetry, SWAP) presents a bright blue target on a yellow background to isolate the short-wavelength (blue) cone pathway and its small bistratified RGCs (). Similarly, red–green (chromatic) tests aim at the long-/medium-wavelength cone pathways (parvocellular system), and flicker/temporal tests (like frequency-doubling perimetry or high-frequency flicker) stress the large parasol (magnocellular) RGCs. By dissecting vision in this way, clinicians hope to catch damage in specific RGC subtypes earlier or more precisely than with white-on-white testing. This article reviews these color- and contrast-specific perimetry methods and how they relate to glaucoma and optic nerve disease. We discuss what blue-yellow and red-green perimetry can reveal about pathway dysfunction, how flicker perimetry examines temporal contrast processing, and how these functional losses map onto structural imaging (OCT) and blood flow metrics (OCT-Angiography). We also consider evidence on whether such targeted tests predict later decline on standard fields, and suggest practical testing protocols that maximize diagnostic insight without overly straining patients. Color- and Contrast-Specific Perimetry Blue–Yellow (SWAP) Perimetry Blue-on-yellow perimetry (SWAP) is a well-known color test. It uses a large, narrowband blue stimulus (around 440 nm) presented on a bright yellow background (). The high-luminance yellow field adapts the red and green cones so that the remaining pathway – the short-wavelength (blue) cones and their small bistratified RGCs – respond mainly. In effect, SWAP “isolates” the blue-cone channel. Early glaucoma often affects these small bistratified cells, so SWAP can reveal field loss sooner than conventional testing (). Indeed, studies report SWAP can detect visual field defects in glaucoma suspects or early glaucoma eyes before standard perimetry shows losses, suggesting higher sensitivity for early damage () (). For example, one study found SWAP deficits strongly correlated with retinal nerve fiber thinning (r≈0.56 in the inferior quadrant) in glaucoma patients (), indicating SWAP loss matches structural damage. However, SWAP has practical limitations. It is sensitive to lens opacity (cataracts make results unreliable) and generally requires longer testing (to overcome adaptation effects). Clinically, SWAP often uses a “SITA-SWAP” algorithm to shorten time, but patients may still fatigue easily. In research, SWAP fields have shown greater mean deficits than white-on-white fields in glaucoma suspects () (), but reproducibility can be an issue. Another SWAP-based approach measures pupil responses (pupillography) to blue vs yellow stimuli, reflecting melanopsin ganglion cell function. One study found blue-light pupillary tests detected early loss slightly better than yellow-light stimuli in mild gSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/inequities-in-access-to-visual-field-testing-and-their-outcome-consequencesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Inequities in Access to Visual Field Testing and Their Consequences Visual field testing (also called perimetry) is a key tool eye doctors use to catch vision-threatening diseases like glaucoma early. In glaucoma, for example, people usually feel no symptoms until serious vision loss has occurred, so doctors rely on tests to measure the full field of a person’s vision (). Routine visual field tests help detect early damage to the optic nerve before it causes blindness. However, not everyone has equal access to these tests. In many parts of the country, people – especially those in rural areas or with low income – face barriers to getting regular eye exams and visual field tests. This article maps out how geography and socioeconomic factors affect who gets tested, how late disease is caught, and what can be done to close these gaps. Uneven Access Across Communities Geographic Barriers Living far from an eye clinic can make testing hard. A recent large study found glaucoma patients in isolated rural areas were far less likely to get the recommended follow-up eye exams than those in cities (). In fact, rural patients’ odds of receiving a needed optic nerve evaluation were 56% lower than urban patients (). Similarly, research of insured patients across the U.S. found wide variation by community in whether newly diagnosed glaucoma patients get any visual field test: in some places as few as 51% got tested within two years of diagnosis, while in others 95% did (). Some communities had over 25% of new glaucoma patients receive no visual field testing at all in the first two years after diagnosis (). These findings show that where a person lives – and the resources of that community – can make a big difference in whether they get basic vision testing. Socioeconomic and Insurance Factors Money matters too. Patients with lower income or without good insurance often get tested less. For example, one study showed that people on Medicaid (public insurance for low-income individuals) with glaucoma were much less likely to get visual field tests compared to patients with commercial insurance (). Only about 35% of Medicaid patients received a visual field test within 15 months of diagnosis, versus 63% of privately insured patients (). This means Medicaid patients were over three times as likely to get no glaucoma testing at all after diagnosis (). Because Medicaid patients are disproportionately low-income and include many racial minorities, these insurance disparities contribute greatly to unequal care. Racial and Ethnic Disparities Race and ethnicity intersect with income and location. Studies have found that Black, Hispanic, and Asian patients with glaucoma often receive fewer visual field tests than White patients, even after accounting for age and severity () (). For instance, Black and Asian glaucoma patients in one clinic-based study underwent about 3–5% fewer tests per visit than White patients, despite having more advanced disease at baseline (). Another analysis showed Black patients had a 17% lower chance of getting the recommended optic nerve exams than White patients, and Hispanic patients also lagged in follow-up visits (). These differences may reflect factors like lower insurance coverage, less access to specialists, or other social determinants of health that vary by race. Consequences: Later DiaSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/low-carb-diets-and-nocturnal-blood-pressure-dips-ocular-perfusion-risks-and-benefitsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Low-carbohydrate diets (such as ketogenic diets) have become popular for weight loss and blood sugar control. These diets can significantly improve metabolic health by lowering insulin, blood sugar, and even blood pressure () (). But for people with eye disease like glaucoma – especially the normal-tension type (NTG) – it is important to consider how major changes in diet and body chemistry might affect blood pressure patterns. In particular, doctors are paying attention to nocturnal hypotension (excessive night-time blood pressure drops) because the optic nerve is sensitive to low perfusion. Here we examine whether cutting carbs could alter the normal day-night blood pressure cycle and eye blood flow, and how to monitor these circadian changes safely. We will also weigh the potential benefits of better metabolic control against the risks of too-low blood pressure at night. Throughout, we rely on evidence from clinical studies and expert reviews () (). Low-Carbohydrate Diets and Blood Pressure Low-carb diets (for example, very-low-calorie or “keto” diets) can improve metabolic markers. They often lead to weight loss, better blood sugar control, and reduced insulin levels (). Multiple studies have found that switching to a low-carbohydrate diet tends to lower blood pressure as well. For instance, in a trial of overweight adults with high blood sugar, a very-low-carb diet lowered systolic blood pressure by nearly 10 mmHg on average over four months – a greater drop than with a standard DASH-style diet (). This effect is likely partly due to losing water weight and salt (since low-carb diets can cause an initial diuresis) and partly due to overall improved cardiovascular health. In fact, one review notes that keto-style diets are specifically recommended by diabetes experts because they improve blood pressure as well as glycemic control (). However, lowering blood pressure quickly can have side effects. When people start a ketogenic diet, many report what is colloquially called the “keto flu”: headaches, lightheadedness, and fatigue (). These symptoms are thought to come from temporary fluid and electrolyte shifts (for example, losing more sodium and dropping blood pressure). In practice, this means that some people on a strict low-carb diet may feel dizzy or unusually tired, especially in the first weeks. For patients already on blood-pressure medications, this added effect can increase the chance of excessive hypotension (too-low blood pressure), especially at night. In summary, low-carb diets often improve blood pressure long-term () (), but they can cause acute dips that should be monitored, especially in sensitive individuals. Nighttime Blood Pressure Dips and Eye Health Our blood pressure normally follows a day-night pattern: it dips during sleep and rises by morning. For most healthy people, night-time blood pressure falls by about 10–20% from daytime levels. This “nocturnal dip” is part of normal physiology. But exaggerated nocturnal dipping (for example, a drop much greater than 10–20%) can be risky for the eyes. The reason is ocular perfusion: the optic nerve and retina need a constant flow of blood. Ocular perfusion pressure (OPP) is roughly the difference between arterial blood pressure forcing blood into the eye and the pressure insiSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/macronutrient-patterns-and-intraocular-pressure-a-systematic-evaluationTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Diet and Eye Pressure: How Proteins, Fats, and Carbs May Affect Glaucoma Glaucoma is a leading cause of irreversible vision loss, usually caused by damage to the optic nerve often driven by high intraocular pressure (IOP) – the fluid pressure inside the eye. Lowering IOP is the main way to treat glaucoma, but eye pressure can be influenced by more than just medications. Recent research suggests that what we eat – especially the balance of proteins, fats and carbohydrates – may play a role in eye pressure and glaucoma health () (). In particular, certain dietary patterns (for example, low-carb or Mediterranean-type diets) have been linked to glaucoma risk and measures like nerve-fiber thickness and visual field loss. At the same time, scientists have begun to uncover biological pathways – from blood sugar and osmotic pressure to insulin effects and lipid signaling – that could explain how diet affects eye fluids and drainage. This article reviews the latest evidence on macronutrient patterns and glaucoma. We will survey epidemiologic studies of diet patterns (low-carbohydrate, low-fat, high-protein and Mediterranean-style diets) in relation to glaucoma, nerve thickness (the retinal nerve fiber layer), and vision loss. We will also explain possible mechanisms – including osmotic shifts from sugar, insulin’s effects on eye fluid, and the role of fats and lipid signals in the eye’s drainage mesh – that might link diet to IOP. Finally, we highlight gaps in the research (notably the lack of long-term trials) and suggest ways future studies can standardize diet tracking and glaucoma measures to get clearer answers. Dietary Patterns and Glaucoma: What the Studies Show Low-Carbohydrate Diets The idea of a low-carbohydrate diet (shifting calories from carbs to more protein and fat) has been widely studied for weight loss and diabetes, but does it affect glaucoma? A large U.S. study examined over 185,000 adults over decades and tracked their diets and glaucoma outcomes. That study found no overall link between long-term low-carb eating and the risk of primary open-angle glaucoma (). In other words, simply eating a low-carb or ketogenic-style diet did not clearly reduce (or increase) glaucoma risk in most people (). However, this same research did find an intriguing hint: if people substituted more vegetable-based fats and proteins (like plant oils, nuts, or beans) for carbohydrates, they tended to have a lower risk of a specific glaucoma pattern (one that affects central vision early) () (). In practical terms, swapping plants and healthy fats for carbs might modestly protect against one subtype of glaucoma () (). In contrast, sugary or high-glycemic carbohydrates seem to raise eye pressure acutely. For example, one Taiwanese health study measured people’s blood sugar two hours after a standard meal and compared it to eye pressure. They found that participants with higher post-meal blood glucose levels had significantly higher IOP – by several millimeters of mercury – than those with lower glucose (). Each rising quartile of after-meal sugar gave a clear trend of higher eye pressure (). This suggests that spikes in blood sugar (which happen with high-carb meals) can temporarily increase IOP. In fact, classic studies in diabetic patients have shown that acute high blood sugar makes the eye fluid more concSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/personalized-nutrition-in-glaucoma-nutrigenomic-interactions-with-macronutrient-metabolismTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a group of eye diseases that damage the optic nerve and can lead to vision loss if not treated. High intraocular pressure (IOP) – the fluid pressure inside the eye – is a major risk factor for glaucoma. Standard treatments (like eye drops and surgery) focus on lowering IOP. But growing research suggests that diet and nutrition may influence glaucoma risk and progression () (). For example, diets rich in vegetables (sources of nitric oxide/nitrates) have been linked to lower glaucoma risk () (). Personalized nutrition (or precision nutrition) is the idea of tailoring a person’s diet to their unique biology, including their genes and metabolism. The new field of nutrigenomics studies how genetic differences affect the way our bodies process nutrients (like fats and carbohydrates) and how these interactions impact health. In glaucoma, nutrigenomics could one day help us recommend the best balance of fats, carbohydrates, and proteins for each patient, based on their genes. This article explores how key genes involved in fat and carbohydrate metabolism (notably APOE, PPAR family genes, FADS, and NOS3) might guide personalized diets for glaucoma; how clinical trials could test such approaches; and what ethical and practical issues arise. Genes and Macronutrient Metabolism Certain genes play major roles in determining how our bodies handle fats and carbohydrates. Variants (different versions) of these genes can change metabolic pathways. In the context of glaucoma, several genes are of interest: APOE (Apolipoprotein E) – This gene makes a protein that transports cholesterol and fats in the body, especially in the brain and retina (). There are three common APOE variants (called ε2, ε3, ε4). People with the ε4 version tend to have higher blood cholesterol levels. In general nutrition science, APOE4 carriers often show larger cholesterol changes when they change their intake of saturated fats (). (For example, cutting saturated fat often lowers cholesterol more in APOE4 individuals than in others.) In glaucoma research, some studies even suggest APOE4 might protect the optic nerve from damage (), though the picture is complex. From a diet viewpoint, an APOE4 carrier might benefit especially from a low saturated-fat diet and increased healthy fats (in line with heart-healthy guidelines). PPARs (Peroxisome Proliferator-Activated Receptors) – These genes (especially PPARα and PPARγ) are regulators that turn on or off pathways controlling fat and sugar metabolism. The PPARγ gene has a well-studied variant called Pro12Ala. People carrying the “Ala12” variant often have greater sensitivity to different types of fat in the diet. For instance, one trial found that carriers of PPARγ Ala12 lowered their cholesterol and triglyceride levels more when their diet had a higher ratio of unsaturated fats (polyunsaturated/saturated fat) (). Another study showed that Ala12 carriers lost more weight on a Mediterranean-style diet rich in olive oil (a monounsaturated fat) than on a standard low-fat diet (). In short, PPAR variants influence how well someone responds to healthy (unsaturated) versus less healthy fats. For glaucoma patients with these PPAR variants, emphasizing omega-3 and monounsaturated fats (from fish, nuts, and olive oil) over saturated fats may be parSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/medium-chain-triglycerides-vs-long-chain-fats-rapid-ketosis-and-visual-functionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Medium-Chain Triglycerides vs Long-Chain Fats: Rapid Ketosis and Visual Function Medium-chain triglycerides (MCTs) are fats with shorter carbon chains (mostly 8–12 carbons, like caprylic and capric acid) that are found naturally in coconut oil and breast milk. Long-chain fats (LCTs) include most other dietary fats (14+ carbons) such as olive or sunflower oil. The body handles them differently: MCTs go straight to the liver through the bloodstream and are rapidly turned into ketones (an alternative fuel), whereas LCTs enter via the gut’s lymph system and take longer to process. In one study, giving healthy adults pure C8 MCT oil caused blood ketone levels to jump roughly four times higher than the same calories of coconut oil^ (). In short, MCTs raise ketones much faster than LCTs. (Ketones are molecules the liver makes from fat that many cells – including brain and retina cells – can burn for energy when glucose is low.) MCTs have been studied for brain and eye health. In ageing and certain eye diseases, glucose uptake can drop and cells starve for fuel. For example, low brain glucose use in Alzheimer’s or ageing has led researchers to try ketone supplements to “bypass” this energy problem. One conclusion from a clinical trial was that optimizing MCT formulas might help counteract declining brain glucose use in aging (). In other words, ketones from MCT could provide extra energy when sugar isn’t enough. Similarly, these extra ketones may help visual processing and cognition when given acutely. In experiments, healthy adults who drank MCT oil (versus the same amount of olive oil) performed better on certain mental tasks – for example, one dose of MCT improved attention and decision-making in a Stroop-type test (). (Working memory also improved after 4 weeks of daily MCT compared to long-chain oil ().) These findings suggest that MCT-derived ketones can give the brain and eyes an energy boost, potentially speeding up cognitive-visual tasks. Importantly, glaucoma – a common disease of the optic nerve – involves energy failure in the retinal ganglion cells (RGCs) that carry vision signals. Research shows glaucoma is tied to metabolic and mitochondrial dysfunction (). RGCs are very active nerve cells with many mitochondria located near the optic nerve head (). They rely heavily on oxygen-based metabolism for ATP energy, so if mitochondria struggle (as can happen in glaucoma), RGCs get damaged. Because ketones can feed mitochondria, scientists are exploring if a ketogenic approach can help. Animal studies support this idea: In a mouse model of chronic glaucoma, feeding an 8-week ketogenic (very low-carb, high-fat) diet protected the RGCs and their axons. The ketogenic mice had more retinal mitochondria and better energy status and far fewer RGCs died, compared to control mice on a regular diet (). That study actually showed ketogenic diet “generated mitochondria, improved energy availability, … [and] protected RGCs” in the optic nerve (). Another recent glaucoma study found that ketones helped clear out damaged mitochondria (via mitophagy) in RGCs under stress, further protecting these cells (). How might ketones reach the nerves? In the optic nerve head, astrocytes (support cells) wrap around RGC axons and shuttle energy. Brain research shows astrocytes can both produce and export Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/protein-intake-homocysteine-and-pseudoexfoliation-glaucoma-riskTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Pseudoexfoliation syndrome (PEX) is an age-related eye condition characterized by the accumulation of flaky, white fibrillar material on structures in the front part of the eye (such as the lens capsule and pupillary border) () (). This material is rich in elastic microfibrils and other extracellular matrix proteins, so PEX is often described as an elastosis – essentially an overproduction of elastic fiber components in the eye () (). Over time, PEX can cause elevated eye pressure and trigger a form of glaucoma (called pseudoexfoliation glaucoma) that damages the optic nerve and can lead to vision loss if untreated. Patients with PEX also appear to have higher rates of vascular diseases (for instance, stroke or heart disease), suggesting systemic factors may be involved. Scientists have noted that patients with PEX glaucoma often have higher blood levels of the amino acid homocysteine than people without the disease. Homocysteine is a byproduct of normal protein metabolism – it comes from the essential amino acid methionine. Diets very high in protein (especially animal protein) can deliver a lot of methionine. If the body cannot fully convert homocysteine back into other useful compounds, homocysteine can accumulate in the blood. In this article, we explore how high-protein diets and one-carbon metabolism (which depends on B vitamins like folate and B12) might influence homocysteine levels and thus potentially affect the risk of developing pseudoexfoliation glaucoma. We will also discuss how abnormal homocysteine might disrupt enzymes involved in building and remodeling the eye’s connective tissue (notably LOXL1, a lysyl oxidase enzyme that cross-links elastin fibers) () (). Finally, we suggest how future studies could be designed to test these links using detailed dietary data, genetic testing, blood biomarkers, and advanced eye imaging. Protein Intake, Methionine, and Homocysteine When you eat protein, your body breaks it down into amino acids – the building blocks of proteins. One amino acid, methionine, is found abundantly in many proteins (especially in red meat, eggs, and dairy). Methionine is converted in the body to homocysteine. Normally, homocysteine is then either recycled back into methionine or converted into cysteine, and this process depends heavily on B vitamins – folate (vitamin B9), vitamin B12, and vitamin B6. If these vitamins are insufficient, or if dietary methionine is very high, blood homocysteine levels can rise. Controlled diet studies in healthy volunteers show exactly this relationship: an 8-day high-protein diet (about 21% of energy from protein, versus only 9% in a low-protein diet) led to significantly higher post-meal homocysteine levels throughout the day, even though fasting homocysteine didn’t change much () (). In other words, after people ate protein-rich meals, their plasma homocysteine spiked higher than it did when they ate low-protein meals () (). The researchers noted that “a high protein intake and hence a high intake of methionine—the sole dietary precursor of homocysteine—may raise plasma tHcy concentrations” (). In practical terms, this means diets very rich in meat, fish, eggs, or other high-methionine foods can transiently increase homocysteine unless balanced by enough folate and B vitamins. It is important to emphasize the role of B vitamins. Even peoSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/mtor-autophagy-modulation-by-amino-acids-in-rgc-degenerationTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Nutrient Sensing and RGC Survival in Glaucoma Glaucoma is a major cause of irreversible blindness worldwide, involving damage and loss of the eye’s retinal ganglion cells (RGCs) and their axons. These cells send visual signals from the eye to the brain, so their health is vital for vision. Current glaucoma treatments lower eye pressure, but many patients still lose vision, highlighting the need for neuroprotective strategies that directly support RGCs () (). Emerging research shows that how RGCs sense and use nutrients (like amino acids) can influence their survival under stress. In particular, the mechanistic target of rapamycin (mTOR) pathway and autophagy – a cell’s recycling program – play key roles in RGC health. This article explores how amino acids (especially leucine, a building-block of protein) affect mTOR and autophagy in RGCs under glaucomatous stress, and how we might test dietary interventions to help protect vision. We also discuss how to measure both structural (OCT imaging) and functional (PERG, VEP) outcomes alongside blood/CSF biomarkers of nutrient signaling, and consider the balance between growth signals and protein cleanup in cells. mTOR and Autophagy: Balancing Growth vs. Cleanup Cells constantly balance between building up structures and recycling damaged parts. mTOR is a Master growth sensor: when nutrients are abundant, mTOR turns on protein production and cell growth () (). Under those conditions, mTOR suppresses autophagy (the cell’s ”recycling bin” that breaks down damaged components) (). In contrast, when nutrients or energy are low (or stress is high), mTOR activity falls and autophagy is activated, helping cells survive by cleaning up waste and providing raw materials for energy. In healthy neurons, a basal level of autophagy is important to remove misfolded proteins and worn-out mitochondria () (). RGCs are especially vulnerable to damage because they are long-lived nerve cells that cannot dilute waste by dividing. Studies show that autophagy protects RGCs under stress. For example, one landmark study found that blocking mTOR with the drug rapamycin (which boosts autophagy) helped RGCs survive after optic nerve injury (). In glaucoma models, enhancing autophagy was generally neuroprotective. As Boya and colleagues explain, stressed RGCs use autophagy to reduce oxidative damage and recycle nutrients, which can prolong cell survival () (). In short, keeping autophagy active helps RGCs stay healthy, especially under the chronic stress of glaucoma. However, too much autophagy or mis-timed autophagy can also be harmful, so the balance is delicate (). Excessive mTOR inhibition (over-activating autophagy) could have broad effects. The interplay between mTOR and autophagy in RGCs is complex. For example, shutting off mTOR can reduce protein synthesis needed for repair, while hyperactive mTOR (from too many nutrients) can starve the recycling system. This balance must be managed carefully in any intervention. Leucine and Amino Acid Signaling Amino acids are not just building blocks of proteins; they are also key regulators of cell metabolism. Leucine is one of the three branched-chain amino acids (BCAAs), along with isoleucine and valine. Leucine is a potent activator of mTORC1 (the nutrient-sensing complex of mTOR) (). When cells detect leucine, a cascade involving sensors like Sestrin2 and Rag GTPases drivSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/nr-vs-nmn-vs-nicotinamide-for-glaucoma-which-nad-booster-has-the-strongest-evidenceTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:NAD+ and Glaucoma: Why Vitamin B₃ Matters Glaucoma is an aging-related eye disease in which retinal ganglion cells (RGCs) – the nerve cells that carry visual signals from the eye to the brain – gradually die off. Pressure-lowering treatments (drops, lasers, surgery) are the standard of care, but many patients still experience slow vision loss. Researchers have therefore been exploring additional neuroprotection strategies. One promising idea is boosting NAD+ (nicotinamide adenine dinucleotide) – a vital cell energy molecule – because NAD+ levels naturally decline with age (). Lower NAD+ may leave RGCs less able to meet their high energy needs, especially under glaucoma stress. In fact, one lab review notes that “glaucoma is a neurodegenerative disease in which neuronal levels of NAD decline,” and shows that nicotinamide (vitamin B₃) can protect RGCs in multiple animal glaucoma models (). This finding has inspired human trials of NAD-boosting supplements in glaucoma. Current research has focused on three NAD precursors: nicotinamide (vitamin B₃), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). All three are natural forms of B₃ that feed into the NAD+ salvage pathway (). Nicotinamide (often called niacinamide) is a form of vitamin B₃ found in foods and multivitamins; NR and NMN are specialized NAD precursors found in small amounts in some foods (and sold as supplements). But do they really help glaucoma? Below we compare what is known about each one in plain language. All claims below are backed by recent science and trials. Nicotinamide for Glaucoma Why is nicotinamide being studied? Researchers study nicotinamide because it directly boosts NAD+ via the cell’s salvage pathway and has strong lab evidence in glaucoma models. In aging cells, NAD+ “declines with age at a systemic level” (). RGCs are very energy-hungry cells in a high-stress environment (high pressure can damage mitochondria inside them). Boosting NAD+ could supercharge RGC metabolism and help them survive. In rodent glaucoma experiments, high-dose nicotinamide dramatically protected RGC bodies and axons. For example, Tribble et al. (2021) report that dietary nicotinamide blocked the early metabolic disruptions caused by high eye pressure and improved mitochondrial function in rat retinas (). In simple terms, vitamin B₃ helped the energy cells in the retina keep working properly under stress. This strong preclinical data has given researchers confidence to try nicotinamide in human glaucoma. Human trial evidence for nicotinamide Human studies are still small but encouraging. A 2022 trial in open-angle glaucoma (with moderate field loss) gave patients high-dose nicotinamide plus another agent (pyruvate). Participants took 1–3 grams of nicotinamide daily. Over ~2 months, the treatment group showed significantly more improvement in visual field test points than placebo did (). Specifically, the median number of improved field locations was 15 in the nicotinamide group versus 7 in placebo (p=0.005) (). Secondary measures of field sensitivity also tended to improve more with treatment. Although this trial was short and combined with pyruvate, it provides a positive signal that NAD boosting can hSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/how-useful-is-oct-at-each-stage-of-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a progressive eye disease where the optic nerve at the back of the eye is damaged, leading to vision loss. Because glaucoma often causes no symptoms until later, doctors use various tests to spot it early and track it. One key tool is Optical Coherence Tomography (OCT). OCT is a non-invasive imaging scan that uses light to make cross-section pictures of the retina (the light-sensing layer of the eye). It can measure the thickness of important retinal layers and the optic nerve head. By tracking these measurements over time, OCT helps doctors see damage to nerve fibers before it shows up on vision tests. However, OCT is not perfect or standalone – it’s one piece of the puzzle in glaucoma care () (). What OCT Measures and How to Read It OCT produces detailed images of the retina, which doctors interpret in simple ways. The main things OCT measures are: Retinal Nerve Fiber Layer (RNFL) Thickness: This is the layer of nerve “wiring” that runs from the retina into the optic nerve. Glaucoma causes this layer to thin over time. OCT scans circle the optic nerve and report the RNFL thickness (often as average thickness and in each quadrant). Thinner-than-normal RNFL can indicate glaucoma damage (). Ganglion Cell Complex (GCC): This is the layer in the macula (central retina) that contains the cell bodies of the retinal ganglion cells (the nerves that carry vision signals to the brain). Since glaucoma kills these cells, doctors also measure the macula’s GCC thickness. OCT can show if these cells (and their inner synapse layer) are thinning. Optic Nerve Head Structure: OCT can image the back of the eye (the optic disc) directly. It measures features like the “cup” and “disc” sizes (with metrics such as the rim area). A large cup or small rim can be a sign of glaucoma. However, OCT’s advantage is mostly its precise thickness measures, not just the cup/disc ratio. Macular (Central Retina) Thickness: Beyond the ganglion cell layer, OCT measures overall macular thickness. Some devices show color maps of the macula. Thinning in parts of the macula may also hint at glaucoma. Progression Over Time: Critically, OCT allows comparison of scans over months and years. The software can flag statistically significant thinning from one visit to the next. For example, a drop of ~4–5 microns in average RNFL over a year can suggest real progression (). Doctors often use “guided progression” tools in OCT to see if areas are getting thinner faster than normal aging. Each OCT result comes with color-coded maps and numbers. Green usually means “within normal limits,” yellow means “borderline,” and red indicates “outside normal limits” (thin) compared to a database of healthy eyes of the same age. Importantly, these colors are just estimates. A “red” area says that part of your retina is thinner than 95% of healthy eyes. It does not by itself confirm glaucoma – it simply flags an unusual finding (). Overall, OCT gives doctors precise physical data—how thick or thin the nerve layers are. These numbers let doctors track change more objectively than subjective exams. OCT in Suspected (Pre-Glaucoma) Conditions Even before glaucoma is officially diagnosed, OCT can be very helpful. This is often called “preperimetric” glaucoma – where the optic nerve looks suspicious but standard visual field tests are still normal. In such cases, OCT often pickSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/new-glaucoma-treatments-in-2026-what-patients-should-know-about-longer-lasting-eye-pressure-controlTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:New Glaucoma Treatments for 2026: Longer-Lasting Pressure Control Glaucoma, a leading cause of vision loss, is driven by high intraocular pressure (IOP) in the eye. Daily eye drops are the main treatment, but many patients find them hard to use consistently. Drops can sting, cause redness, or simply be forgotten in the busy routines of life () (). Missing doses can let eye pressure creep up, risking vision loss. Sustained-release glaucoma treatments aim to solve this by steadily delivering medication without daily drops. Instead of an eyedrop bottle, a doctor places a tiny implant or device that continuously releases glaucoma medicine for months. These approaches remove the need to remember daily drops and help keep pressure controlled around the clock () (). Below we explain how these new treatments work, who might benefit, and how they compare to traditional drops. We focus on the options most talked about for 2026, separating those already FDA-approved from those still being studied. How Sustained-Release Treatments Work Traditional glaucoma drops deliver medication onto the eye surface, but much of it washes away before it can work. Sustained-release devices sit inside the eye or on eye tissue and let out drug slowly over time. For example, Durysta is a tiny biodegradable rod (about 1.1 mm long) that an eye doctor injects into the anterior chamber (the front part of the eye) (). It contains 10 micrograms of bimatoprost (the medicine in Lumigan drops) embedded in a dissolving polymer. Once placed, Durysta releases bimatoprost steadily for about 4–6 months () (). The implant then dissolves on its own, so no second procedure is needed. Another approach, used by iDose TR, is a tiny titanium implant anchored into the eye wall. This anchoring device contains a reservoir of travoprost (another prostaglandin drug). About 75 micrograms of travoprost continuously elutes (seeps out) into the eye through a controlled membrane (). The iDose TR device stays in place for up to 2–3 years, delivering medication 24/7. (As of early 2026, the FDA has even approved re-administering iDose TR when the first dose runs out () ().) Both Durysta and iDose TR release prostaglandin-type drugs that help fluid drain out of the eye, lowering pressure. Similarly, experimental implants like OTX-TIC (Paxtrava), PA5108, and ENV515 are designed as tiny biodegradable implants or particles that doctors insert into the eye. They work the same way: a drug (e.g. travoprost or latanoprost) is slowly released over months () (). Punctal plugs, by contrast, sit in the tear drainage ducts (near the nose) and gently release medication into the tears () (). Each system steadily bathes the eye in medicine, nearly eliminating the peaks and troughs of pressure seen with once-daily drops. Who might benefit? These devices are best for people with open-angle glaucoma or ocular hypertension who need regular IOP control but struggle with daily drops. Older patients, those with limited mobility or trouble handling eye drops, or anyone who miss doses are prime candidates () (). Because the drugs are in continuous contact with the eye, these devices often work as well as or better than drops while leaving the patient with fewer steps in daily routine. FDA-Approved Drop-Free Options Durysta (bimSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/endothelin-1-peptide-and-glaucoma-targeting-a-problem-pathwayTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Endothelin-1 Peptide and Glaucoma: Targeting a Problem Pathway Glaucoma is an eye disease in which the optic nerve is damaged, often by high pressure inside the eye. Standard treatment focuses on lowering intraocular pressure (IOP). However, doctors increasingly recognize that poor blood flow and other factors also contribute to nerve damage. One molecule under study is endothelin-1 (ET-1). ET-1 is a natural peptide (small protein) made by blood vessel cells and eye tissues that is the most potent vasoconstrictor in the body (). In other words, it strongly narrows blood vessels. When ET-1 levels are high, retinal and optic nerve blood vessels can tighten, reducing oxygen and nutrients to the optic nerve. In this way, too much ET-1 may “stress” the optic nerve fibers and contribute to glaucoma damage (). In fact, many studies find ET-1 is elevated in glaucoma patients’ blood and eye fluid () (). Here we explain what ET-1 does in the eye, summarize the evidence linking ET-1 to glaucoma damage, and discuss possible treatments that block its pathway (rather than using ET-1 itself as a drug). What is Endothelin-1 and How Does It Affect the Eye? Endothelin-1 (ET-1) is made by cells lining blood vessels throughout the body, and it helps regulate normal blood pressure and flow. In the eye, ET-1 is produced in several places: the retina, the blood vessels of the eye, the retinal pigment epithelium, the optic nerve head, and the structures that make and drain fluid (aqueous humor) (). Under normal conditions, ET-1 keeps a balance: it tightens vessels when needed and releases them when other signals come in. However, ET-1 is a very powerful constrictor. Rosenthal and Fromm describe ET-1 as “the most potent vasoactive peptide known to date” (), meaning none of the body’s chemicals narrows vessels more strongly. In the eye’s tiny blood vessels, overactive ET-1 can seriously reduce blood flow. For example, if ET-1 rises, it causes vasoconstriction (narrowing) of blood vessels in the retina and optic nerve head (). This can trigger ischemia (low blood supply) in the optic nerve. Over time, that lack of oxygen and nutrients can injure or kill the retinal ganglion cells (the nerve cells in the retina whose fibers form the optic nerve). Rosenthal et al. note that such ischemia “is assumed to contribute to the degeneration of retinal ganglion cells” in glaucoma (). ET-1 also affects fluid drainage in the eye. Aqueous humor (the fluid in the eye) normally drains out through a spongy tissue called the trabecular meshwork. ET-1 makes those meshwork cells contract (), which can reduce outflow and potentially raise eye pressure. Indeed, Rosenthal’s review suggests that inhibiting ET-1 can lower IOP and protect nerves (), although not all studies agree on ET-1’s pressure effects. In summary, too much ET-1 can both increase eye pressure slightly and pinch the eye’s blood supply, creating a “double hit” to the optic nerve. Evidence Linking ET-1 to Glaucoma Damage Many clinical studies find that ET-1 levels are higher in glaucoma. For example, a recent meta-analysis pooled data from over 1,000 glaucoma patients and healthy people. It found that plasma ET-1 was significantly higher in patients with primary open-angle, normal-tension, and angle-closure glaucoma than in controls (). The difference was large enough that high ET-1 could Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/substance-p-pain-and-neuroinflammation-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Substance P, Pain, and Neuroinflammation in Glaucoma Glaucoma is a chronic eye disease that damages the optic nerve and can lead to vision loss. Many people with glaucoma also suffer from ocular surface discomfort – redness, burning, or dryness of the eye – especially if they use eye drops or have surgery. These symptoms are not only uncomfortable, but they can make it harder to stick to glaucoma treatment. Researchers have discovered that Substance P – a small protein (neuropeptide) released by nerve endings – plays a key role in eye pain and inflammation. Understanding how Substance P works may help us treat these symptoms. This article explains Substance P’s role in eye inflammation and pain, why that matters for glaucoma patients, and what studies tell us about drugs that block this pathway. Importantly, we distinguish easing symptoms (like dryness or pain relief) from protecting vision (slowing the nerve damage in glaucoma). Substance P and Neuroinflammation Substance P (SP) is a signaling molecule made by nerve cells. When nerves are irritated or injured, they release Substance P into the surrounding tissue. Substance P then binds to its receptor (called the neurokinin-1 receptor, or NK1R) on nearby cells. This triggers several effects: blood vessels in the tissue expand and become leaky, immune cells (like white blood cells) are recruited, and inflammatory chemicals (cytokines) are released (). In simple terms, Substance P tells the body, “Something’s wrong here – send help!” This process is called neurogenic inflammation. It helps fight infection or heal damage, but it also causes redness, swelling, and pain. For example, in the cornea (the clear front of the eye), Substance P causes blood vessels to dilate and immune cells to come in (). It also directly amplifies pain signals by acting on nerve fibers (Aδ and C fibers) that carry pain to the brain (). Because the cornea is one of the most heavily-innervated tissues in the body, it can produce and respond to a lot of Substance P () (). Normally, a small amount of SP helps regulate tear production and blink reflexes (). But after injury or chronic irritation (such as allergic or dry eye), SP levels can surge. High SP can make the cornea and conjunctiva (the white part of the eye) much more sensitive and inflamed. In experiments, blocking SP’s action strongly reduces inflammation: nerves that lack the SP receptor show fewer immune cells arrive, and mice missing SP themselves have less swelling () (). In other words, Substance P turns up the inflammation—and pain—in the eye. Why Substance P Matters for Glaucoma and Ocular Discomfort Glaucoma itself is characterized by loss of retinal ganglion cells (RGCs) in the back of the eye (the retina). However, many people with glaucoma experience ocular surface symptoms unrelated to vision: dryness, burning, soreness, or red eyes. These often come from eye drop preservatives or inflammation from surgeries, and they can involve Substance P. For example, irritating drops or foreign substances on the eye surface make corneal nerves release more SP (), which then increases inflammation and pain. Studies show that when the ocular surface is inflamed, trigeminal nerves (the ones sensing the eye) begin to express much more Substance P () (). This creates a vicious cycle: dry or injured eyes produce SP, SP causes more inflammation and nerve sensitization, which tSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/glp-1-peptides-and-glaucoma-risk-what-we-know-and-what-to-watchTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction GLP-1 receptor agonists (glucagon-like peptide-1 analogs) are a class of medicines originally developed to treat type 2 diabetes. By mimicking a natural gut hormone (GLP-1), drugs like semaglutide (Ozempic®, Wegovy®) and liraglutide (Victoza®, Saxenda®) help lower blood sugar and often cause weight loss 7{reference-type="ref"}. They are now used by millions of patients worldwide for diabetes and obesity. Interestingly, recent studies have observed that people taking these GLP-1 medicines seem to develop glaucoma – an eye disease that damages the optic nerve – less often than expected. In this article, we explain what GLP-1 agonists are, summarize the human evidence about glaucoma risk, describe how they might protect the eye, and discuss what kind of proof (randomized trials) is still needed. We also cover safety and regulatory issues. What Are GLP-1 Receptor Agonists? GLP-1 (glucagon-like peptide-1) is a natural hormone that helps the body release insulin and control appetite after eating. GLP-1 receptor agonists are medicines designed to act like GLP-1. Besides semaglutide and liraglutide, other examples include exenatide (Byetta®) and dulaglutide (Trulicity®). These drugs improve glycemic control (lower blood sugar) and often promote significant weight loss () (). Some newer GLP-1 agonists even come in pill form (e.g. oral semaglutide) (). Because they have “pleiotropic” effects, they also protect blood vessels and reduce inflammation in various parts of the body (). For instance, research in animals and humans has found that GLP-1 agonists improve heart and kidney health in diabetes (). GLP-1 RAs and the Eye GLP-1 receptors are present in many eye tissues, including nerve cells and blood vessel cells in the retina (). Laboratory studies show that activating these receptors can have powerful effects in the eye. GLP-1 drugs have anti-inflammatory, antioxidant, and neuroprotective actions in the retina (). For example, one experimental GLP-1 agonist (called NLY01) reduced damaging inflammation and prevented retinal ganglion cell death in a mouse model of glaucoma (). Another line of research found that GLP-1 analogs stabilize small blood vessels and the blood–retina barrier (the tight layer that protects the eye) (). In short, GLP-1 RAs have been shown to block multiple harmful processes in the eye – inflammation, oxidative stress, and nerve-cell damage – that are linked to glaucoma and other eye diseases () (). These findings have raised the idea that GLP-1 drugs might protect vision independently of their blood-sugar effects. Observational Evidence: Lower Glaucoma Rates Among GLP-1 Users? Several recent observational studies (looking at real-world patient data) have noted that people taking GLP-1 RAs develop glaucoma less often than similar patients who do not take them. For example, a U.S. insurance claims study compared about 1,961 new users of GLP-1 RAs to over 4,300 matched diabetic patients on other medications. After balancing the groups for age, gender, and diabetes control, the GLP-1 group had only 10 new cases of glaucoma (0.51%) versus 58 cases (1.33%) in controls. Statistically, this corresponded to a 44% lower hazard of glaucoma in the GLP-1 users (adjusted hazard ratio 0.56, 95% confidence interval 0.36–0.89, p=0.01) (). In plain language, GLP-1 treated patients had rSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/nerve-growth-factor-based-peptides-and-optic-nerve-protectionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a common cause of vision loss that happens when the retinal ganglion cells (RGCs) – the nerve cells connecting the eye to the brain – gradually die. As one review notes, glaucoma is “characterized by RGC degeneration and loss of visual field” (pmc.ncbi.nlm.nih.gov). In other words, patients slowly lose side vision and eventually central vision. Current glaucoma medicines all lower eye pressure, but doctors are actively looking for ways to protect the optic nerve cells directly. One idea is to use nerve growth factor (NGF), a natural protein that helps nerves survive and grow. NGF is like a fertilizer for certain nerve cells (pmc.ncbi.nlm.nih.gov). In healthy eyes it supports RGC survival – in glaucoma, NGF levels may drop, so adding extra NGF might slow RGC loss.NGF and Neuroprotection NGF is a small protein (a neurotrophin) that binds to receptors on neurons and tells them “grow and live.” Animal and lab studies show NGF “plays a crucial role in neuronal survival, differentiation, and growth” (pmc.ncbi.nlm.nih.gov). In the eye, retinal ganglion cells have NGF receptors, meaning they can respond when NGF is present. The idea is that supplying more NGF could neuroprotect these cells. In other words, NGF might block the cell-death signals in glaucoma and keep RGCs alive longer.... Continue reading at https://visualfieldtest.com/en/nerve-growth-factor-based-peptides-and-optic-nerve-protectionSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/heat-shock-protein-derived-peptides-and-autoimmunity-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Heat Shock Proteins and Immune Responses in Glaucoma Glaucoma is a leading cause of irreversible vision loss, affecting tens of millions of people worldwide (). Normally, glaucoma is linked to high eye pressure, but many patients – especially those with normal-tension glaucoma – have nerve damage despite normal pressure. This has led researchers to look beyond pressure and investigate the immune system’s role. In particular, eye experts have focused on heat shock proteins (HSPs), which are stress-related proteins that help keep nerve cells alive. Under some conditions these HSPs themselves may become targets of the immune system, contributing to nerve damage (). Evidence suggests that T cells (a type of white blood cell) reacting against HSPs can harm the optic nerve. For example, patient studies have found abnormally high levels of antibodies (proteins made by immune B cells) against HSPs in many glaucoma patients. In fact, multiple studies report that glaucoma patients often have elevated serum autoantibodies to HSP27 and HSP60, two common HSPs () (). In the lab, adding these patient antibodies to retinal cells can trigger cell death (), suggesting they are not just markers but may be damaging. In eye fluid (aqueous humor), glaucoma patients also show unique autoantibody “fingerprints,” including unusually high anti–HSP27 levels compared to healthy controls (). Taken together, these human findings point to an autoimmune tendency against HSPs in glaucoma. Evidence from Animal Models Studies in animals strongly support the idea that HSP-specific immune reactions can cause glaucoma-like damage. In classic experiments, scientists immunized healthy rats with HSP-derived peptides (for example, pieces of HSP27 or HSP60). Remarkably, these rats later developed nerve damage very similar to glaucoma () (). For instance, Wax and colleagues (2008) found that rats given HSP27 or HSP60 peptides lost large numbers of retinal ganglion cells (RGCs) – the neurons that form the optic nerve – and their axons in a pattern that closely mimics human glaucoma (). This damage occurred even though eye pressure stayed normal. Another group confirmed that immunizing rats with an optic-nerve extract (which contains many antigens, including HSPs) similarly caused RGC death and optic nerve thinning (). Importantly, these models also showed earlier immune changes: T cells infiltrated the retina days after immunization, and support cells (microglia) became activated, long before the neurons started dying () (). These animal experiments provide direct proof that an HSP-driven immune response can cause glaucoma-like neurodegeneration. Autoantibody Profiles in Patients Studies of glaucoma patients have found immune “signatures” consistent with HSP involvement. Many patients (especially with normal-tension glaucoma) carry autoantibodies against retina and optic nerve proteins, including HSPs () (). For example, researchers have detected antibodies to HSP27 and HSP60 in the blood of these patients (). In postmortem analyses, donor retinas from glaucoma patients showed antibody binding to HSP27 and HSP60 (). Laboratory tests imply these antibodies could be harmful: when anti-HSP27 antibodies from patients are applied to living retinal cells, the cells undergo apoptosis (self-destruct) (). Even the eye fluid of glaucoma patients contSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/endothelin-pathway-peptides-and-optic-nerve-head-ischemia-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Endothelin-1 and Glaucoma: Blood Flow, Astrocytes, and Therapy Endothelin-1 (ET-1) is a very strong vasoconstrictor (makes blood vessels tighten) found naturally in the body. In the eye, ET-1 levels and signaling have been linked to damage in glaucoma, a disease of the optic nerve. Glaucoma often involves high intraocular pressure (IOP), but other factors – especially reduced blood flow and oxygen (ischemia) at the optic nerve head – can contribute. ET-1 can narrow small blood vessels around the optic nerve and in the retina, leading to poor oxygen supply. It also affects astrocytes, the support cells of the optic nerve, which can become overactive when stressed. In this article, we explain how ET-1 and its receptors (called ETA and ETB) are involved in glaucoma, how ET-1 interacts with nitric oxide (a blood‐vessel relaxer), evidence that ET-1 levels are higher in glaucoma patients, and finally how blocking ET-1 receptors might help protect the eye (along with the challenges of such treatments). How ET-1 Affects Eye Blood Flow ET-1 is produced by many eye tissues (retina, ciliary body, trabecular meshwork, etc.). It normally helps regulate blood flow and aqueous humor outflow. However, high ET-1 causes excessive vasoconstriction. For example, human lab studies found that injecting ET-1 into the eye rapidly decreases blood flow in the retina and optic nerve head (). Blood vessel narrowing leads to local ischemia (low oxygen), which can injure retinal ganglion cell (RGC) axons. ET-1 even has a direct toxic effect: it can trigger RGCs to undergo apoptosis (cell death) () (). Astrocytes – star-shaped glial cells in the optic nerve – also respond to ET-1. When ET-1 is high, astrocytes can multiply and change shape (a process called astrogliosis). This reactive gliosis can further harm the optic nerve environment. In lab cultures, ET-1 causes optic nerve astrocytes to proliferate, and this effect is blocked by either ETA or ETB receptor inhibitors (). In glaucomatous optic nerves (from humans and animals), researchers have observed more astrocyte proliferation and GFAP (a stress protein) when ET-1 is elevated (). Nitric Oxide and ET-1: Balancing Vessel Tone In healthy eyes, nitric oxide (NO) and ET-1 balance each other. NO is a vasodilator (it widens vessels), whereas ET-1 constricts them. Endothelial cells lining blood vessels release NO under normal conditions, relaxing the vessel walls (). Any disturbance in this balance – for example, too much ET-1 or too little NO – can impair blood flow. In the human ophthalmic (eye) artery, experiments showed that blocking NO causes vessels to constrict and that adding ET-1 causes strong constriction (). Thus, ET-1’s vasoconstriction can overcome NO’s dilating effect. Indeed, in glaucoma, impaired NO production (often due to endothelial dysfunction) is thought to worsen ET-1–induced ischemia. In some studies, giving ET-1 to people or animals reduced NO-mediated blood flow significantly, and an ETA-blocker (like BQ-123) could prevent that reduction (). This cross-talk means that high ET-1 disrupts the normal NO-driven relaxation, promoting a harmful cycle of poor blood supply. ET-1 Receptors: ETA and ETB Signaling ET-1 works by binding two main receptors on cells, ETA (ETA) and ETB (ETB), which are on blood vessels and many eye cells (including neurons, gliSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/mots-c-and-glaucoma-a-mitochondrial-signal-with-bigger-implications-than-eye-pressureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure? Glaucoma is an optic nerve disease often linked to high eye pressure, but it involves many cellular stress pathways. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a tiny peptide made by mitochondria that helps cells cope with stress. Could it influence glaucoma progression or vulnerability beyond just controlling pressure? This article examines the mechanistic links between MOTS-c and glaucoma. We separate established facts from indirect clues and educated speculation. Every big claim is cited to the literature. What MOTS-c Is In 2015, researchers discovered MOTS-c – a 16-amino-acid peptide encoded in mitochondrial DNA (mtDNA) (). It is produced from a short open reading frame in the mitochondrial 12S rRNA gene (). MOTS-c levels rise in response to stress or exercise and decline with age (). Under stress, MOTS-c moves from the mitochondria to the cell nucleus, where it helps activate antioxidant and stress-defense genes (). MOTS-c acts mainly through cellular energy sensors. It boosts the AMP-activated protein kinase (AMPK) pathway by diverting substrates toward AICAR production, mimicking a fasting/exercise signal () (). AMPK is a key regulator of energy balance in cells. When AMPK is activated, it in turn can increase PGC-1α, a master regulator of mitochondrial function (). Thus, MOTS-c indirectly drives cells to make more energy and repair mitochondria. MOTS-c also influences inflammation and oxidative stress. In cell studies, treating stressed cells with MOTS-c increased AMPK and PGC-1α levels and lowered reactive oxygen species (ROS) and inflammatory signals (). Specifically, MOTS-c reduced activation of NF-κB (a protein that drives inflammation) and cut levels of pro-inflammatory cytokines (like TNF-α, IL-1β, IL-6) while boosting anti-inflammatory IL-10 (). It can also activate NRF2 pathways, which turn on antioxidant defenses () (). In simpler terms, MOTS-c is a stress-adaptive hormone made by mitochondria. It helps cells cope with metabolic and oxidative challenges by fueling energy production and calming inflammation () (). It is being studied for benefits in diabetes, neurodegeneration, and aging-related conditions () (). However, its role in eye diseases (especially glaucoma) is not established. Why Glaucoma Might Intersect with MOTS-c Glaucoma damages the optic nerve and kills retinal ganglion cells (RGCs). Classic glaucoma causes are high intraocular pressure (IOP) and aging, but pressure-independent factors also play a major role. Key features of glaucoma biology may interact with what MOTS-c does: Retinal Ganglion Cell Energy Needs: RGCs have high metabolic demand. Their unmyelinated axons use many ATP-driven ion pumps and are packed with mitochondria (). These cells depend heavily on oxidative phosphorylation (OXPHOS) for energy (). If mitochondria falter, RGCs quickly suffer. In principle, MOTS-c’s ability to boost mitochondrial energy production could protect such high-demand neurons. (This is speculative: RGC-specific data on MOTS-c are lacking.) Mitochondrial Dysfunction in Glaucoma: A growing body of evidence implicates mitochondrial failure in glaucoma () (). For instance, glaucoma patients’ eye tissues and blood show signs of damageSupport the show